FCY personal page - To The Moon

FCY

FCY

No personal profile

18Follow

3Followers

0Topic

0Badge

2021-08-02

Why still negotiating with the vaccine makers when the covid is still rampant in india?

India says J&J withdraws proposal for speedy vaccine approval

2021-08-02

Nice! No issue on chip shortage?

Xpeng Motors delivered 8,040 vehicles in July 2021,a record month with a 228% increase YOY

2021-07-25

Looks like a change in stance

Some Americans likely to need COVID-19 vaccine booster -Fauci

2021-07-25

This article does not touch upon the valuation and the potential of moderna. Pity.

Sorry, the original content has been removed

2021-07-22

Ok

4 Biotech Stocks That Could Be Bargains

2021-07-19

Really?!

Sorry, the original content has been removed

2021-07-19

Seems like ample liquidity

US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week

2021-07-16

Up up and away!

Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.

2021-07-16

What does it mean? Is it negative? If so, why?

DIDI shares falls more than 8% in premarket trading.

2021-07-16

Oh no

Why Tesla Slipped Thursday

2021-07-16

Any details on the tie up?

BRIEF-Marqeta And Payfare Enter Into Strategic Partnership

2021-07-16

How many would be keen given the latest delay by Grab to list by SPAC as a result of accounting issues?

SPACs are targeting Southeast Asia’s start-ups and investors are taking note

2021-07-15

$Moderna, Inc.(MRNA)$Game changer and disruptor to the biotech firms. This is evident in how it has managed to produce effective vaccines in the shortest time than what many would expect.

2021-06-29

Time for moderna to quickly up its production capacity

Moderna's stock gains as it announces authorization for its COVID-19 shot in India

2021-06-12

Good update

New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects

2021-06-06

Really?

3 Technology Stocks You Can Buy and Hold for the Next Decade

2021-06-05

What about its woes on airplane manufacturing

Buy Boeing Stock Because ‘a Change Is Gonna Come’

2021-06-03

Too much regulatory opaqueness

Alibaba: One Of The Really Cheap Bargains In This Market

2021-05-30

$Moderna, Inc.(MRNA)$What is the right way to value Moderna? What is it forecast PE at current level?

2021-05-27

What is the fair value for Moderna?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3574987111088333","uuid":"3574987111088333","gmtCreate":1611895414225,"gmtModify":1622084542469,"name":"FCY","pinyin":"fcy","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":18,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":805438269,"gmtCreate":1627897494651,"gmtModify":1703497421005,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Why still negotiating with the vaccine makers when the covid is still rampant in india?","listText":"Why still negotiating with the vaccine makers when the covid is still rampant in india?","text":"Why still negotiating with the vaccine makers when the covid is still rampant in india?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805438269","repostId":"2156191887","repostType":4,"repost":{"id":"2156191887","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627893983,"share":"https://ttm.financial/m/news/2156191887?lang=&edition=fundamental","pubTime":"2021-08-02 16:46","market":"us","language":"en","title":"India says J&J withdraws proposal for speedy vaccine approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2156191887","media":"Reuters","summary":"(Adds details, background)\nBENGALURU, Aug 2 (Reuters) - India's drug regulator said on Monday that J","content":"<p>(Adds details, background)</p>\n<p>BENGALURU, Aug 2 (Reuters) - India's drug regulator said&nbsp;on Monday that Johnson &amp; Johnson withdrew its proposal seeking accelerated approval of its COVID-19 vaccine in the country, without giving additional details.</p>\n<p>The U.S.-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen COVID-19 vaccine candidate in India. Trials in the United States at that time were paused on reports&nbsp;of rare blood clots.</p>\n<p>The drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.</p>\n<p>\"This team is in continuous dialogue with Pfizer, Moderna and Johnson &amp; Johnson to discuss and address various issues including the issue of indemnity,\" Bharati Pravin Pawar had said.</p>\n<p>Johnson &amp; Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to Reuters' requests for comments on why the company withdrew its application.</p>\n<p>As of July 31, Johnson &amp; Johnson is yet to request a full approval for its shot with the U.S. FDA, while Pfizer Inc, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> , and Moderna Inc have already sought full approval of their vaccines with the FDA.</p>\n<p>In India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June.</p>\n<p>(Reporting by Shivani Singh in Bengaluru; editing by Uttaresh.V)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India says J&J withdraws proposal for speedy vaccine approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia says J&J withdraws proposal for speedy vaccine approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-02 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Adds details, background)</p>\n<p>BENGALURU, Aug 2 (Reuters) - India's drug regulator said&nbsp;on Monday that Johnson &amp; Johnson withdrew its proposal seeking accelerated approval of its COVID-19 vaccine in the country, without giving additional details.</p>\n<p>The U.S.-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen COVID-19 vaccine candidate in India. Trials in the United States at that time were paused on reports&nbsp;of rare blood clots.</p>\n<p>The drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.</p>\n<p>\"This team is in continuous dialogue with Pfizer, Moderna and Johnson &amp; Johnson to discuss and address various issues including the issue of indemnity,\" Bharati Pravin Pawar had said.</p>\n<p>Johnson &amp; Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to Reuters' requests for comments on why the company withdrew its application.</p>\n<p>As of July 31, Johnson &amp; Johnson is yet to request a full approval for its shot with the U.S. FDA, while Pfizer Inc, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> , and Moderna Inc have already sought full approval of their vaccines with the FDA.</p>\n<p>In India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June.</p>\n<p>(Reporting by Shivani Singh in Bengaluru; editing by Uttaresh.V)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156191887","content_text":"(Adds details, background)\nBENGALURU, Aug 2 (Reuters) - India's drug regulator said on Monday that Johnson & Johnson withdrew its proposal seeking accelerated approval of its COVID-19 vaccine in the country, without giving additional details.\nThe U.S.-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen COVID-19 vaccine candidate in India. Trials in the United States at that time were paused on reports of rare blood clots.\nThe drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.\n\"This team is in continuous dialogue with Pfizer, Moderna and Johnson & Johnson to discuss and address various issues including the issue of indemnity,\" Bharati Pravin Pawar had said.\nJohnson & Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to Reuters' requests for comments on why the company withdrew its application.\nAs of July 31, Johnson & Johnson is yet to request a full approval for its shot with the U.S. FDA, while Pfizer Inc, BioNTech SE , and Moderna Inc have already sought full approval of their vaccines with the FDA.\nIn India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June.\n(Reporting by Shivani Singh in Bengaluru; editing by Uttaresh.V)","news_type":1},"isVote":1,"tweetType":1,"viewCount":539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805317160,"gmtCreate":1627860853050,"gmtModify":1703496570444,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Nice! No issue on chip shortage?","listText":"Nice! No issue on chip shortage?","text":"Nice! No issue on chip shortage?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/805317160","repostId":"1154563656","repostType":2,"repost":{"id":"1154563656","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627858903,"share":"https://ttm.financial/m/news/1154563656?lang=&edition=fundamental","pubTime":"2021-08-02 07:01","market":"us","language":"en","title":"Xpeng Motors delivered 8,040 vehicles in July 2021,a record month with a 228% increase YOY","url":"https://stock-news.laohu8.com/highlight/detail?id=1154563656","media":"Tiger Newspress","summary":"XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month.8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year. 6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch. 38,778 total vehicles delivered year-to-date, a 388% increase year-over-year. Deliveries in July 2021 consisted of 6,054 ","content":"<p>XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month. </p>\n<ul>\n <li>8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year </li>\n</ul>\n<ul>\n <li>6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch </li>\n</ul>\n<ul>\n <li>38,778 total vehicles delivered year-to-date, a 388% increase year-over-year </li>\n</ul>\n<p>Deliveries in July 2021 consisted of 6,054 P7s, the Company’s sports smart sedan, and 1,986 G3s, its smart compact SUV. </p>\n<p>As of 31 July 2021, year-to-date total deliveries of the Company reached 38,778 units, representing a 388% increase year-over-year. </p>\n<p>P7 deliveries continued record-breaking momentum in July 2021, reflecting the P7’s rising popularity among China’s tech-savvy consumers. In July 2021, at its first-year anniversary of customer deliveries, total P7 deliveries reach 40,612 since the launch. The P7’s Navigation Guided Pilot (NGP) highway solutions continuously increase appeal to a wider customer base, underpinning the Company’s commitment to technology innovation. </p>\n<p>The Company further expanded its product portfolio in July 2021, launching the G3i, the G3 SUV’s mid-phase facelift version with deliveries expected in September 2021. </p>\n<p>In July 2021, the Company announced the pre-sale price range of RMB160,000–RMB230,000 (post subsidies) for its third production model, the P5 family-friendly smart sedan. Being the world’s first mass-produced Smart EV equipped with auto-grade LiDAR technology, the P5 is already generating an enthusiastic response from consumers in the presale phase. The Company plans to launch the P5 in the third quarter 2021 with deliveries expected in the fourth quarter 2021.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Motors delivered 8,040 vehicles in July 2021,a record month with a 228% increase YOY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Motors delivered 8,040 vehicles in July 2021,a record month with a 228% increase YOY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month. </p>\n<ul>\n <li>8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year </li>\n</ul>\n<ul>\n <li>6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch </li>\n</ul>\n<ul>\n <li>38,778 total vehicles delivered year-to-date, a 388% increase year-over-year </li>\n</ul>\n<p>Deliveries in July 2021 consisted of 6,054 P7s, the Company’s sports smart sedan, and 1,986 G3s, its smart compact SUV. </p>\n<p>As of 31 July 2021, year-to-date total deliveries of the Company reached 38,778 units, representing a 388% increase year-over-year. </p>\n<p>P7 deliveries continued record-breaking momentum in July 2021, reflecting the P7’s rising popularity among China’s tech-savvy consumers. In July 2021, at its first-year anniversary of customer deliveries, total P7 deliveries reach 40,612 since the launch. The P7’s Navigation Guided Pilot (NGP) highway solutions continuously increase appeal to a wider customer base, underpinning the Company’s commitment to technology innovation. </p>\n<p>The Company further expanded its product portfolio in July 2021, launching the G3i, the G3 SUV’s mid-phase facelift version with deliveries expected in September 2021. </p>\n<p>In July 2021, the Company announced the pre-sale price range of RMB160,000–RMB230,000 (post subsidies) for its third production model, the P5 family-friendly smart sedan. Being the world’s first mass-produced Smart EV equipped with auto-grade LiDAR technology, the P5 is already generating an enthusiastic response from consumers in the presale phase. The Company plans to launch the P5 in the third quarter 2021 with deliveries expected in the fourth quarter 2021.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","09868":"小鹏汽车-W"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154563656","content_text":"XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month. \n\n8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year \n\n\n6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch \n\n\n38,778 total vehicles delivered year-to-date, a 388% increase year-over-year \n\nDeliveries in July 2021 consisted of 6,054 P7s, the Company’s sports smart sedan, and 1,986 G3s, its smart compact SUV. \nAs of 31 July 2021, year-to-date total deliveries of the Company reached 38,778 units, representing a 388% increase year-over-year. \nP7 deliveries continued record-breaking momentum in July 2021, reflecting the P7’s rising popularity among China’s tech-savvy consumers. In July 2021, at its first-year anniversary of customer deliveries, total P7 deliveries reach 40,612 since the launch. The P7’s Navigation Guided Pilot (NGP) highway solutions continuously increase appeal to a wider customer base, underpinning the Company’s commitment to technology innovation. \nThe Company further expanded its product portfolio in July 2021, launching the G3i, the G3 SUV’s mid-phase facelift version with deliveries expected in September 2021. \nIn July 2021, the Company announced the pre-sale price range of RMB160,000–RMB230,000 (post subsidies) for its third production model, the P5 family-friendly smart sedan. Being the world’s first mass-produced Smart EV equipped with auto-grade LiDAR technology, the P5 is already generating an enthusiastic response from consumers in the presale phase. The Company plans to launch the P5 in the third quarter 2021 with deliveries expected in the fourth quarter 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":337,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3569320299762451","authorId":"3569320299762451","name":"DreamyLucid","avatar":"https://community-static.tradeup.com/news/df94d831afbfa80ddda11b9d4ff73cf1","crmLevel":1,"crmLevelSwitch":0,"idStr":"3569320299762451","authorIdStr":"3569320299762451"},"content":"No. They do not have that problem.","text":"No. They do not have that problem.","html":"No. They do not have that problem."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177287104,"gmtCreate":1627224438808,"gmtModify":1703485740300,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Looks like a change in stance","listText":"Looks like a change in stance","text":"Looks like a change in stance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/177287104","repostId":"2154893446","repostType":2,"repost":{"id":"2154893446","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627219014,"share":"https://ttm.financial/m/news/2154893446?lang=&edition=fundamental","pubTime":"2021-07-25 21:16","market":"us","language":"en","title":"Some Americans likely to need COVID-19 vaccine booster -Fauci","url":"https://stock-news.laohu8.com/highlight/detail?id=2154893446","media":"Reuters","summary":"By Linda So   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci sai","content":"<html><body><p>By Linda So</p><p>   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci said on Sunday that Americans who are immune compromised may end up needing COVID-19 vaccine booster shots. </p><p>   \"Those who are transplant patients, cancer chemotherapy, auto-immune diseases, that are on immunosuppresant regimens, those are the kind of individuals that if there's going to be a third booster, which might likely happen, would be among first the vulnerable,\" Fauci said during a CNN interview. </p><p> (Reporting by Linda So; Editing by Tim Ahmann)</p><p>((tim.ahmann@thomsonreuters.com; +1 202 898-8370; Reuters Messaging: tim.ahmann.reuters.com@reuters.net))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Americans likely to need COVID-19 vaccine booster -Fauci</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Americans likely to need COVID-19 vaccine booster -Fauci\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-25 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>By Linda So</p><p>   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci said on Sunday that Americans who are immune compromised may end up needing COVID-19 vaccine booster shots. </p><p>   \"Those who are transplant patients, cancer chemotherapy, auto-immune diseases, that are on immunosuppresant regimens, those are the kind of individuals that if there's going to be a third booster, which might likely happen, would be among first the vulnerable,\" Fauci said during a CNN interview. </p><p> (Reporting by Linda So; Editing by Tim Ahmann)</p><p>((tim.ahmann@thomsonreuters.com; +1 202 898-8370; Reuters Messaging: tim.ahmann.reuters.com@reuters.net))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","JNJ":"强生"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154893446","content_text":"By Linda So   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci said on Sunday that Americans who are immune compromised may end up needing COVID-19 vaccine booster shots.    \"Those who are transplant patients, cancer chemotherapy, auto-immune diseases, that are on immunosuppresant regimens, those are the kind of individuals that if there's going to be a third booster, which might likely happen, would be among first the vulnerable,\" Fauci said during a CNN interview.  (Reporting by Linda So; Editing by Tim Ahmann)((tim.ahmann@thomsonreuters.com; +1 202 898-8370; Reuters Messaging: tim.ahmann.reuters.com@reuters.net))","news_type":1},"isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3569477879515338","authorId":"3569477879515338","name":"EmmanuelQeen","avatar":"https://static.tigerbbs.com/229c717db2c50af149c3454594cc38dd","crmLevel":4,"crmLevelSwitch":0,"idStr":"3569477879515338","authorIdStr":"3569477879515338"},"content":"[grin] pls gimme a like. tq!","text":"[grin] pls gimme a like. tq!","html":"[grin] pls gimme a like. tq!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177049380,"gmtCreate":1627171936240,"gmtModify":1703484927690,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"This article does not touch upon the valuation and the potential of moderna. Pity.","listText":"This article does not touch upon the valuation and the potential of moderna. Pity.","text":"This article does not touch upon the valuation and the potential of moderna. Pity.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/177049380","repostId":"2153989989","repostType":2,"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172197506,"gmtCreate":1626942744005,"gmtModify":1703481005696,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172197506","repostId":"1197792637","repostType":4,"repost":{"id":"1197792637","kind":"news","pubTimestamp":1626941717,"share":"https://ttm.financial/m/news/1197792637?lang=&edition=fundamental","pubTime":"2021-07-22 16:15","market":"us","language":"en","title":"4 Biotech Stocks That Could Be Bargains","url":"https://stock-news.laohu8.com/highlight/detail?id=1197792637","media":"Barron's","summary":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnol","content":"<p>Biotech stocks have had an uneven 2021 so far.</p>\n<p>One major biotech fund, the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b>, which focuses on the bigger biotech players, is up 9%, just behind the&nbsp;S&amp;P 500 index,which is up 14.3%. Another important fund, the<b>&nbsp;<a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b>, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.</p>\n<p>The success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.</p>\n<p>Picking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.</p>\n<p>For those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.</p>\n<h3><b>4 Undervalued Biotech Stocks</b></h3>\n<p>These are the four biotech stocks in the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b> and the <b><a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b> with market values over $5 billion that trade the farthest below their average analyst price targets.</p>\n<table>\n <thead>\n  <tr>\n   <th>Company / Ticker</th>\n   <th>Recent Price</th>\n   <th>Average Target Price</th>\n   <th>Implied Gain</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>TG Therapeutics / TGTX</td>\n   <td>$37.32</td>\n   <td>$75.88</td>\n   <td>103.3%</td>\n  </tr>\n  <tr>\n   <td>Vir Biotechnology / VIR</td>\n   <td>$37.91</td>\n   <td>$74.29</td>\n   <td>96.0%</td>\n  </tr>\n  <tr>\n   <td>Ultragenyx Pharmaceutical / RARE</td>\n   <td>$85.49</td>\n   <td>$153.12</td>\n   <td>79.1%</td>\n  </tr>\n  <tr>\n   <td>Exelixis / EXEL</td>\n   <td>$16.67</td>\n   <td>$29.54</td>\n   <td>77.2%</td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: FactSet</i></p>\n<p>Analysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we&nbsp;looked at the five health-care stocks in the S&amp;P 500 that trade the farthest below their average analyst&nbsp;price&nbsp;targets.</p>\n<p>This time, we’ve looked at the stocks in the SPDR S&amp;P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.</p>\n<p>We set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.</p>\n<p>The stocks that passed the screen are&nbsp;<b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a></b>, and<b>&nbsp;<a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.</p>\n<p>The stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.</p>\n<p><b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b> stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.</p>\n<p>Analysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.</p>\n<p>The average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.</p>\n<p>Another stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy&nbsp;jointly developed by Vir and&nbsp;<b><a href=\"https://laohu8.com/S/GSK\">GlaxoSmithKline PLC</a></b> to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.</p>\n<p>Vir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.</p>\n<p>Of the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.</p>\n<p>Also on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.</p>\n<p>The company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.</p>\n<p>“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.</p>\n<p>The average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.</p>\n<p>The final stock to pass our screen was <b><a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.</p>\n<p>The average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Biotech Stocks That Could Be Bargains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Biotech Stocks That Could Be Bargains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which ...</p>\n\n<a href=\"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","RARE":"Ultragenyx Pharmaceutical Inc","TGTX":"TG Therapeutics Inc.","IBB":"生物科技指数ETF-iShares Nasdaq","VIR":"Vir Biotechnology, Inc.","XBI":"SPDR S&P Biotech ETF","GSK":"葛兰素史克"},"source_url":"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197792637","content_text":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which is up 14.3%. Another important fund, the Spdr S&P Biotech Etf, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.\nThe success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.\nPicking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.\nFor those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.\n4 Undervalued Biotech Stocks\nThese are the four biotech stocks in the iShares Nasdaq Biotechnology ETF and the Spdr S&P Biotech Etf with market values over $5 billion that trade the farthest below their average analyst price targets.\n\n\n\nCompany / Ticker\nRecent Price\nAverage Target Price\nImplied Gain\n\n\n\n\nTG Therapeutics / TGTX\n$37.32\n$75.88\n103.3%\n\n\nVir Biotechnology / VIR\n$37.91\n$74.29\n96.0%\n\n\nUltragenyx Pharmaceutical / RARE\n$85.49\n$153.12\n79.1%\n\n\nExelixis / EXEL\n$16.67\n$29.54\n77.2%\n\n\n\nSource: FactSet\nAnalysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we looked at the five health-care stocks in the S&P 500 that trade the farthest below their average analyst price targets.\nThis time, we’ve looked at the stocks in the SPDR S&P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.\nWe set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.\nThe stocks that passed the screen are TG Therapeutics, Vir Biotechnology, Inc., Ultragenyx Pharmaceutical, and Exelixis, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.\nThe stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.\nTG Therapeutics stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.\nAnalysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.\nThe average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.\nAnother stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy jointly developed by Vir and GlaxoSmithKline PLC to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.\nVir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.\nOf the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.\nAlso on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.\nThe company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.\n“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.\nThe average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.\nThe final stock to pass our screen was Exelixis, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.\nThe average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173589204,"gmtCreate":1626669935108,"gmtModify":1703763062231,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Really?!","listText":"Really?!","text":"Really?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173589204","repostId":"2152368129","repostType":4,"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173589371,"gmtCreate":1626669900793,"gmtModify":1703763060612,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Seems like ample liquidity&nbsp;","listText":"Seems like ample liquidity&nbsp;","text":"Seems like ample liquidity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173589371","repostId":"1183956332","repostType":4,"repost":{"id":"1183956332","kind":"news","pubTimestamp":1626568120,"share":"https://ttm.financial/m/news/1183956332?lang=&edition=fundamental","pubTime":"2021-07-18 08:28","market":"us","language":"en","title":"US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1183956332","media":"renaissancecap...","summary":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.The largest deal of the week, specialty insurance brokerage Ryan Specialty Group plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in t","content":"<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.</p>\n<p>The largest deal of the week, specialty insurance brokerage&nbsp;<b>Ryan Specialty Group</b>(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.</p>\n<p>Water infrastructure company&nbsp;<b>Core &amp; Main</b>(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.</p>\n<p>HR software provider&nbsp;<b>Paycor HCM</b>(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.</p>\n<p>Latin <a href=\"https://laohu8.com/S/AFG\">American</a> e-commerce platform&nbsp;<b><a href=\"https://laohu8.com/S/VTEX\">VTEX</a></b>(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&amp;A and R&amp;D have weighed on profits.</p>\n<p>Learning management platform&nbsp;<b>Instructure Holdings</b>(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.</p>\n<p>Protein discovery and development platform&nbsp;<b>AbSci</b>(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include <a href=\"https://laohu8.com/S/MRK\">Merck</a> and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.</p>\n<p>Organic beverage brand&nbsp;<b><a href=\"https://laohu8.com/S/ZVIA\">Zevia PBC</a></b>(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.</p>\n<p>Content marketing platform&nbsp;<b>Outbrain</b>(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.</p>\n<p>Fitness franchisor&nbsp;<b>Xponential Fitness</b>(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.</p>\n<p>Legal software provider&nbsp;<b>CS Disco</b>(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.</p>\n<p>Following its postponement in May, Brazil’s&nbsp;<b>Zenvia</b>(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.</p>\n<p><b>Couchbase</b>(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&amp;M costs.</p>\n<p>Following its postponement in April,<b>Kaltura</b>(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.</p>\n<p><b>Gambling.com Group</b>(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.</p>\n<p>Three biotechs are expected to round out the week: cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech&nbsp;<b>Ocean Biomedical</b>(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech&nbsp;<b>Elicio Therapeutics</b>(ELTX), which plans to raise $40 million at a $201 million market cap.</p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-18 08:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BASE":"Couchbase, Inc.","ABSI":"Absci Corporation.","LAW":"CS Disco, Inc.","CNM":"Core & Main, Inc.","GAMB":"Gambling.com Group Limited","OB":"Outbrain Inc.","ELTX":"Elicio Therapeutics","CADL":"Candel Therapeutics, Inc.","OCEA":"Ocean Biomedical","VTEX":"VTEX","INST":"Instructure Holdings, Inc.","ZVIA":"Zevia PBC","PYCR":"Paycor HCM, Inc.","RYAN":"Ryan Specialty Group Holdings, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183956332","content_text":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan Specialty Group(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.\nWater infrastructure company Core & Main(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.\nHR software provider Paycor HCM(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.\nLatin American e-commerce platform VTEX(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&A and R&D have weighed on profits.\nLearning management platform Instructure Holdings(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.\nProtein discovery and development platform AbSci(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include Merck and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.\nOrganic beverage brand Zevia PBC(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.\nContent marketing platform Outbrain(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.\nFitness franchisor Xponential Fitness(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.\nLegal software provider CS Disco(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.\nFollowing its postponement in May, Brazil’s Zenvia(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.\nCouchbase(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&M costs.\nFollowing its postponement in April,Kaltura(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.\nGambling.com Group(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.\nThree biotechs are expected to round out the week: cancer biotech Candel Therapeutics(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech Ocean Biomedical(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech Elicio Therapeutics(ELTX), which plans to raise $40 million at a $201 million market cap.","news_type":1},"isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170201552,"gmtCreate":1626432389176,"gmtModify":1703760050374,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Up up and away!","listText":"Up up and away!","text":"Up up and away!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170201552","repostId":"1166310062","repostType":4,"repost":{"id":"1166310062","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626425479,"share":"https://ttm.financial/m/news/1166310062?lang=&edition=fundamental","pubTime":"2021-07-16 16:51","market":"us","language":"en","title":"Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.","url":"https://stock-news.laohu8.com/highlight/detail?id=1166310062","media":"Tiger Newspress","summary":"Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.\nModerna Inc. will replace ","content":"<p>Moderna&nbsp;shares&nbsp;jumps&nbsp;6.85% in premarket&nbsp;trading,as&nbsp;to&nbsp;be&nbsp;joining S&amp;P 500.</p>\n<p><img src=\"https://static.tigerbbs.com/67fe1c018d8b5dfd6c9ed79f6402e3f0\" tg-width=\"1290\" tg-height=\"612\" referrerpolicy=\"no-referrer\">Moderna Inc.&nbsp;will replace Alexion Pharmaceuticals Inc. &nbsp;in the S&amp;P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc&nbsp;is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna shares jumps 6.85% in premarket trading,as to be joining S&P 500.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna&nbsp;shares&nbsp;jumps&nbsp;6.85% in premarket&nbsp;trading,as&nbsp;to&nbsp;be&nbsp;joining S&amp;P 500.</p>\n<p><img src=\"https://static.tigerbbs.com/67fe1c018d8b5dfd6c9ed79f6402e3f0\" tg-width=\"1290\" tg-height=\"612\" referrerpolicy=\"no-referrer\">Moderna Inc.&nbsp;will replace Alexion Pharmaceuticals Inc. &nbsp;in the S&amp;P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc&nbsp;is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","ALXN":"亚力兄制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166310062","content_text":"Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.\nModerna Inc. will replace Alexion Pharmaceuticals Inc.  in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170849435,"gmtCreate":1626422793827,"gmtModify":1703759870374,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"What does it mean? Is it negative? If so, why?","listText":"What does it mean? Is it negative? If so, why?","text":"What does it mean? Is it negative? If so, why?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170849435","repostId":"1194487154","repostType":4,"repost":{"id":"1194487154","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626422505,"share":"https://ttm.financial/m/news/1194487154?lang=&edition=fundamental","pubTime":"2021-07-16 16:01","market":"us","language":"en","title":"DIDI shares falls more than 8% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1194487154","media":"Tiger Newspress","summary":"DIDI shares falls more than 8% in premarket trading.\n\nOfficials from seven Chinese government depart","content":"<p>DIDI&nbsp;shares&nbsp;falls&nbsp;more&nbsp;than 8% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/85b87d4a938496df4bd4077b1058de3b\" tg-width=\"1284\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<p>Officials from seven Chinese government department visited Didi's offices to conduct a cybersecurity review on Friday.</p>\n<p>This month, days after its high-profile listing in the U.S., the Cyberspace Administration of China (CAC)announced a cybersecurity review of Didi.</p>\n<p>The ride-hailing giant was forced to stop signing up new users and itsapp was also removed from Chinese app stores.</p>\n<p>The CAC, China's top cyberspace regulator, alleged that Didi had illegally collected users' data.</p>\n<p>The CAC as well as the State Administration for Market Regulation (SAMR), the leading antitrust regulator, were among the seven departments that visited Didi for the network security review.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DIDI shares falls more than 8% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDIDI shares falls more than 8% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DIDI&nbsp;shares&nbsp;falls&nbsp;more&nbsp;than 8% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/85b87d4a938496df4bd4077b1058de3b\" tg-width=\"1284\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<p>Officials from seven Chinese government department visited Didi's offices to conduct a cybersecurity review on Friday.</p>\n<p>This month, days after its high-profile listing in the U.S., the Cyberspace Administration of China (CAC)announced a cybersecurity review of Didi.</p>\n<p>The ride-hailing giant was forced to stop signing up new users and itsapp was also removed from Chinese app stores.</p>\n<p>The CAC, China's top cyberspace regulator, alleged that Didi had illegally collected users' data.</p>\n<p>The CAC as well as the State Administration for Market Regulation (SAMR), the leading antitrust regulator, were among the seven departments that visited Didi for the network security review.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194487154","content_text":"DIDI shares falls more than 8% in premarket trading.\n\nOfficials from seven Chinese government department visited Didi's offices to conduct a cybersecurity review on Friday.\nThis month, days after its high-profile listing in the U.S., the Cyberspace Administration of China (CAC)announced a cybersecurity review of Didi.\nThe ride-hailing giant was forced to stop signing up new users and itsapp was also removed from Chinese app stores.\nThe CAC, China's top cyberspace regulator, alleged that Didi had illegally collected users' data.\nThe CAC as well as the State Administration for Market Regulation (SAMR), the leading antitrust regulator, were among the seven departments that visited Didi for the network security review.","news_type":1},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170962535,"gmtCreate":1626400181227,"gmtModify":1703759399010,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170962535","repostId":"1156481169","repostType":4,"repost":{"id":"1156481169","kind":"news","pubTimestamp":1626399008,"share":"https://ttm.financial/m/news/1156481169?lang=&edition=fundamental","pubTime":"2021-07-16 09:30","market":"us","language":"en","title":"Why Tesla Slipped Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1156481169","media":"Motley Fool","summary":"Elon utters the \"F\" word.\n\nWhat happened\nTesla(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, ","content":"<blockquote>\n Elon utters the \"F\" word.\n</blockquote>\n<p><b>What happened</b></p>\n<p><b>Tesla</b>(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, depending on your point of view -- for his pronouncements. The electric vehicle (EV) maker's stock price can gyrate up or down depending on what Musk expresses on a particular day.</p>\n<p>Sure enough, the boss' comment about an upcoming product made for lively trading Thursday with the shares, the price of which ended the day marginally lower.</p>\n<p><b>So what</b></p>\n<p>The subject was the futuristic Cybertruck, Tesla's version of a pickup. In an exchange on<b>Twitter</b>, Musk wrote the following:</p>\n<p>\"To be frank, there is always some chance that Cybertruck will flop, because it is so unlike anything else. I don't care. I love it so much even if others don't.\"</p>\n<p>Musk was only repeating the \"F\" word. His tweet was a reaction to a story published Thursday on niche website The Truth About Cars with the incendiary headline \"Opinion: Tesla's Cybertruck Will Be Company's First Flop.\"</p>\n<p>In the story, writer Tim Healey took aim at theEV's looks, and opined that rival pickups -- including the high-profile<b>Ford</b>(NYSE:F)F-150 Lightning-- will likely be \"more usable as trucks.\"</p>\n<p><b>Now what</b></p>\n<p>CEOs aren't supposed to admit that their products could be duds. But Musk has a high profile and a following largely because he<i>isn't</i>a CEO in the traditional mold. While some people undoubtedly turned bearish on his pronouncement about the Cybertruck, plenty of investors clearly still believe in the company's mission -- and in the actions of its colorful leader.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tesla Slipped Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tesla Slipped Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 09:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/why-tesla-slipped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Elon utters the \"F\" word.\n\nWhat happened\nTesla(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, depending on your point of view -- for his pronouncements. The electric vehicle (EV) maker's stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/why-tesla-slipped-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/07/15/why-tesla-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156481169","content_text":"Elon utters the \"F\" word.\n\nWhat happened\nTesla(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, depending on your point of view -- for his pronouncements. The electric vehicle (EV) maker's stock price can gyrate up or down depending on what Musk expresses on a particular day.\nSure enough, the boss' comment about an upcoming product made for lively trading Thursday with the shares, the price of which ended the day marginally lower.\nSo what\nThe subject was the futuristic Cybertruck, Tesla's version of a pickup. In an exchange onTwitter, Musk wrote the following:\n\"To be frank, there is always some chance that Cybertruck will flop, because it is so unlike anything else. I don't care. I love it so much even if others don't.\"\nMusk was only repeating the \"F\" word. His tweet was a reaction to a story published Thursday on niche website The Truth About Cars with the incendiary headline \"Opinion: Tesla's Cybertruck Will Be Company's First Flop.\"\nIn the story, writer Tim Healey took aim at theEV's looks, and opined that rival pickups -- including the high-profileFord(NYSE:F)F-150 Lightning-- will likely be \"more usable as trucks.\"\nNow what\nCEOs aren't supposed to admit that their products could be duds. But Musk has a high profile and a following largely because heisn'ta CEO in the traditional mold. While some people undoubtedly turned bearish on his pronouncement about the Cybertruck, plenty of investors clearly still believe in the company's mission -- and in the actions of its colorful leader.","news_type":1},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170968780,"gmtCreate":1626400110740,"gmtModify":1703759396877,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Any details on the tie up?","listText":"Any details on the tie up?","text":"Any details on the tie up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170968780","repostId":"2151856310","repostType":2,"repost":{"id":"2151856310","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626175200,"share":"https://ttm.financial/m/news/2151856310?lang=&edition=fundamental","pubTime":"2021-07-13 19:20","market":"us","language":"en","title":"BRIEF-Marqeta And Payfare Enter Into Strategic Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2151856310","media":"Reuters","summary":"July 13 (Reuters) - Marqeta Inc   :   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIPSource t","content":"<html><body><p>July 13 (Reuters) - Marqeta Inc   :</p><p>   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIP</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Marqeta And Payfare Enter Into Strategic Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Marqeta And Payfare Enter Into Strategic Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-13 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>July 13 (Reuters) - Marqeta Inc   :</p><p>   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIP</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CGEM":"Cullinan Therapeutics","LHDX":"Lucira Health, Inc.","MQ":"Marqeta, Inc.","LABP":"Landos Biopharma, Inc.","APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc."},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151856310","content_text":"July 13 (Reuters) - Marqeta Inc   :   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIPSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170961517,"gmtCreate":1626400056239,"gmtModify":1703759395732,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"How many would be keen given the latest delay by Grab to list by SPAC as a result of accounting issues?","listText":"How many would be keen given the latest delay by Grab to list by SPAC as a result of accounting issues?","text":"How many would be keen given the latest delay by Grab to list by SPAC as a result of accounting issues?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/170961517","repostId":"1177508529","repostType":4,"repost":{"id":"1177508529","kind":"news","pubTimestamp":1626399640,"share":"https://ttm.financial/m/news/1177508529?lang=&edition=fundamental","pubTime":"2021-07-16 09:40","market":"sg","language":"en","title":"SPACs are targeting Southeast Asia’s start-ups and investors are taking note","url":"https://stock-news.laohu8.com/highlight/detail?id=1177508529","media":"cnbc","summary":"KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region","content":"<div>\n<p>KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SPACs are targeting Southeast Asia’s start-ups and investors are taking note</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSPACs are targeting Southeast Asia’s start-ups and investors are taking note\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 09:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1177508529","content_text":"KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate Ventures.\nOther late-stage investors, including private equity players, are taking note and writing large checks in the region, he said.\nSPACs are shell companies set up to raise money through an IPO, with the sole purpose of merging with or acquiring an existing private company and taking it public.\n\nSINGAPORE — Southeast Asia’s late-stage start-ups are attracting growing interest from blank-check companies that want to take them public, a venture investor told CNBC.\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate Ventures.\n“SPACs have really put ASEAN on the map,” Lauria said Thursday on CNBC’s “Street Signs Asia,” referring to Southeast Asia’s economic bloc comprising 10 member states. Other late-stage investors, includingprivate equity players, are taking note and writing large checks in the region, he said.\n“The next decade is going to be a very competitive decade for CEOs. You are going to have to scale from 5 to 5,000 much quicker, to be more competitive, (and for) more money,” Lauria said.\nSPACs are shell companiesset up to raise money through an initial public offering, with the sole purpose of merging with or acquiring an existing private company and taking it public.\nFundraising in SEA\nSoutheast Asia’s start-ups reportedly raiseda record $6 billion in the first three months of the year, including anover $2 billion funding roundby logistics and courier service company J&T Express. Last month, Singapore-based start-up Carro, which operates an online marketplace predominantly for pre-owned cars,snagged $360 million in fresh funds.\nThe more established names in the region are preparing to list in public markets. Ride-hailing giantGrab announced in April that it would go public through a SPAC merger valued at $39.6 billion, one of the largest ever blank-check deal. The newly merged Indonesian tech giant, GoTo Group, isalso planning to go public soon.\nLauria told CNBC that a number of Golden Gate’s portfolio companies have been approached by SPACs, and that many of them have said they are not yet ready to go public as being a private firm has its advantages.\n“For a lot of our companies, they see (going public) as something one, two, or three years away. So they’re not just automatically jumping on a SPAC,” Lauria said. “When they are ready to go public, whether that’s a SPAC or traditional IPO, they will be making that call.”\nOnline classifieds business Carousell — one of Golden Gate’s portfolio names — isreportedly exploring listing options via the SPAC route.\nTrends\nGolden Gate said in a report released Thursday that by 2030, the number of IPOs in Southeast Asia will cross 300 as more local start-ups seek to list in domestic public markets. The venture firm expects a rise in medical technology start-ups, as well as for social commerce to dominate online transactions.\nAs the coronavirus pandemic pushed manyphysical business transactions online, Lauria pointed out that tech firms in areas such as food delivery, telemedicine, e-commerce and financial technology have seen strong growth. That trend is expected to continue in the near future.\nSoutheast Asia is home to some400 million internet users and 10% of them went online for the first time in 2020. The internet economy in Singapore, Malaysia, Indonesia, the Philippines, Vietnam and Thailand — the largest economies in the region — is predicted to cross $300 billion by 2025, according to a report last year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3585873168332779","authorId":"3585873168332779","name":"ilovekirby","avatar":"https://static.tigerbbs.com/150e39396270b3385fcaa9d5b241a4e1","crmLevel":4,"crmLevelSwitch":0,"idStr":"3585873168332779","authorIdStr":"3585873168332779"},"content":"Well Grab is also considering secondary listing in Singapore, which may not be a bad thing if investors are concerned about the listing in US.","text":"Well Grab is also considering secondary listing in Singapore, which may not be a bad thing if investors are concerned about the listing in US.","html":"Well Grab is also considering secondary listing in Singapore, which may not be a bad thing if investors are concerned about the listing in US."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147603448,"gmtCreate":1626353994784,"gmtModify":1703758477945,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Game changer and disruptor to the biotech firms. This is evident in how it has&nbsp;managed to produce effective vaccines in the shortest&nbsp;time than what many would expect.","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Game changer and disruptor to the biotech firms. This is evident in how it has&nbsp;managed to produce effective vaccines in the shortest&nbsp;time than what many would expect.","text":"$Moderna, Inc.(MRNA)$Game changer and disruptor to the biotech firms. This is evident in how it has managed to produce effective vaccines in the shortest time than what many would expect.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147603448","isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159733748,"gmtCreate":1624979339584,"gmtModify":1703849441034,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Time for moderna to quickly up its production capacity","listText":"Time for moderna to quickly up its production capacity","text":"Time for moderna to quickly up its production capacity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/159733748","repostId":"2147614088","repostType":2,"repost":{"id":"2147614088","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1624978500,"share":"https://ttm.financial/m/news/2147614088?lang=&edition=fundamental","pubTime":"2021-06-29 22:55","market":"us","language":"en","title":"Moderna's stock gains as it announces authorization for its COVID-19 shot in India","url":"https://stock-news.laohu8.com/highlight/detail?id=2147614088","media":"Dow Jones","summary":"MW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n\n\n  Shares of ","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n</p>\n<p>\n  Shares of Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> gained 6.3% in trading on Tuesday after the company said its COVID-19 vaccine has been authorized for adults in India. Moderna's shot has already been authorized in more than 50 countries, including the U.S. Moderna's stock is up 118.5% this year, while the broader S&amp;P 500  has gained 14.2%. \n</p>\n<p>\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 29, 2021 10:55 ET (14:55 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's stock gains as it announces authorization for its COVID-19 shot in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's stock gains as it announces authorization for its COVID-19 shot in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-29 22:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n</p>\n<p>\n  Shares of Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> gained 6.3% in trading on Tuesday after the company said its COVID-19 vaccine has been authorized for adults in India. Moderna's shot has already been authorized in more than 50 countries, including the U.S. Moderna's stock is up 118.5% this year, while the broader S&amp;P 500  has gained 14.2%. \n</p>\n<p>\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 29, 2021 10:55 ET (14:55 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147614088","content_text":"MW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n\n\n  Shares of Moderna Inc. $(MRNA)$ gained 6.3% in trading on Tuesday after the company said its COVID-19 vaccine has been authorized for adults in India. Moderna's shot has already been authorized in more than 50 countries, including the U.S. Moderna's stock is up 118.5% this year, while the broader S&P 500  has gained 14.2%. \n\n\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  June 29, 2021 10:55 ET (14:55 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186964108,"gmtCreate":1623470024704,"gmtModify":1704204535113,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Good update","listText":"Good update","text":"Good update","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186964108","repostId":"2142204460","repostType":2,"repost":{"id":"2142204460","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623438180,"share":"https://ttm.financial/m/news/2142204460?lang=&edition=fundamental","pubTime":"2021-06-12 03:03","market":"us","language":"en","title":"New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204460","media":"Dow Jones","summary":"MW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow wi","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n</p>\n<p>\n  Tomi Kilgore \n</p>\n<p>\n  Current vaccination rates suggest U.S. will fall well short of President Biden's vaccination goal \n</p>\n<p>\n  The number of new daily COVID-19 cases and deaths fell for the first time in four days, but vaccine hesitancy, amid reports of a heart inflammation side effect in teens and some supply concerns, is increasing the risk that President Biden's vaccination goal may not be reached. \n</p>\n<p>\n  There were at least 11,841 new cases of the coronavirus-borne illness on Thursday, down from 20,153 new cases on Wednesday, according to a New York Times tracker , to snap a three-day streak of increases. \n</p>\n<p>\n  Deaths fell to 412 on Thursday from 449 the day before, to also snap a 3-day rising streak. \n</p>\n<p>\n  The seven-day average of cases declined to 13,409 from 14,505, down 42% from two weeks ago and the lowest count since March 2020. For deaths, the seven-day average dropped to 387, the lowest since June 1, from 417 on Wednesday, and was 22% below where it was two weeks ago. \n</p>\n<p>\n  There are 12 states showing an increase in the weekly trend in cases on Friday, JHU data show , down from 15 on Thursday. \n</p>\n<p>\n  On the vaccination front, 305.69 million COVID-19 vaccines have been administered, and 165.12 million people aged at least 18 years old, or 64.0% of the U.S.'s adult population, have received at least <a href=\"https://laohu8.com/S/AONE\">one</a> shot, the latest data from the Centers for Disease Control and Prevention . \n</p>\n<p>\n  At that daily pace of vaccinations, the U.S. will fall well short of Biden's goal of 70% of adult Americans receiving at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> shot by the Fourth of July. About 15.48 million more adults need to get one vaccine dose to reach Biden's goal, which translates to roughly 700,000 a day. \n</p>\n<p>\n  The number of fully vaccinated Americans increased to 141.58 million, or 42.6% of the total population. \n</p>\n<p>\n  Within age groups, 50.5% of Americans who are at least 12 years old are fully vaccinated, as are 53.4% of the U.S. adult population and 75.8% of Americans at least 65 years old. \n</p>\n<p>\n  In the U.S., fully vaccinated means it has been two weeks since the second of the two-dose vaccines developed by Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) or Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> have been administered, or it's been two weeks since receiving the lone dose of Johnson &amp; Johnson's <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine. \n</p>\n<p>\n  Regarding the J&amp;J vaccine, the CDC temporarily halted shipments in an effort to clear a backlog of unused doses, according to a report in The Wall Street Journal  this month. \n</p>\n<p>\n  On Friday, the U.S. Food and Drug Administration said it extended the expiration dating for J&amp;J's vaccine to 4 1/2 months from 3 months when refrigerated at 2 degrees to 8 degrees Celsius (35.6 degrees-46.4 degrees Fahrenheit). \n</p>\n<p>\n  Separately, the FDA said it has authorized for use  Baltimore facility, even though it is \"not yet ready\" to include the plant in the EUA as an authorized facility. \n</p>\n<p>\n  \"Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson &amp; Johnson) COVID-19 vaccine to be made available,\" the FDA said in a statement. \n</p>\n<p>\n  The statement comes as the New York Times reported , citing people familiar with the situation, that the FDA told J&amp;J to discard 60 million doses of its vaccine made at the Baltimore plant because of possible contamination. \n</p>\n<p>\n  Separately, vaccine hesitancy has been fueled as reports circulated that mRNA vaccines, the kind made by Pfizer-BioNTech and Moderna, have led to a small number of reports of myocarditis , or heart inflammation, in teens. \n</p>\n<p>\n  Dr. Ashish Jha, a dean of the Brown University School of Public Health, said on NBC's \"Today\"  that it increasingly looks like the vaccine is leading to some \"rare\" cases in teens. \n</p>\n<p>\n  He tried to dispel concerns, however, saying that almost all of the cases of myocarditis are \"incredibly mild\" and people recover \"very, very quickly,\" but acknowledged that \"it's not irrelevant\" and can occasionally be more severe. \n</p>\n<p>\n  When asked about how that might fuel vaccine hesitancy, Jha noted that \"every vaccine, every medicine\" can have side effects. \n</p>\n<p>\n  \"You can get myocarditis, you can get many other things, with COVID infection itself, \"Jha said. \"And your risk of having complications from infection remain way higher than your risk from vaccines.\" \n</p>\n<p>\n  In the U.S., there are now four states with more than half of their population fully vaccinated -- Vermont (54.3%), Massachusetts (53.5%), Connecticut (51.4%) and Maine (50.22%) -- and 16 states and the District of Columbia have fully vaccinated more than the U.S. average, according to JHU data . \n</p>\n<p>\n  The states with the lowest percentage of their populations fully vaccinated are Mississippi (26.2%), Alabama (27.8%) and Louisiana (29.8%) \n</p>\n<p>\n  Latest tallies \n</p>\n<p>\n  The global case tally for the coronavirus-borne illness rose to 175.01 million on Thursday, while the death toll rose to 3,776,263, according to JHU data  and about 1.8 million deaths. \n</p>\n<p>\n  There have been 2.28 million vaccine doses administered worldwide as of Thursday, the data show. \n</p>\n<p>\n  The U.S. leads the world in total cases with 33.43 million and deaths with 599,023. \n</p>\n<p>\n  India continues to move closer to the U.S., with cases rising to 29.27 million, but is third in the world in deaths with 363,079. \n</p>\n<p>\n  Brazil is second in deaths at 482,019 and third in cases with 17.21 million. \n</p>\n<p>\n  The U.K. is fourth in deaths worldwide, and it leads Europe, at 28,148, while France is fourth globally in cases and leads Europe with 5.80 million. \n</p>\n<p>\n  China, where the virus was first discovered late in 2019,  has had 103,285 cases and has held steady at 4,846 deaths, according to its official numbers, which are widely held to be massively underreported. \n</p>\n<p>\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 11, 2021 15:03 ET (19:03 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-12 03:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n</p>\n<p>\n  Tomi Kilgore \n</p>\n<p>\n  Current vaccination rates suggest U.S. will fall well short of President Biden's vaccination goal \n</p>\n<p>\n  The number of new daily COVID-19 cases and deaths fell for the first time in four days, but vaccine hesitancy, amid reports of a heart inflammation side effect in teens and some supply concerns, is increasing the risk that President Biden's vaccination goal may not be reached. \n</p>\n<p>\n  There were at least 11,841 new cases of the coronavirus-borne illness on Thursday, down from 20,153 new cases on Wednesday, according to a New York Times tracker , to snap a three-day streak of increases. \n</p>\n<p>\n  Deaths fell to 412 on Thursday from 449 the day before, to also snap a 3-day rising streak. \n</p>\n<p>\n  The seven-day average of cases declined to 13,409 from 14,505, down 42% from two weeks ago and the lowest count since March 2020. For deaths, the seven-day average dropped to 387, the lowest since June 1, from 417 on Wednesday, and was 22% below where it was two weeks ago. \n</p>\n<p>\n  There are 12 states showing an increase in the weekly trend in cases on Friday, JHU data show , down from 15 on Thursday. \n</p>\n<p>\n  On the vaccination front, 305.69 million COVID-19 vaccines have been administered, and 165.12 million people aged at least 18 years old, or 64.0% of the U.S.'s adult population, have received at least <a href=\"https://laohu8.com/S/AONE\">one</a> shot, the latest data from the Centers for Disease Control and Prevention . \n</p>\n<p>\n  At that daily pace of vaccinations, the U.S. will fall well short of Biden's goal of 70% of adult Americans receiving at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> shot by the Fourth of July. About 15.48 million more adults need to get one vaccine dose to reach Biden's goal, which translates to roughly 700,000 a day. \n</p>\n<p>\n  The number of fully vaccinated Americans increased to 141.58 million, or 42.6% of the total population. \n</p>\n<p>\n  Within age groups, 50.5% of Americans who are at least 12 years old are fully vaccinated, as are 53.4% of the U.S. adult population and 75.8% of Americans at least 65 years old. \n</p>\n<p>\n  In the U.S., fully vaccinated means it has been two weeks since the second of the two-dose vaccines developed by Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) or Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> have been administered, or it's been two weeks since receiving the lone dose of Johnson &amp; Johnson's <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine. \n</p>\n<p>\n  Regarding the J&amp;J vaccine, the CDC temporarily halted shipments in an effort to clear a backlog of unused doses, according to a report in The Wall Street Journal  this month. \n</p>\n<p>\n  On Friday, the U.S. Food and Drug Administration said it extended the expiration dating for J&amp;J's vaccine to 4 1/2 months from 3 months when refrigerated at 2 degrees to 8 degrees Celsius (35.6 degrees-46.4 degrees Fahrenheit). \n</p>\n<p>\n  Separately, the FDA said it has authorized for use  Baltimore facility, even though it is \"not yet ready\" to include the plant in the EUA as an authorized facility. \n</p>\n<p>\n  \"Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson &amp; Johnson) COVID-19 vaccine to be made available,\" the FDA said in a statement. \n</p>\n<p>\n  The statement comes as the New York Times reported , citing people familiar with the situation, that the FDA told J&amp;J to discard 60 million doses of its vaccine made at the Baltimore plant because of possible contamination. \n</p>\n<p>\n  Separately, vaccine hesitancy has been fueled as reports circulated that mRNA vaccines, the kind made by Pfizer-BioNTech and Moderna, have led to a small number of reports of myocarditis , or heart inflammation, in teens. \n</p>\n<p>\n  Dr. Ashish Jha, a dean of the Brown University School of Public Health, said on NBC's \"Today\"  that it increasingly looks like the vaccine is leading to some \"rare\" cases in teens. \n</p>\n<p>\n  He tried to dispel concerns, however, saying that almost all of the cases of myocarditis are \"incredibly mild\" and people recover \"very, very quickly,\" but acknowledged that \"it's not irrelevant\" and can occasionally be more severe. \n</p>\n<p>\n  When asked about how that might fuel vaccine hesitancy, Jha noted that \"every vaccine, every medicine\" can have side effects. \n</p>\n<p>\n  \"You can get myocarditis, you can get many other things, with COVID infection itself, \"Jha said. \"And your risk of having complications from infection remain way higher than your risk from vaccines.\" \n</p>\n<p>\n  In the U.S., there are now four states with more than half of their population fully vaccinated -- Vermont (54.3%), Massachusetts (53.5%), Connecticut (51.4%) and Maine (50.22%) -- and 16 states and the District of Columbia have fully vaccinated more than the U.S. average, according to JHU data . \n</p>\n<p>\n  The states with the lowest percentage of their populations fully vaccinated are Mississippi (26.2%), Alabama (27.8%) and Louisiana (29.8%) \n</p>\n<p>\n  Latest tallies \n</p>\n<p>\n  The global case tally for the coronavirus-borne illness rose to 175.01 million on Thursday, while the death toll rose to 3,776,263, according to JHU data  and about 1.8 million deaths. \n</p>\n<p>\n  There have been 2.28 million vaccine doses administered worldwide as of Thursday, the data show. \n</p>\n<p>\n  The U.S. leads the world in total cases with 33.43 million and deaths with 599,023. \n</p>\n<p>\n  India continues to move closer to the U.S., with cases rising to 29.27 million, but is third in the world in deaths with 363,079. \n</p>\n<p>\n  Brazil is second in deaths at 482,019 and third in cases with 17.21 million. \n</p>\n<p>\n  The U.K. is fourth in deaths worldwide, and it leads Europe, at 28,148, while France is fourth globally in cases and leads Europe with 5.80 million. \n</p>\n<p>\n  China, where the virus was first discovered late in 2019,  has had 103,285 cases and has held steady at 4,846 deaths, according to its official numbers, which are widely held to be massively underreported. \n</p>\n<p>\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 11, 2021 15:03 ET (19:03 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","MRNA":"Moderna, Inc.","JNJ":"强生","EBS":"Emergent Biosolutions","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142204460","content_text":"MW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n\n\n  Tomi Kilgore \n\n\n  Current vaccination rates suggest U.S. will fall well short of President Biden's vaccination goal \n\n\n  The number of new daily COVID-19 cases and deaths fell for the first time in four days, but vaccine hesitancy, amid reports of a heart inflammation side effect in teens and some supply concerns, is increasing the risk that President Biden's vaccination goal may not be reached. \n\n\n  There were at least 11,841 new cases of the coronavirus-borne illness on Thursday, down from 20,153 new cases on Wednesday, according to a New York Times tracker , to snap a three-day streak of increases. \n\n\n  Deaths fell to 412 on Thursday from 449 the day before, to also snap a 3-day rising streak. \n\n\n  The seven-day average of cases declined to 13,409 from 14,505, down 42% from two weeks ago and the lowest count since March 2020. For deaths, the seven-day average dropped to 387, the lowest since June 1, from 417 on Wednesday, and was 22% below where it was two weeks ago. \n\n\n  There are 12 states showing an increase in the weekly trend in cases on Friday, JHU data show , down from 15 on Thursday. \n\n\n  On the vaccination front, 305.69 million COVID-19 vaccines have been administered, and 165.12 million people aged at least 18 years old, or 64.0% of the U.S.'s adult population, have received at least one shot, the latest data from the Centers for Disease Control and Prevention . \n\n\n  At that daily pace of vaccinations, the U.S. will fall well short of Biden's goal of 70% of adult Americans receiving at least one shot by the Fourth of July. About 15.48 million more adults need to get one vaccine dose to reach Biden's goal, which translates to roughly 700,000 a day. \n\n\n  The number of fully vaccinated Americans increased to 141.58 million, or 42.6% of the total population. \n\n\n  Within age groups, 50.5% of Americans who are at least 12 years old are fully vaccinated, as are 53.4% of the U.S. adult population and 75.8% of Americans at least 65 years old. \n\n\n  In the U.S., fully vaccinated means it has been two weeks since the second of the two-dose vaccines developed by Pfizer Inc. $(PFE)$ and partner BioNTech SE (BNTX) or Moderna Inc. $(MRNA)$ have been administered, or it's been two weeks since receiving the lone dose of Johnson & Johnson's $(JNJ)$ vaccine. \n\n\n  Regarding the J&J vaccine, the CDC temporarily halted shipments in an effort to clear a backlog of unused doses, according to a report in The Wall Street Journal  this month. \n\n\n  On Friday, the U.S. Food and Drug Administration said it extended the expiration dating for J&J's vaccine to 4 1/2 months from 3 months when refrigerated at 2 degrees to 8 degrees Celsius (35.6 degrees-46.4 degrees Fahrenheit). \n\n\n  Separately, the FDA said it has authorized for use  Baltimore facility, even though it is \"not yet ready\" to include the plant in the EUA as an authorized facility. \n\n\n  \"Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 vaccine to be made available,\" the FDA said in a statement. \n\n\n  The statement comes as the New York Times reported , citing people familiar with the situation, that the FDA told J&J to discard 60 million doses of its vaccine made at the Baltimore plant because of possible contamination. \n\n\n  Separately, vaccine hesitancy has been fueled as reports circulated that mRNA vaccines, the kind made by Pfizer-BioNTech and Moderna, have led to a small number of reports of myocarditis , or heart inflammation, in teens. \n\n\n  Dr. Ashish Jha, a dean of the Brown University School of Public Health, said on NBC's \"Today\"  that it increasingly looks like the vaccine is leading to some \"rare\" cases in teens. \n\n\n  He tried to dispel concerns, however, saying that almost all of the cases of myocarditis are \"incredibly mild\" and people recover \"very, very quickly,\" but acknowledged that \"it's not irrelevant\" and can occasionally be more severe. \n\n\n  When asked about how that might fuel vaccine hesitancy, Jha noted that \"every vaccine, every medicine\" can have side effects. \n\n\n  \"You can get myocarditis, you can get many other things, with COVID infection itself, \"Jha said. \"And your risk of having complications from infection remain way higher than your risk from vaccines.\" \n\n\n  In the U.S., there are now four states with more than half of their population fully vaccinated -- Vermont (54.3%), Massachusetts (53.5%), Connecticut (51.4%) and Maine (50.22%) -- and 16 states and the District of Columbia have fully vaccinated more than the U.S. average, according to JHU data . \n\n\n  The states with the lowest percentage of their populations fully vaccinated are Mississippi (26.2%), Alabama (27.8%) and Louisiana (29.8%) \n\n\n  Latest tallies \n\n\n  The global case tally for the coronavirus-borne illness rose to 175.01 million on Thursday, while the death toll rose to 3,776,263, according to JHU data  and about 1.8 million deaths. \n\n\n  There have been 2.28 million vaccine doses administered worldwide as of Thursday, the data show. \n\n\n  The U.S. leads the world in total cases with 33.43 million and deaths with 599,023. \n\n\n  India continues to move closer to the U.S., with cases rising to 29.27 million, but is third in the world in deaths with 363,079. \n\n\n  Brazil is second in deaths at 482,019 and third in cases with 17.21 million. \n\n\n  The U.K. is fourth in deaths worldwide, and it leads Europe, at 28,148, while France is fourth globally in cases and leads Europe with 5.80 million. \n\n\n  China, where the virus was first discovered late in 2019,  has had 103,285 cases and has held steady at 4,846 deaths, according to its official numbers, which are widely held to be massively underreported. \n\n\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  June 11, 2021 15:03 ET (19:03 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":115658480,"gmtCreate":1622989794540,"gmtModify":1704194126169,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/115658480","repostId":"2140540596","repostType":4,"repost":{"id":"2140540596","kind":"highlight","pubTimestamp":1622820692,"share":"https://ttm.financial/m/news/2140540596?lang=&edition=fundamental","pubTime":"2021-06-04 23:31","market":"us","language":"en","title":"3 Technology Stocks You Can Buy and Hold for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2140540596","media":"Motley Fool","summary":"It can be tough to get married to stocks -- especially tech -- but here are three to leave alone for the long haul.","content":"<p>Let's be honest. A lot of people say their positions in flashy technology companies are meant to be long-term holdings, but they're really just an effort to make a quick buck. And that's OK. Any profitable trade is technically a good trade. If you can get in and out at the right time, so be it.</p>\n<p>Thing is, there are plenty of tech names that are more than just flash-in-the-pan prospects, and are better suited for holding periods measured in years rather than weeks.</p>\n<p>Here's a closer look at three such technology companies. Not only will they be just as impressive 10 years from now as they are today, but their stocks should be trading at much higher prices.</p>\n<h2>Microsoft</h2>\n<p>It's tough to imagine a world without <b>Microsoft</b> (NASDAQ:MSFT). Its Windows operating system is installed on three-fourths of the world's desktops and laptops, according to GlobalStats, and its Office productivity software remains the gold standard for the category. <b>Sony</b>'s PlayStation gaming console enjoys more worldwide market share than Microsoft's Xbox, but the Xbox is closing the gap, and is still the most popular game console in the U.S.</p>\n<p>And these are things consumers can readily see. There's a whole different unseen array of Microsoft-made products that are doing similarly well. For instance, Canalys reports Microsoft's cloud computing business accounted for a second-best 19% of the world's first-quarter cloud infrastructure spending, and the company continues to close the gap with market-leader <b>Amazon</b>.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/362a8a5cb8d412d4e3895fa185d236b7\" tg-width=\"700\" tg-height=\"484\"><span>Image source: Getty Images.</span></p>\n<p>Now take a step back and ask a thoughtful, critical question: Is there any chance the world will have less need for computers, cloud computing, productivity software, or game consoles 10 years from now?</p>\n<p>Any reasonable and realistic answer has to be \"no.\" Indeed, it would be surprising if demand for these products and services wasn't considerably greater a decade from now. Being a market leader in multiple categories, Microsoft can steer the market's ongoing growth in a way that serves itself best. For example, the Windows operating system comes with trial versions of Office software pre-installed.</p>\n<p>Bolstering the bullish argument for long-term ownership of Microsoft is the company's evolving business model. Access to Azure, Office, and even video games can now be utilized on a monthly subscription basis, accessible via the cloud. This shift not only makes the company's products more affordable to begin using but also gives Microsoft a better chance of keeping those customers by making it easy to update and upgrade software.</p>\n<p>Last year, the last time Microsoft disclosed such data, it had already lined up more than $100 billion worth of subscription cloud revenue that had yet to be booked -- a figure that continues to edge upward.</p>\n<h2><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></h2>\n<p>Even after several high-profile cybersecurity gaffes embarrassed organizations ranging from <b>Target </b>to <b>Equifax</b> to Yahoo!, some of the world's most important companies are still being hacked. Most recently, Colonial Pipeline agreed to fork over $4.4 million to a computer hacking group known as Darkside to regain control of its 5,500 miles worth of refined oil pipelines.</p>\n<p>These things are preventable. They're just not being prevented, as too many organizations don't utilize all the digital defenses available to them. Perhaps the Colonial Pipeline debacle will encourage procurement of this protection.</p>\n<p>Enter <b>Palo Alto Networks</b> (NYSE:PANW). Simply put, Palo Alto offers software preventing unauthorized access to a company's network, internal apps, and data. It's even got a ransomware protection solution in its lineup that might have been able to save Colonial Pipeline a few million bucks.</p>\n<p>The opportunity is incredible, and should remain so for a while. P&amp;S Intelligence believes the cybersecurity market will grow at an average annual pace of 12.6%, from 2019's $120 billion to $434 billion by 2030. That's a lot, but it's only a fraction of the $10.5 trillion that Cybersecurity Ventures believes cybercrime will cost the world in 2025 alone if enterprises don't step up their digital defense games.</p>\n<p>Palo Alto is doing fine, logging more than seven consecutive years of rising revenue as more and more outfits build their digital moats. Given the outlook, more of the same kind of growth is in the cards for a while.</p>\n<h2>International Business Machines</h2>\n<p>Finally, add <b>International Business Machines</b> (NYSE:IBM) to your list of technology stocks to buy and hold for the next decade.</p>\n<p>Yes, this is the same IBM that failed to respond to the advent of things like cloud computing, mobile devices, and all that goes with both. The company's \"strategic imperatives\" plan unveiled in 2015 was meant to steer the company away from a legacy mainframe business that was already dying and toward more contemporary opportunities like the aforementioned cloud and mobile security. By and large, though, it was too little too late.</p>\n<p>The IBM of today, however, isn't the IBM from even as recently as two years ago. It's ready to compete where it counts.</p>\n<p>Take last month's revelation of new technologies capable of fabricating a 2-nanometer microchip as an example. The microscopic measure is in reference to how small a chip's transistors can be made and still function properly. The smaller, the better, as smaller transistors consume less power, operate faster, and require less space when room is a factor. For perspective, 7-nanometer chips are the best the market has to offer right now.</p>\n<p>It's not just more functional chips IBM is starting to develop, either. Just within the past few weeks, the company has unveiled a way for data centers to more efficiently store and retrieve data, and launched AutoSQL, which is capable of retrieving data eight times faster than previous approaches are. Both technologies have a myriad of potential uses, including in the artificial intelligence arena.</p>\n<p>Read between the lines. This isn't yesteryear's IBM.</p>\n<p>It could still take years for the company to fully monetize these and other breakthroughs, but they're worth the wait.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Technology Stocks You Can Buy and Hold for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Technology Stocks You Can Buy and Hold for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/04/3-technology-stocks-you-can-buy-and-hold-for-the-n/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Let's be honest. A lot of people say their positions in flashy technology companies are meant to be long-term holdings, but they're really just an effort to make a quick buck. And that's OK. Any ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/04/3-technology-stocks-you-can-buy-and-hold-for-the-n/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PANW":"Palo Alto Networks","IBM":"IBM","MSFT":"微软"},"source_url":"https://www.fool.com/investing/2021/06/04/3-technology-stocks-you-can-buy-and-hold-for-the-n/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140540596","content_text":"Let's be honest. A lot of people say their positions in flashy technology companies are meant to be long-term holdings, but they're really just an effort to make a quick buck. And that's OK. Any profitable trade is technically a good trade. If you can get in and out at the right time, so be it.\nThing is, there are plenty of tech names that are more than just flash-in-the-pan prospects, and are better suited for holding periods measured in years rather than weeks.\nHere's a closer look at three such technology companies. Not only will they be just as impressive 10 years from now as they are today, but their stocks should be trading at much higher prices.\nMicrosoft\nIt's tough to imagine a world without Microsoft (NASDAQ:MSFT). Its Windows operating system is installed on three-fourths of the world's desktops and laptops, according to GlobalStats, and its Office productivity software remains the gold standard for the category. Sony's PlayStation gaming console enjoys more worldwide market share than Microsoft's Xbox, but the Xbox is closing the gap, and is still the most popular game console in the U.S.\nAnd these are things consumers can readily see. There's a whole different unseen array of Microsoft-made products that are doing similarly well. For instance, Canalys reports Microsoft's cloud computing business accounted for a second-best 19% of the world's first-quarter cloud infrastructure spending, and the company continues to close the gap with market-leader Amazon.\nImage source: Getty Images.\nNow take a step back and ask a thoughtful, critical question: Is there any chance the world will have less need for computers, cloud computing, productivity software, or game consoles 10 years from now?\nAny reasonable and realistic answer has to be \"no.\" Indeed, it would be surprising if demand for these products and services wasn't considerably greater a decade from now. Being a market leader in multiple categories, Microsoft can steer the market's ongoing growth in a way that serves itself best. For example, the Windows operating system comes with trial versions of Office software pre-installed.\nBolstering the bullish argument for long-term ownership of Microsoft is the company's evolving business model. Access to Azure, Office, and even video games can now be utilized on a monthly subscription basis, accessible via the cloud. This shift not only makes the company's products more affordable to begin using but also gives Microsoft a better chance of keeping those customers by making it easy to update and upgrade software.\nLast year, the last time Microsoft disclosed such data, it had already lined up more than $100 billion worth of subscription cloud revenue that had yet to be booked -- a figure that continues to edge upward.\nPalo Alto Networks\nEven after several high-profile cybersecurity gaffes embarrassed organizations ranging from Target to Equifax to Yahoo!, some of the world's most important companies are still being hacked. Most recently, Colonial Pipeline agreed to fork over $4.4 million to a computer hacking group known as Darkside to regain control of its 5,500 miles worth of refined oil pipelines.\nThese things are preventable. They're just not being prevented, as too many organizations don't utilize all the digital defenses available to them. Perhaps the Colonial Pipeline debacle will encourage procurement of this protection.\nEnter Palo Alto Networks (NYSE:PANW). Simply put, Palo Alto offers software preventing unauthorized access to a company's network, internal apps, and data. It's even got a ransomware protection solution in its lineup that might have been able to save Colonial Pipeline a few million bucks.\nThe opportunity is incredible, and should remain so for a while. P&S Intelligence believes the cybersecurity market will grow at an average annual pace of 12.6%, from 2019's $120 billion to $434 billion by 2030. That's a lot, but it's only a fraction of the $10.5 trillion that Cybersecurity Ventures believes cybercrime will cost the world in 2025 alone if enterprises don't step up their digital defense games.\nPalo Alto is doing fine, logging more than seven consecutive years of rising revenue as more and more outfits build their digital moats. Given the outlook, more of the same kind of growth is in the cards for a while.\nInternational Business Machines\nFinally, add International Business Machines (NYSE:IBM) to your list of technology stocks to buy and hold for the next decade.\nYes, this is the same IBM that failed to respond to the advent of things like cloud computing, mobile devices, and all that goes with both. The company's \"strategic imperatives\" plan unveiled in 2015 was meant to steer the company away from a legacy mainframe business that was already dying and toward more contemporary opportunities like the aforementioned cloud and mobile security. By and large, though, it was too little too late.\nThe IBM of today, however, isn't the IBM from even as recently as two years ago. It's ready to compete where it counts.\nTake last month's revelation of new technologies capable of fabricating a 2-nanometer microchip as an example. The microscopic measure is in reference to how small a chip's transistors can be made and still function properly. The smaller, the better, as smaller transistors consume less power, operate faster, and require less space when room is a factor. For perspective, 7-nanometer chips are the best the market has to offer right now.\nIt's not just more functional chips IBM is starting to develop, either. Just within the past few weeks, the company has unveiled a way for data centers to more efficiently store and retrieve data, and launched AutoSQL, which is capable of retrieving data eight times faster than previous approaches are. Both technologies have a myriad of potential uses, including in the artificial intelligence arena.\nRead between the lines. This isn't yesteryear's IBM.\nIt could still take years for the company to fully monetize these and other breakthroughs, but they're worth the wait.","news_type":1},"isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":112337985,"gmtCreate":1622851001347,"gmtModify":1704192297645,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"What about its woes on airplane manufacturing&nbsp;","listText":"What about its woes on airplane manufacturing&nbsp;","text":"What about its woes on airplane manufacturing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112337985","repostId":"1180386317","repostType":2,"repost":{"id":"1180386317","kind":"news","pubTimestamp":1622616520,"share":"https://ttm.financial/m/news/1180386317?lang=&edition=fundamental","pubTime":"2021-06-02 14:48","market":"us","language":"en","title":"Buy Boeing Stock Because ‘a Change Is Gonna Come’","url":"https://stock-news.laohu8.com/highlight/detail?id=1180386317","media":"Barrons","summary":"Stock in Boeing caught an upgrade Tuesday as a Wall Street analyst noted that things are looking up for the commercial aerospace giant and the industry as a whole.Cowen analyst Cai von Rumohr upgraded the shares to Buy from Hold and raised his target for the price to $290 from $240 a share. His belief that “a change is gonna come” underpins his more bullish view.The first change is air traffic. Air travel is picking up after a moribund, pandemic-affected 2020. More than1.9 million people boarded","content":"<p>Stock in Boeing caught an upgrade Tuesday as a Wall Street analyst noted that things are looking up for the commercial aerospace giant and the industry as a whole.</p>\n<p>Boeing stock (ticker: BA) was up 3% on Tuesday. </p>\n<p>Cowen analyst&nbsp;Cai von Rumohr&nbsp;upgraded the shares to Buy from Hold and raised his target for the price to $290 from $240 a share. His belief that “a change is gonna come” underpins his more bullish view.</p>\n<p>The first change is air traffic. Air travel is picking up after a moribund, pandemic-affected 2020. More than1.9 million people&nbsp;boarded planes in the U.S. on Monday, the highest level since March 2020. Over the holiday weekend, U.S. commercial air traffic was down less than 30% compared with 2019, a smaller drop than on recent weekends.</p>\n<p>More people on planes is good news for all aerospace-related stocks.</p>\n<p>Von Rumohr also sees a change coming in demand for commercial aircraft. Governments and airlines are increasingly focused on reducing emissions of carbon dioxide, and new planes emit less of the greenhouse gas, so replacement demand could rise faster than investors expect. Lower operating costs, of course, are an additional reason to replace planes.</p>\n<p>He also pointed out that the global fleet of wide-body, or twin-aisle aircraft, is older than the narrow-body aircraft in use. That makes them more likely to be replaced. A snapback in wide-body order rates has the potential to help Boeing a little more than&nbsp;Airbus&nbsp;(AIR.France) because Boeing has a bigger market share in wide-bodies. Still, any order pickup will benefit both.</p>\n<p>As air traffic returns to normal, potentially emboldening airlines to buy, von Rumohr projects Boeing will generate $21 of free cash flow per share by 2024. That cash flow supports his $290&nbsp;target price.</p>\n<p>Right now, Boeing is burning through cash because deliveries dropped dramatically amid Covid-19 lockdowns. In 2017 and 2018, before the pandemic, and before the 737 MAX jet was grounded in 2019, Boeing generated more than $20 in free cash flow per share.</p>\n<p>While the S&amp;P 500 trades for a free cash yield—essentially free cash flow divided by the stock price—of about 3%, Boeing has historically traded for a yield closer to 6%. With $21 in free cash flow and a yield of 6%, a share price of $350 is possible by 2024, offering attractive returns in coming years with shares trading at about $250.</p>\n<p>With the upgrade, 53% of analysts covering the stock rate shares at Buy. The&nbsp;average&nbsp;Buy-rating ratio for stocks in the S&amp;P 500 is about 55%.</p>\n<p>Boeing was a much more popular stock before the pandemic and the grounding of the 737 MAX jet between March 2019 and December 2020. In February 2019, more than 76% of analysts covering the company rated shares Buy. The share price was almost $400.</p>\n<p>Boeing stock rose 1% in 2019 and dropped 34% in 2020. Shares are up about 19% year to date, better than comparable gains of the overall market.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy Boeing Stock Because ‘a Change Is Gonna Come’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy Boeing Stock Because ‘a Change Is Gonna Come’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-02 14:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-boeing-stock-cowen-rating-upgrade-51622566557?mod=hp_LEADSUPP_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stock in Boeing caught an upgrade Tuesday as a Wall Street analyst noted that things are looking up for the commercial aerospace giant and the industry as a whole.\nBoeing stock (ticker: BA) was up 3% ...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-boeing-stock-cowen-rating-upgrade-51622566557?mod=hp_LEADSUPP_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"source_url":"https://www.barrons.com/articles/buy-boeing-stock-cowen-rating-upgrade-51622566557?mod=hp_LEADSUPP_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180386317","content_text":"Stock in Boeing caught an upgrade Tuesday as a Wall Street analyst noted that things are looking up for the commercial aerospace giant and the industry as a whole.\nBoeing stock (ticker: BA) was up 3% on Tuesday. \nCowen analyst Cai von Rumohr upgraded the shares to Buy from Hold and raised his target for the price to $290 from $240 a share. His belief that “a change is gonna come” underpins his more bullish view.\nThe first change is air traffic. Air travel is picking up after a moribund, pandemic-affected 2020. More than1.9 million people boarded planes in the U.S. on Monday, the highest level since March 2020. Over the holiday weekend, U.S. commercial air traffic was down less than 30% compared with 2019, a smaller drop than on recent weekends.\nMore people on planes is good news for all aerospace-related stocks.\nVon Rumohr also sees a change coming in demand for commercial aircraft. Governments and airlines are increasingly focused on reducing emissions of carbon dioxide, and new planes emit less of the greenhouse gas, so replacement demand could rise faster than investors expect. Lower operating costs, of course, are an additional reason to replace planes.\nHe also pointed out that the global fleet of wide-body, or twin-aisle aircraft, is older than the narrow-body aircraft in use. That makes them more likely to be replaced. A snapback in wide-body order rates has the potential to help Boeing a little more than Airbus (AIR.France) because Boeing has a bigger market share in wide-bodies. Still, any order pickup will benefit both.\nAs air traffic returns to normal, potentially emboldening airlines to buy, von Rumohr projects Boeing will generate $21 of free cash flow per share by 2024. That cash flow supports his $290 target price.\nRight now, Boeing is burning through cash because deliveries dropped dramatically amid Covid-19 lockdowns. In 2017 and 2018, before the pandemic, and before the 737 MAX jet was grounded in 2019, Boeing generated more than $20 in free cash flow per share.\nWhile the S&P 500 trades for a free cash yield—essentially free cash flow divided by the stock price—of about 3%, Boeing has historically traded for a yield closer to 6%. With $21 in free cash flow and a yield of 6%, a share price of $350 is possible by 2024, offering attractive returns in coming years with shares trading at about $250.\nWith the upgrade, 53% of analysts covering the stock rate shares at Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%.\nBoeing was a much more popular stock before the pandemic and the grounding of the 737 MAX jet between March 2019 and December 2020. In February 2019, more than 76% of analysts covering the company rated shares Buy. The share price was almost $400.\nBoeing stock rose 1% in 2019 and dropped 34% in 2020. Shares are up about 19% year to date, better than comparable gains of the overall market.","news_type":1},"isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111595568,"gmtCreate":1622685595454,"gmtModify":1704188888520,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Too much regulatory opaqueness&nbsp;","listText":"Too much regulatory opaqueness&nbsp;","text":"Too much regulatory opaqueness","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111595568","repostId":"1138216687","repostType":2,"repost":{"id":"1138216687","kind":"news","pubTimestamp":1622552095,"share":"https://ttm.financial/m/news/1138216687?lang=&edition=fundamental","pubTime":"2021-06-01 20:54","market":"hk","language":"en","title":"Alibaba: One Of The Really Cheap Bargains In This Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1138216687","media":"seekingalpha","summary":"Alibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.The company is clearly facing risks due to the tension between Jack Ma and the Chinese government, but I consider these risks to be only temporary.Alibaba is growing with a high pace, has a very stable balance sheet and outperforming many of its peers.So far, I have published over 300 articles on this site and the focus has been clearly on companies having the headquarters in the United Sta","content":"<p><b>Summary</b></p>\n<ul>\n <li>Alibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.</li>\n <li>The company is clearly facing risks due to the tension between Jack Ma and the Chinese government, but I consider these risks to be only temporary.</li>\n <li>Alibaba is growing with a high pace, has a very stable balance sheet and outperforming many of its peers.</li>\n <li>In my opinion, the stock is severely undervalued.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/15ac5f97c66688f6d16ce98819ebce4a\" tg-width=\"768\" tg-height=\"512\"><span>Photo by maybefalse/iStock Unreleased via Getty Images</span></p>\n<p>So far, I have published over 300 articles on this site and the focus has been clearly on companies having the headquarters in the United States and stocks listed on an US-based stock exchange. And while I am covering also companies from Germany, France, Great Britain, Sweden or Denmark, I have avoided one country almost completely although it has many interesting investment opportunities: Mainland China.The only company I covered so far&nbsp;is Tencent Holdings Limited (OTCPK:TCEHY).</p>\n<p>And although China has hundreds or thousands of successful companies, most of them are almost unknown in the Western Hemisphere (especially when moving outside of the investing world). And while most investors are familiar with Tencent, there is at least one other company almost every investor has heard of: Alibaba Group Holding Limited (BABA). In the following article, I will analyze Alibaba in my usual way. I will try to determine if Alibaba is a solid business with a wide economic moat and try to answer the question if Alibaba is a solid investment right now.</p>\n<p><b>Business Description</b></p>\n<p>Alibaba Group was founded in 1999 by 18 individuals. Nevertheless, one of these 18 stands out – the former English teacher from Hangzhou, Jack Ma. Over the years, Alibaba evolved in a multinational technology company and with a market capitalization of $570 billion, Alibaba is on the 10thspot on the list of most valuable companies in the world (by market cap). And behind Tencent, which is on the 7thspot on that list, Alibaba is the second most valuable company in China.</p>\n<p>While Alibaba is mostly focused on e-commerce and retail operations, the Alibaba Group is actually a holding company with many different sales services. This includes C2C services, B2C services and B2B services. Aside from retail, the Alibaba Group also offers electronic payment services, shipping search engines and could computing services. The group owns and operates a diverse portfolio of companies around the world in numerous business sectors.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b315044f4644568e7df5d95cc6720995\" tg-width=\"640\" tg-height=\"479\"><span>(Source:Alibaba Q4/20 Presentation)</span></p>\n<p>Alibaba is reporting in four different segments:</p>\n<ul>\n <li><b>Core Commerce Revenue</b>: This segment is comprised of platforms operating in retail and wholesale commerce in China as well as logistics services and local consumer services. In fiscal 2021, this segment generated RMB 621.1 billion in revenue and RMB 159 billion in income from operations.</li>\n <li><b>Cloud Computing Revenue</b>: This segment is comprised of Alibaba Cloud, which offers different cloud services to customers worldwide like database, storage, big data analytics, a machine learning platform and large-scale computing security. In fiscal 2021, this segment generated RMB 60.1 billion, but the segment was not profitable so far (a loss of RMB 9 billion).</li>\n <li><b>Digital Media and Entertainment Revenue</b>: This segment uses the deep data insights to serve the broader interests of consumers through key distribution platforms Youku and Alibaba Pictures as well as other content platforms that provide online videos, films, live events, literature and music. In fiscal 2021, this segment generated RMB 31.2 billion, but was also not profitable.</li>\n <li><b>Innovation Initiatives and Others Revenue</b>: This segment includes businesses like Amap, DingTalk, Tmall Genie and others. In fiscal 2021, this segment generated RMB 4.8 billion in revenue, but also an operating loss.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0529c547e87a4c0b023289ecb1822cbc\" tg-width=\"640\" tg-height=\"478\"><span>(Source: Alibaba Q4/20 Presentation)</span></p>\n<p>When looking at the last annual results (fiscal 2021), Alibaba generated RMB 717.3 billion in revenue. Compared to fiscal 2020 (RMB 509.7 billion) this is reflecting an increase of 41%. Adjusted EBITDA in fiscal 2021 was RMB 196.8 billion – an increase of 25% compared to fiscal 2020 (adjusted EBITA of RMB 157.7 billion). Diluted earnings per share actually decreased from RMB 6.99 in fiscal 2020 to RMB 6.84 in fiscal 2021 – reflecting a decrease of 2.1%. But we should not pay too much attention to the earnings per share. Instead, it makes much more sense to look at the free cash flow Alibaba is generating. In fiscal 2021, Alibaba generated RMB 172.7 billion in free cash flow compared to RMB 130.9 billion in free cash flow one year earlier.</p>\n<p><b>Strong Business Among Strong Competitors</b></p>\n<p>What is striking when looking at Alibaba – and what has been discussed several times – is the low multiple for which Alibaba is currently trading. When using the trailing twelve-month GAAP numbers, Alibaba is trading for 25 times earnings, when using the non-GAAP forward numbers, it is trading for a P/E ratio of 20.</p>\n<p>We can compare Alibaba to its peers – companies like Amazon (AMZN), Tencent, Facebook (FB), Microsoft (MSFT) or Alphabet (GOOG). And Alibaba actually belongs in that list as it is not only operating in similar business segments, but it is also growing with similarly high rates. And Alibaba is not only growing with a similar pace; it is actually outperforming most of its peers.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b576dcef2e37a02a6eba5677fded8ef8\" tg-width=\"640\" tg-height=\"299\"><span>(Source:Alibaba 2020 Investor Presentations)</span></p>\n<p>While Alibaba is growing with a similar pace like these companies, it is trading for a completely different multiple. Right now, Alibaba is trading for a price-cash-flow ratio of 17, while competitors like Tencent, Facebook or Microsoft are trading for a P/FCF ratio between 35 and 40. It is striking, that the market is assigning these competitors a multiple twice as high and Amazon is actually trading for a multiple more than 4 times higher (price-free-cash-flow ratio of 76).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6d2f58771a8062c7bb980622b93073e5\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p>\n<p>Right now, readers might point out, that the comparison to Amazon is misleading as Amazon is still spending a lot of money to achieve future growth and therefore has a lower profit than other companies. And it certainly is true, that Amazon is still focusing on top line growth – sometimes at the expense of bottom-line growth – but so does Alibaba.</p>\n<p>While Amazon spent 10.4% of its revenue as capital expenditures in the last fiscal year, Alibaba spent almost the same amount – 8.9% of revenue. And when looking at the expenses for research and development, we once again see similar numbers. In the last five years, Amazon spent 12.16% of revenue on R&amp;D on average while Alibaba spent 10.38% of its revenue on R&amp;D.</p>\n<p>But while these numbers are quite similar for both companies – Amazon is spending a bit more on R&amp;D than Alibaba – the free cash flow these two companies can generate is completely different. While Amazon only generated 6.7% of revenue as free cash flow in the last fiscal year, Alibaba generated 26.5% of revenue as free cash flow in the last fiscal year – almost four times higher.</p>\n<p>And Alibaba is not only extremely profitable – it was growing with an extremely high pace in the past. During the past ten years, Alibaba could not only grow revenue every single year, it also grew revenue with a CAGR of 62.6%. Earnings per share fluctuated a little bit during these ten years but grew with an even higher pace – a CAGR of 76.29% during the last decade. And finally, free cash flow increased with a CAGR of 59.62% during the last decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d3ccaf170c0d86cd8022a68bc3657c30\" tg-width=\"640\" tg-height=\"404\"><span>(Source: Author’s work based on numbers from Morningstar)</span></p>\n<p>When looking at Alibaba’s growth rates in the last few years compared to its competitors, Alibaba is also outperforming. When looking at the revenue CAGR of the last 5 years, we get the following numbers:</p>\n<ul>\n <li>Amazon: 29.26%</li>\n <li>Facebook: 36.82%</li>\n <li>Tencent: 36.20%</li>\n <li>Alphabet: 19.47%</li>\n <li>Microsoft: 8.85%</li>\n <li>Alibaba: 46.24%</li>\n</ul>\n<p>We can spin it how we want: Alibaba is an extremely profitable company growing with extremely high rates but is trading at an extremely low multiple compared to its competitors. It is growing with a higher pace than Microsoft and Facebook, but trading for half the multiple. It is much more profitable than Amazon and also growing at a higher pace, but trading for a quarter of the valuation multiple. At this point, profitability and growth of Alibaba on the one side and the valuation multiple on the other side does not add up. And we have to ask the question, why Alibaba is trading for such a low multiple although it is outperforming many of its peers that trade for much higher multiples.</p>\n<p><b>Risks</b></p>\n<p>When looking at the past performance of Alibaba, we can see, that steep selloffs are quite common as a similar sell-off happened already three times since the IPO in 2014 with the steepest sell-off being more than 50% off the previous high.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4da83a08f0dcfc73534c206e43cb09d3\" tg-width=\"635\" tg-height=\"403\"><span>Data byYCharts</span></p>\n<p>While this might help us a bit, we are still facing high levels of uncertainty and investors usually don’t like uncertainty. Basically, this uncertainty can be summed up in one short sentence: The tense relationship between Alibaba’s founder Jack Ma and the Chinese government is worrying for investors. And this tense relationship is exemplified by several events. It started last year, when the IPO of the company’s fintech affiliate Ant Financial was cancelled. </p>\n<p>This was followed by theinitiation of an antitrust investigation, in which it is investigated if Alibaba had engaged in monopolistic practices (like preventing vendors from selling on other platforms). Additionally, new supervision for Ant Group was also discussed. And finally, at the end of 2020, Jack Ma went missing and it took about three months before the public would hear from him again – another worrying aspect for investors.</p>\n<p>As long as we are talking about risks, there are other aspect I like to mention. I compared Alibaba to Amazon above – and I still think that comparison is appropriate. But we also have to acknowledge, that Alibaba growth potential is limited as the company is mostly focused on China and might have more difficulties to expand globally – compared to Amazon. But considering the growing middle class in China and the high pace with which the economy is still growing we should not worry too much about Alibaba’s growth potential.</p>\n<p>There is a final risk Imentioned in my last article about Tencentand that risk is also applying to Alibaba:</p>\n<blockquote>\n And a final risk is the fact that Tencent is a Chinese company. It is especially difficult to understand different trends before they are happening and predict the future, but while I am familiar with the German culture and the people (habits, preferences, etc.) and can deal with similar countries like France, the United Kingdom, Sweden or the United States, it is rather difficult for me to understand and analyze the consumer behavior and preferences of the Chinese population. This makes it difficult to assess the potential and development of the products and services Tencent offers.\n</blockquote>\n<p>But despite all these issues, there is a comparison I like very much. Very recently,one of my fellow contributorscompared Alibaba’s situation right now to Facebook a few years ago, when it was facing the Cambridge Analytics scandal and also trading for extremely low multiples due to the uncertainties. And it is also interesting, that Wall Street analysts as well as Seeking Alpha contributors are extremely bullish about Alibaba right now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44d2ece5c1460e539c9fd4fb4ba63bf7\" tg-width=\"640\" tg-height=\"195\"><span>(Source:Seeking Alpha)</span></p>\n<p><b>Balance Sheet</b></p>\n<p>When facing challenges, it is especially reassuring if we are dealing with a solid balance sheet enabling the company to withstand challenges and stormy market conditions. And similar to many companies mentioned above – like Facebook or Alphabet – Alibaba also has a great balance sheet. We don’t have to worry about high debt levels although Alibaba has current bank borrowings of RMB 3.6 billion and non-current bank borrowings of RMB 38.3 billion on its balance sheet. But compared to a total equity of RMB 1,075 billion, we get a D/E ratio of 0.04, which is negligible. Aside from the debt, the biggest problem is probably the company’s goodwill. On March 31, 2021, Alibaba had RMB 292.8 billion in goodwill. This means, that 17.3% of total assets (RMB 1,690 billion) is goodwill.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/532919e61e3feb83d46cbce44e3f3c42\" tg-width=\"640\" tg-height=\"354\"><span>(Source:Alibaba Q4/21 Earnings Release)</span></p>\n<p>But aside from goodwill, Alibaba also has RMB 321.3 billion in cash and cash equivalents as well as RMB 152.4 billion in short-term investments on its balance sheet. Aside from these rather liquid assets, Alibaba also has RMB 237.2 billion in equity securities and other investments, that are also worth mentioning. I included a screenshot of the latest balance sheet, which is also including the numbers in US$. Especially $72 billion in very liquid assets give Alibaba a lot of “financial power” and the ability to negative troubles.</p>\n<p><b>Intrinsic Value Calculation</b></p>\n<p>I already mentioned above that Alibaba is trading at rather low multiples – at least when compared to its peers and especially for a company growing with a high pace. And compared to the company’s history, the stock is right now trading almost for its lowest P/FCF ratio since the IPO. A few times – in 2016, 2018 and 2020 – the stock was trading at a similar low P/FCF ratio. From that point of view, Alibaba has to be considered extremely cheap.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d1da4ac18557b21c43feb2a338de9a3b\" tg-width=\"640\" tg-height=\"221\"><span>(Source:Seeking Alpha Charting)</span></p>\n<p>When you are familiar with my past articles, you know that I don’t just use valuation multiples but also a discount cash flow analysis, which is considered to be much more precise (although we have to make a lot more assumptions). When taking the free cash flow of fiscal 2021 (RMB 172.7 billion) as basis, Alibaba has to grow about 5.5% annually from now till perpetuity for the stock to be fairly valued (the intrinsic value is RMB 1,367; discount rate 10%).</p>\n<p>Instead, we can also calculate with more realistic growth rates. If we assume, that Alibaba won’t go under, we have to assume at least 20% growth for the next year. Let’s be rather pessimistic and assume, that growth will slowly decline over the next decade and in 10 years from now, the growth rate will only be 6% till perpetuity. When using these numbers, we get an intrinsic value of&nbsp;<b>RMB 2,596</b>. And we have to assume, that these growth assumptions are rather cautious for a company like Alibaba.</p>\n<p><b>Conclusion</b></p>\n<p>So far, we talked about risks, about past growth rates, compared Alibaba to its peers and provided an intrinsic value calculation. I also wanted to write about the growth potential as well as the wide economic moat, that Alibaba has without any doubt – similar toAmazon,FacebookorTencent. But the article would probably be too long then. Instead, I included links to three articles in which I described the economic moat of these businesses.</p>\n<p>When summing up, it is quite simple. When we assume, that Alibaba is in serious trouble and might be brought down in some way or is facing troubles, that will seriously mess with the company’s ability to grow, we should not invest in Alibaba. These risks are present, and we actually don’t know what could happen in the coming quarters (or years). However, I consider it extremely unlikely, that China will destroy its second most-valuable company. If we assume on the other side, that this is just a small hick-up and troubles Alibaba can work through in the coming quarters and Alibaba will continue to perform in a similar way as in the past (even with growth rates slowing down), Alibaba is probably one of the most undervalued stocks out there and an extreme bargain.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba: One Of The Really Cheap Bargains In This Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba: One Of The Really Cheap Bargains In This Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 20:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4432358-alibaba-one-of-the-really-cheap-bargains-in-market><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAlibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.\nThe company is clearly facing risks due to the tension between Jack Ma and the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4432358-alibaba-one-of-the-really-cheap-bargains-in-market\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://seekingalpha.com/article/4432358-alibaba-one-of-the-really-cheap-bargains-in-market","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1138216687","content_text":"Summary\n\nAlibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.\nThe company is clearly facing risks due to the tension between Jack Ma and the Chinese government, but I consider these risks to be only temporary.\nAlibaba is growing with a high pace, has a very stable balance sheet and outperforming many of its peers.\nIn my opinion, the stock is severely undervalued.\n\nPhoto by maybefalse/iStock Unreleased via Getty Images\nSo far, I have published over 300 articles on this site and the focus has been clearly on companies having the headquarters in the United States and stocks listed on an US-based stock exchange. And while I am covering also companies from Germany, France, Great Britain, Sweden or Denmark, I have avoided one country almost completely although it has many interesting investment opportunities: Mainland China.The only company I covered so far is Tencent Holdings Limited (OTCPK:TCEHY).\nAnd although China has hundreds or thousands of successful companies, most of them are almost unknown in the Western Hemisphere (especially when moving outside of the investing world). And while most investors are familiar with Tencent, there is at least one other company almost every investor has heard of: Alibaba Group Holding Limited (BABA). In the following article, I will analyze Alibaba in my usual way. I will try to determine if Alibaba is a solid business with a wide economic moat and try to answer the question if Alibaba is a solid investment right now.\nBusiness Description\nAlibaba Group was founded in 1999 by 18 individuals. Nevertheless, one of these 18 stands out – the former English teacher from Hangzhou, Jack Ma. Over the years, Alibaba evolved in a multinational technology company and with a market capitalization of $570 billion, Alibaba is on the 10thspot on the list of most valuable companies in the world (by market cap). And behind Tencent, which is on the 7thspot on that list, Alibaba is the second most valuable company in China.\nWhile Alibaba is mostly focused on e-commerce and retail operations, the Alibaba Group is actually a holding company with many different sales services. This includes C2C services, B2C services and B2B services. Aside from retail, the Alibaba Group also offers electronic payment services, shipping search engines and could computing services. The group owns and operates a diverse portfolio of companies around the world in numerous business sectors.\n(Source:Alibaba Q4/20 Presentation)\nAlibaba is reporting in four different segments:\n\nCore Commerce Revenue: This segment is comprised of platforms operating in retail and wholesale commerce in China as well as logistics services and local consumer services. In fiscal 2021, this segment generated RMB 621.1 billion in revenue and RMB 159 billion in income from operations.\nCloud Computing Revenue: This segment is comprised of Alibaba Cloud, which offers different cloud services to customers worldwide like database, storage, big data analytics, a machine learning platform and large-scale computing security. In fiscal 2021, this segment generated RMB 60.1 billion, but the segment was not profitable so far (a loss of RMB 9 billion).\nDigital Media and Entertainment Revenue: This segment uses the deep data insights to serve the broader interests of consumers through key distribution platforms Youku and Alibaba Pictures as well as other content platforms that provide online videos, films, live events, literature and music. In fiscal 2021, this segment generated RMB 31.2 billion, but was also not profitable.\nInnovation Initiatives and Others Revenue: This segment includes businesses like Amap, DingTalk, Tmall Genie and others. In fiscal 2021, this segment generated RMB 4.8 billion in revenue, but also an operating loss.\n\n(Source: Alibaba Q4/20 Presentation)\nWhen looking at the last annual results (fiscal 2021), Alibaba generated RMB 717.3 billion in revenue. Compared to fiscal 2020 (RMB 509.7 billion) this is reflecting an increase of 41%. Adjusted EBITDA in fiscal 2021 was RMB 196.8 billion – an increase of 25% compared to fiscal 2020 (adjusted EBITA of RMB 157.7 billion). Diluted earnings per share actually decreased from RMB 6.99 in fiscal 2020 to RMB 6.84 in fiscal 2021 – reflecting a decrease of 2.1%. But we should not pay too much attention to the earnings per share. Instead, it makes much more sense to look at the free cash flow Alibaba is generating. In fiscal 2021, Alibaba generated RMB 172.7 billion in free cash flow compared to RMB 130.9 billion in free cash flow one year earlier.\nStrong Business Among Strong Competitors\nWhat is striking when looking at Alibaba – and what has been discussed several times – is the low multiple for which Alibaba is currently trading. When using the trailing twelve-month GAAP numbers, Alibaba is trading for 25 times earnings, when using the non-GAAP forward numbers, it is trading for a P/E ratio of 20.\nWe can compare Alibaba to its peers – companies like Amazon (AMZN), Tencent, Facebook (FB), Microsoft (MSFT) or Alphabet (GOOG). And Alibaba actually belongs in that list as it is not only operating in similar business segments, but it is also growing with similarly high rates. And Alibaba is not only growing with a similar pace; it is actually outperforming most of its peers.\n(Source:Alibaba 2020 Investor Presentations)\nWhile Alibaba is growing with a similar pace like these companies, it is trading for a completely different multiple. Right now, Alibaba is trading for a price-cash-flow ratio of 17, while competitors like Tencent, Facebook or Microsoft are trading for a P/FCF ratio between 35 and 40. It is striking, that the market is assigning these competitors a multiple twice as high and Amazon is actually trading for a multiple more than 4 times higher (price-free-cash-flow ratio of 76).\nData by YCharts\nRight now, readers might point out, that the comparison to Amazon is misleading as Amazon is still spending a lot of money to achieve future growth and therefore has a lower profit than other companies. And it certainly is true, that Amazon is still focusing on top line growth – sometimes at the expense of bottom-line growth – but so does Alibaba.\nWhile Amazon spent 10.4% of its revenue as capital expenditures in the last fiscal year, Alibaba spent almost the same amount – 8.9% of revenue. And when looking at the expenses for research and development, we once again see similar numbers. In the last five years, Amazon spent 12.16% of revenue on R&D on average while Alibaba spent 10.38% of its revenue on R&D.\nBut while these numbers are quite similar for both companies – Amazon is spending a bit more on R&D than Alibaba – the free cash flow these two companies can generate is completely different. While Amazon only generated 6.7% of revenue as free cash flow in the last fiscal year, Alibaba generated 26.5% of revenue as free cash flow in the last fiscal year – almost four times higher.\nAnd Alibaba is not only extremely profitable – it was growing with an extremely high pace in the past. During the past ten years, Alibaba could not only grow revenue every single year, it also grew revenue with a CAGR of 62.6%. Earnings per share fluctuated a little bit during these ten years but grew with an even higher pace – a CAGR of 76.29% during the last decade. And finally, free cash flow increased with a CAGR of 59.62% during the last decade.\n(Source: Author’s work based on numbers from Morningstar)\nWhen looking at Alibaba’s growth rates in the last few years compared to its competitors, Alibaba is also outperforming. When looking at the revenue CAGR of the last 5 years, we get the following numbers:\n\nAmazon: 29.26%\nFacebook: 36.82%\nTencent: 36.20%\nAlphabet: 19.47%\nMicrosoft: 8.85%\nAlibaba: 46.24%\n\nWe can spin it how we want: Alibaba is an extremely profitable company growing with extremely high rates but is trading at an extremely low multiple compared to its competitors. It is growing with a higher pace than Microsoft and Facebook, but trading for half the multiple. It is much more profitable than Amazon and also growing at a higher pace, but trading for a quarter of the valuation multiple. At this point, profitability and growth of Alibaba on the one side and the valuation multiple on the other side does not add up. And we have to ask the question, why Alibaba is trading for such a low multiple although it is outperforming many of its peers that trade for much higher multiples.\nRisks\nWhen looking at the past performance of Alibaba, we can see, that steep selloffs are quite common as a similar sell-off happened already three times since the IPO in 2014 with the steepest sell-off being more than 50% off the previous high.\nData byYCharts\nWhile this might help us a bit, we are still facing high levels of uncertainty and investors usually don’t like uncertainty. Basically, this uncertainty can be summed up in one short sentence: The tense relationship between Alibaba’s founder Jack Ma and the Chinese government is worrying for investors. And this tense relationship is exemplified by several events. It started last year, when the IPO of the company’s fintech affiliate Ant Financial was cancelled. \nThis was followed by theinitiation of an antitrust investigation, in which it is investigated if Alibaba had engaged in monopolistic practices (like preventing vendors from selling on other platforms). Additionally, new supervision for Ant Group was also discussed. And finally, at the end of 2020, Jack Ma went missing and it took about three months before the public would hear from him again – another worrying aspect for investors.\nAs long as we are talking about risks, there are other aspect I like to mention. I compared Alibaba to Amazon above – and I still think that comparison is appropriate. But we also have to acknowledge, that Alibaba growth potential is limited as the company is mostly focused on China and might have more difficulties to expand globally – compared to Amazon. But considering the growing middle class in China and the high pace with which the economy is still growing we should not worry too much about Alibaba’s growth potential.\nThere is a final risk Imentioned in my last article about Tencentand that risk is also applying to Alibaba:\n\n And a final risk is the fact that Tencent is a Chinese company. It is especially difficult to understand different trends before they are happening and predict the future, but while I am familiar with the German culture and the people (habits, preferences, etc.) and can deal with similar countries like France, the United Kingdom, Sweden or the United States, it is rather difficult for me to understand and analyze the consumer behavior and preferences of the Chinese population. This makes it difficult to assess the potential and development of the products and services Tencent offers.\n\nBut despite all these issues, there is a comparison I like very much. Very recently,one of my fellow contributorscompared Alibaba’s situation right now to Facebook a few years ago, when it was facing the Cambridge Analytics scandal and also trading for extremely low multiples due to the uncertainties. And it is also interesting, that Wall Street analysts as well as Seeking Alpha contributors are extremely bullish about Alibaba right now.\n(Source:Seeking Alpha)\nBalance Sheet\nWhen facing challenges, it is especially reassuring if we are dealing with a solid balance sheet enabling the company to withstand challenges and stormy market conditions. And similar to many companies mentioned above – like Facebook or Alphabet – Alibaba also has a great balance sheet. We don’t have to worry about high debt levels although Alibaba has current bank borrowings of RMB 3.6 billion and non-current bank borrowings of RMB 38.3 billion on its balance sheet. But compared to a total equity of RMB 1,075 billion, we get a D/E ratio of 0.04, which is negligible. Aside from the debt, the biggest problem is probably the company’s goodwill. On March 31, 2021, Alibaba had RMB 292.8 billion in goodwill. This means, that 17.3% of total assets (RMB 1,690 billion) is goodwill.\n(Source:Alibaba Q4/21 Earnings Release)\nBut aside from goodwill, Alibaba also has RMB 321.3 billion in cash and cash equivalents as well as RMB 152.4 billion in short-term investments on its balance sheet. Aside from these rather liquid assets, Alibaba also has RMB 237.2 billion in equity securities and other investments, that are also worth mentioning. I included a screenshot of the latest balance sheet, which is also including the numbers in US$. Especially $72 billion in very liquid assets give Alibaba a lot of “financial power” and the ability to negative troubles.\nIntrinsic Value Calculation\nI already mentioned above that Alibaba is trading at rather low multiples – at least when compared to its peers and especially for a company growing with a high pace. And compared to the company’s history, the stock is right now trading almost for its lowest P/FCF ratio since the IPO. A few times – in 2016, 2018 and 2020 – the stock was trading at a similar low P/FCF ratio. From that point of view, Alibaba has to be considered extremely cheap.\n(Source:Seeking Alpha Charting)\nWhen you are familiar with my past articles, you know that I don’t just use valuation multiples but also a discount cash flow analysis, which is considered to be much more precise (although we have to make a lot more assumptions). When taking the free cash flow of fiscal 2021 (RMB 172.7 billion) as basis, Alibaba has to grow about 5.5% annually from now till perpetuity for the stock to be fairly valued (the intrinsic value is RMB 1,367; discount rate 10%).\nInstead, we can also calculate with more realistic growth rates. If we assume, that Alibaba won’t go under, we have to assume at least 20% growth for the next year. Let’s be rather pessimistic and assume, that growth will slowly decline over the next decade and in 10 years from now, the growth rate will only be 6% till perpetuity. When using these numbers, we get an intrinsic value of RMB 2,596. And we have to assume, that these growth assumptions are rather cautious for a company like Alibaba.\nConclusion\nSo far, we talked about risks, about past growth rates, compared Alibaba to its peers and provided an intrinsic value calculation. I also wanted to write about the growth potential as well as the wide economic moat, that Alibaba has without any doubt – similar toAmazon,FacebookorTencent. But the article would probably be too long then. Instead, I included links to three articles in which I described the economic moat of these businesses.\nWhen summing up, it is quite simple. When we assume, that Alibaba is in serious trouble and might be brought down in some way or is facing troubles, that will seriously mess with the company’s ability to grow, we should not invest in Alibaba. These risks are present, and we actually don’t know what could happen in the coming quarters (or years). However, I consider it extremely unlikely, that China will destroy its second most-valuable company. If we assume on the other side, that this is just a small hick-up and troubles Alibaba can work through in the coming quarters and Alibaba will continue to perform in a similar way as in the past (even with growth rates slowing down), Alibaba is probably one of the most undervalued stocks out there and an extreme bargain.","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":137222802,"gmtCreate":1622352887006,"gmtModify":1704183385009,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>What is the right way to value Moderna? What is it forecast PE at current level?","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>What is the right way to value Moderna? What is it forecast PE at current level?","text":"$Moderna, Inc.(MRNA)$What is the right way to value Moderna? What is it forecast PE at current level?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/137222802","isVote":1,"tweetType":1,"viewCount":278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132442471,"gmtCreate":1622110404093,"gmtModify":1704179642436,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"What is the fair value for Moderna?","listText":"What is the fair value for Moderna?","text":"What is the fair value for Moderna?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132442471","isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":805317160,"gmtCreate":1627860853050,"gmtModify":1703496570444,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Nice! No issue on chip shortage?","listText":"Nice! No issue on chip shortage?","text":"Nice! No issue on chip shortage?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/805317160","repostId":"1154563656","repostType":2,"repost":{"id":"1154563656","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627858903,"share":"https://ttm.financial/m/news/1154563656?lang=&edition=fundamental","pubTime":"2021-08-02 07:01","market":"us","language":"en","title":"Xpeng Motors delivered 8,040 vehicles in July 2021,a record month with a 228% increase YOY","url":"https://stock-news.laohu8.com/highlight/detail?id=1154563656","media":"Tiger Newspress","summary":"XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month.8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year. 6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch. 38,778 total vehicles delivered year-to-date, a 388% increase year-over-year. Deliveries in July 2021 consisted of 6,054 ","content":"<p>XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month. </p>\n<ul>\n <li>8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year </li>\n</ul>\n<ul>\n <li>6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch </li>\n</ul>\n<ul>\n <li>38,778 total vehicles delivered year-to-date, a 388% increase year-over-year </li>\n</ul>\n<p>Deliveries in July 2021 consisted of 6,054 P7s, the Company’s sports smart sedan, and 1,986 G3s, its smart compact SUV. </p>\n<p>As of 31 July 2021, year-to-date total deliveries of the Company reached 38,778 units, representing a 388% increase year-over-year. </p>\n<p>P7 deliveries continued record-breaking momentum in July 2021, reflecting the P7’s rising popularity among China’s tech-savvy consumers. In July 2021, at its first-year anniversary of customer deliveries, total P7 deliveries reach 40,612 since the launch. The P7’s Navigation Guided Pilot (NGP) highway solutions continuously increase appeal to a wider customer base, underpinning the Company’s commitment to technology innovation. </p>\n<p>The Company further expanded its product portfolio in July 2021, launching the G3i, the G3 SUV’s mid-phase facelift version with deliveries expected in September 2021. </p>\n<p>In July 2021, the Company announced the pre-sale price range of RMB160,000–RMB230,000 (post subsidies) for its third production model, the P5 family-friendly smart sedan. Being the world’s first mass-produced Smart EV equipped with auto-grade LiDAR technology, the P5 is already generating an enthusiastic response from consumers in the presale phase. The Company plans to launch the P5 in the third quarter 2021 with deliveries expected in the fourth quarter 2021.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xpeng Motors delivered 8,040 vehicles in July 2021,a record month with a 228% increase YOY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXpeng Motors delivered 8,040 vehicles in July 2021,a record month with a 228% increase YOY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-02 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month. </p>\n<ul>\n <li>8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year </li>\n</ul>\n<ul>\n <li>6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch </li>\n</ul>\n<ul>\n <li>38,778 total vehicles delivered year-to-date, a 388% increase year-over-year </li>\n</ul>\n<p>Deliveries in July 2021 consisted of 6,054 P7s, the Company’s sports smart sedan, and 1,986 G3s, its smart compact SUV. </p>\n<p>As of 31 July 2021, year-to-date total deliveries of the Company reached 38,778 units, representing a 388% increase year-over-year. </p>\n<p>P7 deliveries continued record-breaking momentum in July 2021, reflecting the P7’s rising popularity among China’s tech-savvy consumers. In July 2021, at its first-year anniversary of customer deliveries, total P7 deliveries reach 40,612 since the launch. The P7’s Navigation Guided Pilot (NGP) highway solutions continuously increase appeal to a wider customer base, underpinning the Company’s commitment to technology innovation. </p>\n<p>The Company further expanded its product portfolio in July 2021, launching the G3i, the G3 SUV’s mid-phase facelift version with deliveries expected in September 2021. </p>\n<p>In July 2021, the Company announced the pre-sale price range of RMB160,000–RMB230,000 (post subsidies) for its third production model, the P5 family-friendly smart sedan. Being the world’s first mass-produced Smart EV equipped with auto-grade LiDAR technology, the P5 is already generating an enthusiastic response from consumers in the presale phase. The Company plans to launch the P5 in the third quarter 2021 with deliveries expected in the fourth quarter 2021.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","09868":"小鹏汽车-W"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154563656","content_text":"XPeng Inc. announced that the Company recorded its highest-ever monthly deliveries in July 2021 of 8,040 Smart EVs, representing a 228% increase year-over-year, and a 22% increase over the last month. \n\n8,040 vehicles delivered in July 2021, a record month with a 228% increase year-over-year \n\n\n6,054 P7s delivered in July 2021, the highest monthly deliveries since the P7’s launch \n\n\n38,778 total vehicles delivered year-to-date, a 388% increase year-over-year \n\nDeliveries in July 2021 consisted of 6,054 P7s, the Company’s sports smart sedan, and 1,986 G3s, its smart compact SUV. \nAs of 31 July 2021, year-to-date total deliveries of the Company reached 38,778 units, representing a 388% increase year-over-year. \nP7 deliveries continued record-breaking momentum in July 2021, reflecting the P7’s rising popularity among China’s tech-savvy consumers. In July 2021, at its first-year anniversary of customer deliveries, total P7 deliveries reach 40,612 since the launch. The P7’s Navigation Guided Pilot (NGP) highway solutions continuously increase appeal to a wider customer base, underpinning the Company’s commitment to technology innovation. \nThe Company further expanded its product portfolio in July 2021, launching the G3i, the G3 SUV’s mid-phase facelift version with deliveries expected in September 2021. \nIn July 2021, the Company announced the pre-sale price range of RMB160,000–RMB230,000 (post subsidies) for its third production model, the P5 family-friendly smart sedan. Being the world’s first mass-produced Smart EV equipped with auto-grade LiDAR technology, the P5 is already generating an enthusiastic response from consumers in the presale phase. The Company plans to launch the P5 in the third quarter 2021 with deliveries expected in the fourth quarter 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":337,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3569320299762451","authorId":"3569320299762451","name":"DreamyLucid","avatar":"https://community-static.tradeup.com/news/df94d831afbfa80ddda11b9d4ff73cf1","crmLevel":1,"crmLevelSwitch":0,"idStr":"3569320299762451","authorIdStr":"3569320299762451"},"content":"No. They do not have that problem.","text":"No. They do not have that problem.","html":"No. They do not have that problem."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170961517,"gmtCreate":1626400056239,"gmtModify":1703759395732,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"How many would be keen given the latest delay by Grab to list by SPAC as a result of accounting issues?","listText":"How many would be keen given the latest delay by Grab to list by SPAC as a result of accounting issues?","text":"How many would be keen given the latest delay by Grab to list by SPAC as a result of accounting issues?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/170961517","repostId":"1177508529","repostType":4,"repost":{"id":"1177508529","kind":"news","pubTimestamp":1626399640,"share":"https://ttm.financial/m/news/1177508529?lang=&edition=fundamental","pubTime":"2021-07-16 09:40","market":"sg","language":"en","title":"SPACs are targeting Southeast Asia’s start-ups and investors are taking note","url":"https://stock-news.laohu8.com/highlight/detail?id=1177508529","media":"cnbc","summary":"KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region","content":"<div>\n<p>KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SPACs are targeting Southeast Asia’s start-ups and investors are taking note</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSPACs are targeting Southeast Asia’s start-ups and investors are taking note\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 09:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.cnbc.com/2021/07/16/spacs-are-targeting-southeast-asias-start-ups-and-investors-are-taking-note.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1177508529","content_text":"KEY POINTS\n\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate Ventures.\nOther late-stage investors, including private equity players, are taking note and writing large checks in the region, he said.\nSPACs are shell companies set up to raise money through an IPO, with the sole purpose of merging with or acquiring an existing private company and taking it public.\n\nSINGAPORE — Southeast Asia’s late-stage start-ups are attracting growing interest from blank-check companies that want to take them public, a venture investor told CNBC.\nMore than 40 SPACs — or special purpose acquisition companies — are targeting the region, according to Vinnie Lauria, managing partner at early-stage venture capital firm Golden Gate Ventures.\n“SPACs have really put ASEAN on the map,” Lauria said Thursday on CNBC’s “Street Signs Asia,” referring to Southeast Asia’s economic bloc comprising 10 member states. Other late-stage investors, includingprivate equity players, are taking note and writing large checks in the region, he said.\n“The next decade is going to be a very competitive decade for CEOs. You are going to have to scale from 5 to 5,000 much quicker, to be more competitive, (and for) more money,” Lauria said.\nSPACs are shell companiesset up to raise money through an initial public offering, with the sole purpose of merging with or acquiring an existing private company and taking it public.\nFundraising in SEA\nSoutheast Asia’s start-ups reportedly raiseda record $6 billion in the first three months of the year, including anover $2 billion funding roundby logistics and courier service company J&T Express. Last month, Singapore-based start-up Carro, which operates an online marketplace predominantly for pre-owned cars,snagged $360 million in fresh funds.\nThe more established names in the region are preparing to list in public markets. Ride-hailing giantGrab announced in April that it would go public through a SPAC merger valued at $39.6 billion, one of the largest ever blank-check deal. The newly merged Indonesian tech giant, GoTo Group, isalso planning to go public soon.\nLauria told CNBC that a number of Golden Gate’s portfolio companies have been approached by SPACs, and that many of them have said they are not yet ready to go public as being a private firm has its advantages.\n“For a lot of our companies, they see (going public) as something one, two, or three years away. So they’re not just automatically jumping on a SPAC,” Lauria said. “When they are ready to go public, whether that’s a SPAC or traditional IPO, they will be making that call.”\nOnline classifieds business Carousell — one of Golden Gate’s portfolio names — isreportedly exploring listing options via the SPAC route.\nTrends\nGolden Gate said in a report released Thursday that by 2030, the number of IPOs in Southeast Asia will cross 300 as more local start-ups seek to list in domestic public markets. The venture firm expects a rise in medical technology start-ups, as well as for social commerce to dominate online transactions.\nAs the coronavirus pandemic pushed manyphysical business transactions online, Lauria pointed out that tech firms in areas such as food delivery, telemedicine, e-commerce and financial technology have seen strong growth. That trend is expected to continue in the near future.\nSoutheast Asia is home to some400 million internet users and 10% of them went online for the first time in 2020. The internet economy in Singapore, Malaysia, Indonesia, the Philippines, Vietnam and Thailand — the largest economies in the region — is predicted to cross $300 billion by 2025, according to a report last year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":174,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3585873168332779","authorId":"3585873168332779","name":"ilovekirby","avatar":"https://static.tigerbbs.com/150e39396270b3385fcaa9d5b241a4e1","crmLevel":4,"crmLevelSwitch":0,"idStr":"3585873168332779","authorIdStr":"3585873168332779"},"content":"Well Grab is also considering secondary listing in Singapore, which may not be a bad thing if investors are concerned about the listing in US.","text":"Well Grab is also considering secondary listing in Singapore, which may not be a bad thing if investors are concerned about the listing in US.","html":"Well Grab is also considering secondary listing in Singapore, which may not be a bad thing if investors are concerned about the listing in US."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132848790,"gmtCreate":1622081813310,"gmtModify":1704179093923,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"My bet is on AMD","listText":"My bet is on AMD","text":"My bet is on AMD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132848790","repostId":"2138149680","repostType":2,"repost":{"id":"2138149680","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1622074620,"share":"https://ttm.financial/m/news/2138149680?lang=&edition=fundamental","pubTime":"2021-05-27 08:17","market":"hk","language":"en","title":"Intel vs. AMD -- should you buy either stock now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2138149680","media":"Dow Jones","summary":"AMD has been an outperformer for years, but Intel is still a dominant presence.Despite its woes, Int","content":"<p>AMD has been an outperformer for years, but Intel is still a dominant presence.</p><p>Despite its woes, Intel Corp. remains the largest provider of core processors for \"x86\" PCs and servers. Its smaller rival for decades has been Advanced Micro Devices Inc. , which has made big strides in the past few years under CEO Lisa Su.</p><p>PC manufacturers and users have their preferences. For investors, Advanced Micro Devices <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> has been the clear winner. But Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> has a tremendous R&amp;D budget, has been an excellent cash-flow grower and has enjoyed decades of dominance in its main area of business.</p><p><b>Where Intel and AMD fit in</b></p><p>\"Intel is the main supplier of x86 processors and the dominant supplier of x86 server CPUs for data center applications,\" according to Dean McCarron, president of Mercury Research, a provider of PC industry data. Most PCs using x86 processors run Microsoft Corp.'s <a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a> Windows operating system.</p><p>Mercury Research provides market-share data based on unit shipments. Here is its worldwide breakdown for overall x86 CPU market share for the first quarter, with comparisons to the previous and year-earlier quarters:</p><p>Intel remains the leader, but you can see that for the first quarter, AMD's market share increased tremendously from a year earlier. Then again, AMD's first-quarter share was down a bit from the previous quarter.</p><p>For graphics processing units (GPUs), AMD competes with Nvidia Corp. <a href=\"https://laohu8.com/S/NVDA\">$(NVDA)$</a>.</p><p>\"In the conventional graphics market, Nvidia is dominant, but AMD is also respectably large,\" McCarron said.</p><p>According to Mercury Research, Nvidia's share in the conventional GPU market was 81%, with a 19% market share for AMD in the fourth quarter (the most recent for which unit sales data is available).</p><p>Competition for data-center GPUs is expected to heat up. Again, Nvidia dominates, as AMD's market share is less than 10%, according to McCarron. But Intel is expected to begin shipping its own data-center GPUs, code-named Ponte Vecchio, in the fourth quarter or early in 2022.</p><p><b>Key metrics</b></p><p><b>1、Size and sales</b></p><p>Here are the companies' sizes by market capitalization and sales, with all figures in millions:</p><p>These numbers are fascinating, as they show how much more the stock market values AMD relative to sales. If we divide AMD's current market cap by first-quarter sales (annualized), we have a price-to-sales ratio of 6.9, against 2.9 for Intel.</p><p>The next chart will help explain why.</p><p><b>2、Sales growth and profitability</b></p><p>Here's a look at both companies' sales growth for the first quarter from the year-earlier quarter, along with gross margins and operating margins.</p><p>Here AMD is the big winner, with first-quarter sales nearly doubling from a year earlier. The overall market is growing and both companies' sales are increasing, but AMD is giving investors what they want.</p><p>A company's gross margin is its net sales, less the cost of goods or services sold, divided by sales. Net sales exclude returns and discounts. The cost of goods or services sold includes the actual costs for making the items sold or providing the services sold. It doesn't reflect other overhead expenses. It is a useful measurement of pricing power, and a combination of high sales growth and improved gross margin is a good sign.</p><p>Intel's first-quarter gross margin narrowed, while AMD's widened.</p><p>A company's operating margin is its earnings before interest, taxes and depreciation divided by net sales. It can be considered \"return on sales.\"</p><p>When comparing the first quarter of 2021 with the year-earlier quarter, you can see a significant narrowing of Intel's operating margin and improvement for AMD's operating margin.</p><p>One advantage of Intel under CEO Pat Gelsinger, who took up his new position in February, is that Intel can spend so much more on research and development. During the first quarter, Intel spent $3.62 billion on R&amp;D, while AMD spent $610 million.</p><p>You can read more about Gelsinger's strategy and challenges here .</p><p><b>3、Free cash flow</b></p><p>A company's free cash flow <a href=\"https://laohu8.com/S/FCF\">$(FCF)$</a> is its remaining cash flow after planned capital expenditures. A company's free cash flow yield can be calculated by dividing the past 12 months' free cash flow per share by the current share price.</p><p>This chart shows both companies have grown free cash flow over the past three full years, and that Intel has a much higher FCF yield than AMD:</p><p>Intel's FCF yield of 8.11% shows the company has plenty of \"headroom\" above its current dividend yield, which is 2.44%. (AMD doesn't pay a dividend.) So Intel is better-positioned than AMD to deploy more cash through expansion, share buybacks or dividend increases.</p><p>Intel made both the three- and five-year lists of free-cash-flow compounders, which you can see here .</p><p><b>4、Stock valuation and performance</b></p><p>Here are forward price-to-earnings ratios based on consensus earnings estimates for the next 12 months among analysts polled by FactSet, along with total return figures:</p><p>Intel has shined this year, as AMD has pulled back. Intel is also far cheaper when you look at forward price-to-earnings ratios. Those are based on current share prices and consensus earnings estimates for the next 12 months among analysts polled by FactSet. In comparison, forward P/Es are 21.5 for the S&amp;P 500 Index , 27 for the Invesco QQQ Trust <a href=\"https://laohu8.com/S/QQQ\">$(QQQ)$</a> (which tracks the Nasdaq-100 Index) and 20.3 for the <a href=\"https://laohu8.com/S/EEME\">iShares</a> PHLX Semiconductor ETF <a href=\"https://laohu8.com/S/SOXX\">$(SOXX)$</a>.</p><p>If you review longer periods, AMD has been the clear outperformer, until you look at the 15-year figures.</p><p>These companies have been competing for the PC CPU market for decades. Here's a 20-year total-return chart:</p><p><b>And 30 years:</b></p><p>You can see from the 20- and 30-year charts that these rivals and swung back and forth in the eyes of investors repeatedly.</p><p><b>Wall Street's opinion</b></p><p>AMD is the favorite among analysts at brokerage firms, who expect great things for the stock over the next 12 months:</p><p>So there you have a clear contrast -- AMD is the up-and-comer, and it has been that way for decades. Intel's stock is cheaply priced to expected earnings, the company has a new CEO with a new strategy and is trying to move into new areas. Competition for Intel and AMD with Nvidia in the data-center space will be hot -- it is a story that will take years to unfold.</p><p>Intel has been a tremendous free-cash-flow grower over the long term, as you can see here . AMD is growing very quickly.</p><p>So maybe each stock is for a different type of investor. Or maybe investors should consider holding both.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel vs. AMD -- should you buy either stock now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel vs. AMD -- should you buy either stock now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-05-27 08:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMD has been an outperformer for years, but Intel is still a dominant presence.</p><p>Despite its woes, Intel Corp. remains the largest provider of core processors for \"x86\" PCs and servers. Its smaller rival for decades has been Advanced Micro Devices Inc. , which has made big strides in the past few years under CEO Lisa Su.</p><p>PC manufacturers and users have their preferences. For investors, Advanced Micro Devices <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a> has been the clear winner. But Intel <a href=\"https://laohu8.com/S/INTC\">$(INTC)$</a> has a tremendous R&amp;D budget, has been an excellent cash-flow grower and has enjoyed decades of dominance in its main area of business.</p><p><b>Where Intel and AMD fit in</b></p><p>\"Intel is the main supplier of x86 processors and the dominant supplier of x86 server CPUs for data center applications,\" according to Dean McCarron, president of Mercury Research, a provider of PC industry data. Most PCs using x86 processors run Microsoft Corp.'s <a href=\"https://laohu8.com/S/MSFT\">$(MSFT)$</a> Windows operating system.</p><p>Mercury Research provides market-share data based on unit shipments. Here is its worldwide breakdown for overall x86 CPU market share for the first quarter, with comparisons to the previous and year-earlier quarters:</p><p>Intel remains the leader, but you can see that for the first quarter, AMD's market share increased tremendously from a year earlier. Then again, AMD's first-quarter share was down a bit from the previous quarter.</p><p>For graphics processing units (GPUs), AMD competes with Nvidia Corp. <a href=\"https://laohu8.com/S/NVDA\">$(NVDA)$</a>.</p><p>\"In the conventional graphics market, Nvidia is dominant, but AMD is also respectably large,\" McCarron said.</p><p>According to Mercury Research, Nvidia's share in the conventional GPU market was 81%, with a 19% market share for AMD in the fourth quarter (the most recent for which unit sales data is available).</p><p>Competition for data-center GPUs is expected to heat up. Again, Nvidia dominates, as AMD's market share is less than 10%, according to McCarron. But Intel is expected to begin shipping its own data-center GPUs, code-named Ponte Vecchio, in the fourth quarter or early in 2022.</p><p><b>Key metrics</b></p><p><b>1、Size and sales</b></p><p>Here are the companies' sizes by market capitalization and sales, with all figures in millions:</p><p>These numbers are fascinating, as they show how much more the stock market values AMD relative to sales. If we divide AMD's current market cap by first-quarter sales (annualized), we have a price-to-sales ratio of 6.9, against 2.9 for Intel.</p><p>The next chart will help explain why.</p><p><b>2、Sales growth and profitability</b></p><p>Here's a look at both companies' sales growth for the first quarter from the year-earlier quarter, along with gross margins and operating margins.</p><p>Here AMD is the big winner, with first-quarter sales nearly doubling from a year earlier. The overall market is growing and both companies' sales are increasing, but AMD is giving investors what they want.</p><p>A company's gross margin is its net sales, less the cost of goods or services sold, divided by sales. Net sales exclude returns and discounts. The cost of goods or services sold includes the actual costs for making the items sold or providing the services sold. It doesn't reflect other overhead expenses. It is a useful measurement of pricing power, and a combination of high sales growth and improved gross margin is a good sign.</p><p>Intel's first-quarter gross margin narrowed, while AMD's widened.</p><p>A company's operating margin is its earnings before interest, taxes and depreciation divided by net sales. It can be considered \"return on sales.\"</p><p>When comparing the first quarter of 2021 with the year-earlier quarter, you can see a significant narrowing of Intel's operating margin and improvement for AMD's operating margin.</p><p>One advantage of Intel under CEO Pat Gelsinger, who took up his new position in February, is that Intel can spend so much more on research and development. During the first quarter, Intel spent $3.62 billion on R&amp;D, while AMD spent $610 million.</p><p>You can read more about Gelsinger's strategy and challenges here .</p><p><b>3、Free cash flow</b></p><p>A company's free cash flow <a href=\"https://laohu8.com/S/FCF\">$(FCF)$</a> is its remaining cash flow after planned capital expenditures. A company's free cash flow yield can be calculated by dividing the past 12 months' free cash flow per share by the current share price.</p><p>This chart shows both companies have grown free cash flow over the past three full years, and that Intel has a much higher FCF yield than AMD:</p><p>Intel's FCF yield of 8.11% shows the company has plenty of \"headroom\" above its current dividend yield, which is 2.44%. (AMD doesn't pay a dividend.) So Intel is better-positioned than AMD to deploy more cash through expansion, share buybacks or dividend increases.</p><p>Intel made both the three- and five-year lists of free-cash-flow compounders, which you can see here .</p><p><b>4、Stock valuation and performance</b></p><p>Here are forward price-to-earnings ratios based on consensus earnings estimates for the next 12 months among analysts polled by FactSet, along with total return figures:</p><p>Intel has shined this year, as AMD has pulled back. Intel is also far cheaper when you look at forward price-to-earnings ratios. Those are based on current share prices and consensus earnings estimates for the next 12 months among analysts polled by FactSet. In comparison, forward P/Es are 21.5 for the S&amp;P 500 Index , 27 for the Invesco QQQ Trust <a href=\"https://laohu8.com/S/QQQ\">$(QQQ)$</a> (which tracks the Nasdaq-100 Index) and 20.3 for the <a href=\"https://laohu8.com/S/EEME\">iShares</a> PHLX Semiconductor ETF <a href=\"https://laohu8.com/S/SOXX\">$(SOXX)$</a>.</p><p>If you review longer periods, AMD has been the clear outperformer, until you look at the 15-year figures.</p><p>These companies have been competing for the PC CPU market for decades. Here's a 20-year total-return chart:</p><p><b>And 30 years:</b></p><p>You can see from the 20- and 30-year charts that these rivals and swung back and forth in the eyes of investors repeatedly.</p><p><b>Wall Street's opinion</b></p><p>AMD is the favorite among analysts at brokerage firms, who expect great things for the stock over the next 12 months:</p><p>So there you have a clear contrast -- AMD is the up-and-comer, and it has been that way for decades. Intel's stock is cheaply priced to expected earnings, the company has a new CEO with a new strategy and is trying to move into new areas. Competition for Intel and AMD with Nvidia in the data-center space will be hot -- it is a story that will take years to unfold.</p><p>Intel has been a tremendous free-cash-flow grower over the long term, as you can see here . AMD is growing very quickly.</p><p>So maybe each stock is for a different type of investor. Or maybe investors should consider holding both.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","09086":"华夏纳指-U","INTC":"英特尔","03086":"华夏纳指","NVDA":"英伟达","SOXX":"iShares费城交易所半导体ETF","AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138149680","content_text":"AMD has been an outperformer for years, but Intel is still a dominant presence.Despite its woes, Intel Corp. remains the largest provider of core processors for \"x86\" PCs and servers. Its smaller rival for decades has been Advanced Micro Devices Inc. , which has made big strides in the past few years under CEO Lisa Su.PC manufacturers and users have their preferences. For investors, Advanced Micro Devices $(AMD)$ has been the clear winner. But Intel $(INTC)$ has a tremendous R&D budget, has been an excellent cash-flow grower and has enjoyed decades of dominance in its main area of business.Where Intel and AMD fit in\"Intel is the main supplier of x86 processors and the dominant supplier of x86 server CPUs for data center applications,\" according to Dean McCarron, president of Mercury Research, a provider of PC industry data. Most PCs using x86 processors run Microsoft Corp.'s $(MSFT)$ Windows operating system.Mercury Research provides market-share data based on unit shipments. Here is its worldwide breakdown for overall x86 CPU market share for the first quarter, with comparisons to the previous and year-earlier quarters:Intel remains the leader, but you can see that for the first quarter, AMD's market share increased tremendously from a year earlier. Then again, AMD's first-quarter share was down a bit from the previous quarter.For graphics processing units (GPUs), AMD competes with Nvidia Corp. $(NVDA)$.\"In the conventional graphics market, Nvidia is dominant, but AMD is also respectably large,\" McCarron said.According to Mercury Research, Nvidia's share in the conventional GPU market was 81%, with a 19% market share for AMD in the fourth quarter (the most recent for which unit sales data is available).Competition for data-center GPUs is expected to heat up. Again, Nvidia dominates, as AMD's market share is less than 10%, according to McCarron. But Intel is expected to begin shipping its own data-center GPUs, code-named Ponte Vecchio, in the fourth quarter or early in 2022.Key metrics1、Size and salesHere are the companies' sizes by market capitalization and sales, with all figures in millions:These numbers are fascinating, as they show how much more the stock market values AMD relative to sales. If we divide AMD's current market cap by first-quarter sales (annualized), we have a price-to-sales ratio of 6.9, against 2.9 for Intel.The next chart will help explain why.2、Sales growth and profitabilityHere's a look at both companies' sales growth for the first quarter from the year-earlier quarter, along with gross margins and operating margins.Here AMD is the big winner, with first-quarter sales nearly doubling from a year earlier. The overall market is growing and both companies' sales are increasing, but AMD is giving investors what they want.A company's gross margin is its net sales, less the cost of goods or services sold, divided by sales. Net sales exclude returns and discounts. The cost of goods or services sold includes the actual costs for making the items sold or providing the services sold. It doesn't reflect other overhead expenses. It is a useful measurement of pricing power, and a combination of high sales growth and improved gross margin is a good sign.Intel's first-quarter gross margin narrowed, while AMD's widened.A company's operating margin is its earnings before interest, taxes and depreciation divided by net sales. It can be considered \"return on sales.\"When comparing the first quarter of 2021 with the year-earlier quarter, you can see a significant narrowing of Intel's operating margin and improvement for AMD's operating margin.One advantage of Intel under CEO Pat Gelsinger, who took up his new position in February, is that Intel can spend so much more on research and development. During the first quarter, Intel spent $3.62 billion on R&D, while AMD spent $610 million.You can read more about Gelsinger's strategy and challenges here .3、Free cash flowA company's free cash flow $(FCF)$ is its remaining cash flow after planned capital expenditures. A company's free cash flow yield can be calculated by dividing the past 12 months' free cash flow per share by the current share price.This chart shows both companies have grown free cash flow over the past three full years, and that Intel has a much higher FCF yield than AMD:Intel's FCF yield of 8.11% shows the company has plenty of \"headroom\" above its current dividend yield, which is 2.44%. (AMD doesn't pay a dividend.) So Intel is better-positioned than AMD to deploy more cash through expansion, share buybacks or dividend increases.Intel made both the three- and five-year lists of free-cash-flow compounders, which you can see here .4、Stock valuation and performanceHere are forward price-to-earnings ratios based on consensus earnings estimates for the next 12 months among analysts polled by FactSet, along with total return figures:Intel has shined this year, as AMD has pulled back. Intel is also far cheaper when you look at forward price-to-earnings ratios. Those are based on current share prices and consensus earnings estimates for the next 12 months among analysts polled by FactSet. In comparison, forward P/Es are 21.5 for the S&P 500 Index , 27 for the Invesco QQQ Trust $(QQQ)$ (which tracks the Nasdaq-100 Index) and 20.3 for the iShares PHLX Semiconductor ETF $(SOXX)$.If you review longer periods, AMD has been the clear outperformer, until you look at the 15-year figures.These companies have been competing for the PC CPU market for decades. Here's a 20-year total-return chart:And 30 years:You can see from the 20- and 30-year charts that these rivals and swung back and forth in the eyes of investors repeatedly.Wall Street's opinionAMD is the favorite among analysts at brokerage firms, who expect great things for the stock over the next 12 months:So there you have a clear contrast -- AMD is the up-and-comer, and it has been that way for decades. Intel's stock is cheaply priced to expected earnings, the company has a new CEO with a new strategy and is trying to move into new areas. Competition for Intel and AMD with Nvidia in the data-center space will be hot -- it is a story that will take years to unfold.Intel has been a tremendous free-cash-flow grower over the long term, as you can see here . AMD is growing very quickly.So maybe each stock is for a different type of investor. Or maybe investors should consider holding both.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177287104,"gmtCreate":1627224438808,"gmtModify":1703485740300,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Looks like a change in stance","listText":"Looks like a change in stance","text":"Looks like a change in stance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/177287104","repostId":"2154893446","repostType":2,"repost":{"id":"2154893446","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627219014,"share":"https://ttm.financial/m/news/2154893446?lang=&edition=fundamental","pubTime":"2021-07-25 21:16","market":"us","language":"en","title":"Some Americans likely to need COVID-19 vaccine booster -Fauci","url":"https://stock-news.laohu8.com/highlight/detail?id=2154893446","media":"Reuters","summary":"By Linda So   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci sai","content":"<html><body><p>By Linda So</p><p>   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci said on Sunday that Americans who are immune compromised may end up needing COVID-19 vaccine booster shots. </p><p>   \"Those who are transplant patients, cancer chemotherapy, auto-immune diseases, that are on immunosuppresant regimens, those are the kind of individuals that if there's going to be a third booster, which might likely happen, would be among first the vulnerable,\" Fauci said during a CNN interview. </p><p> (Reporting by Linda So; Editing by Tim Ahmann)</p><p>((tim.ahmann@thomsonreuters.com; +1 202 898-8370; Reuters Messaging: tim.ahmann.reuters.com@reuters.net))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Americans likely to need COVID-19 vaccine booster -Fauci</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Americans likely to need COVID-19 vaccine booster -Fauci\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-25 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>By Linda So</p><p>   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci said on Sunday that Americans who are immune compromised may end up needing COVID-19 vaccine booster shots. </p><p>   \"Those who are transplant patients, cancer chemotherapy, auto-immune diseases, that are on immunosuppresant regimens, those are the kind of individuals that if there's going to be a third booster, which might likely happen, would be among first the vulnerable,\" Fauci said during a CNN interview. </p><p> (Reporting by Linda So; Editing by Tim Ahmann)</p><p>((tim.ahmann@thomsonreuters.com; +1 202 898-8370; Reuters Messaging: tim.ahmann.reuters.com@reuters.net))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","JNJ":"强生"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154893446","content_text":"By Linda So   WASHINGTON, July 25 (Reuters) - Top U.S. infectious disease official Anthony Fauci said on Sunday that Americans who are immune compromised may end up needing COVID-19 vaccine booster shots.    \"Those who are transplant patients, cancer chemotherapy, auto-immune diseases, that are on immunosuppresant regimens, those are the kind of individuals that if there's going to be a third booster, which might likely happen, would be among first the vulnerable,\" Fauci said during a CNN interview.  (Reporting by Linda So; Editing by Tim Ahmann)((tim.ahmann@thomsonreuters.com; +1 202 898-8370; Reuters Messaging: tim.ahmann.reuters.com@reuters.net))","news_type":1},"isVote":1,"tweetType":1,"viewCount":511,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3569477879515338","authorId":"3569477879515338","name":"EmmanuelQeen","avatar":"https://static.tigerbbs.com/229c717db2c50af149c3454594cc38dd","crmLevel":4,"crmLevelSwitch":0,"idStr":"3569477879515338","authorIdStr":"3569477879515338"},"content":"[grin] pls gimme a like. tq!","text":"[grin] pls gimme a like. tq!","html":"[grin] pls gimme a like. tq!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132842367,"gmtCreate":1622081842959,"gmtModify":1704179095742,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Right move? Going down the value chain?","listText":"Right move? Going down the value chain?","text":"Right move? Going down the value chain?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/132842367","repostId":"2138233141","repostType":2,"repost":{"id":"2138233141","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622071748,"share":"https://ttm.financial/m/news/2138233141?lang=&edition=fundamental","pubTime":"2021-05-27 07:29","market":"us","language":"en","title":"Tesla set to pay for chips in advance to overcome shortage - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2138233141","media":"Reuters","summary":"May 26  - Tesla Inc plans to pay in advance for chips to secure its supply of the crucial materials in a move to overcome the global chip shortage, the Financial Times reported on Wednesday, citing people familiar with the matter.The electric-car maker is also exploring buying a plant as a part of the efforts, according to the report. (). Tesla could not immediately be reached for comment.","content":"<p>May 26 (Reuters) - Tesla Inc plans to pay in advance for chips to secure its supply of the crucial materials in a move to overcome the global chip shortage, the Financial Times reported on Wednesday, citing people familiar with the matter.</p><p>The electric-car maker is also exploring buying a plant as a part of the efforts, according to the report. ()</p><p>Tesla could not immediately be reached for comment.</p><p>Tesla&nbsp;fell&nbsp;slightly&nbsp;in&nbsp;afterhours&nbsp;trading.</p><p><img src=\"https://static.tigerbbs.com/059f3b7dd6a1d08878750fbd032ee671\" tg-width=\"662\" tg-height=\"466\"></p><p>(Reporting by Sahil Shaw in Bengaluru; Editing by Shounak Dasgupta)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla set to pay for chips in advance to overcome shortage - FT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla set to pay for chips in advance to overcome shortage - FT\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-27 07:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>May 26 (Reuters) - Tesla Inc plans to pay in advance for chips to secure its supply of the crucial materials in a move to overcome the global chip shortage, the Financial Times reported on Wednesday, citing people familiar with the matter.</p><p>The electric-car maker is also exploring buying a plant as a part of the efforts, according to the report. ()</p><p>Tesla could not immediately be reached for comment.</p><p>Tesla&nbsp;fell&nbsp;slightly&nbsp;in&nbsp;afterhours&nbsp;trading.</p><p><img src=\"https://static.tigerbbs.com/059f3b7dd6a1d08878750fbd032ee671\" tg-width=\"662\" tg-height=\"466\"></p><p>(Reporting by Sahil Shaw in Bengaluru; Editing by Shounak Dasgupta)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138233141","content_text":"May 26 (Reuters) - Tesla Inc plans to pay in advance for chips to secure its supply of the crucial materials in a move to overcome the global chip shortage, the Financial Times reported on Wednesday, citing people familiar with the matter.The electric-car maker is also exploring buying a plant as a part of the efforts, according to the report. ()Tesla could not immediately be reached for comment.Tesla fell slightly in afterhours trading.(Reporting by Sahil Shaw in Bengaluru; Editing by Shounak Dasgupta)","news_type":1},"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132855323,"gmtCreate":1622081413362,"gmtModify":1704179084045,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/132855323","repostId":"2138149518","repostType":4,"repost":{"id":"2138149518","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1622074860,"share":"https://ttm.financial/m/news/2138149518?lang=&edition=fundamental","pubTime":"2021-05-27 08:21","market":"hk","language":"en","title":"Retail traders keep meme stocks short squeezed for third straight day","url":"https://stock-news.laohu8.com/highlight/detail?id=2138149518","media":"Dow Jones","summary":"GameStop and AMC surge again as retail traders see proof that short sellers are still messing with t","content":"<blockquote>\n GameStop and AMC surge again as retail traders see proof that short sellers are still messing with their favorite stocks.\n</blockquote>\n<p>These shorts are on fire. Again.</p>\n<p>For a third straight day soared to massive gains on Wednesday as retail traders piled into what is now another short squeeze on hedge funds and other institutional investors shorting the stock.</p>\n<p>GameStop was up almost 16%, pushing it to price levels not seen since early March, while AMC popped almost 19%, putting it back near $20 a share after increasing by roughly 95% in May, the highest it has been since January's wild short squeeze that introduced the world to the idea of meme stocks.</p>\n<p>Both stocks wildly outperformed the major indices which remained relatively flat on the day.</p>\n<p>On social media, talk of \"Diamond hands\", meant to convey an intense aversion to selling shares, turned to a new iteration of \"Diamond fists\", encapsulating the more militant outlook on \"HODLing\" shares to keep pumping them up in the face of hedge funds that new data shows are still shorting both stocks even after getting pummeled in January's squeeze.</p>\n<p>\"The short interest in GameStop is still remarkably high compared to the average company on the US stock market,\" said Peter Hillerberg, co-founder and chief technical officer of Ortex Analytics.</p>\n<p>According to Hillerberg, short positions in both GameStop and AMC have remained at high levels after falling in the wake of January's squeeze, with more than 20% of GameStop's entire float being shorted at <a href=\"https://laohu8.com/S/AONE\">one</a> point on Wednesday.</p>\n<p>But after creeping back up over the course of a few weeks, shorts have started to jump ship this week as retail investors on social media platforms like Reddit used the scarcity of available shares to tilt the trade back in their favor.</p>\n<p>\"Again, this is not the squeeze. This is just resets of their FTDs,\" posted user Damselindistress on Reddit board r/Superstonk, referring to the theory that hedge funds failed to deliver on their shorts the first time. \"It proves, again, that their shorts were never closed.\"</p>\n<p>And while both GameStop and AMC have used retail investor interest to fuel their growth by issuing new equity to pay down major debt loads, the most recent squeeze shows that the line between retail and short sellers is more of a taut rope.</p>\n<p>\"There is often a causality with the short interest and the share price,\" mused Hillerberg. \"This week, that causality has gone crazy.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Retail traders keep meme stocks short squeezed for third straight day</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRetail traders keep meme stocks short squeezed for third straight day\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-05-27 08:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n GameStop and AMC surge again as retail traders see proof that short sellers are still messing with their favorite stocks.\n</blockquote>\n<p>These shorts are on fire. Again.</p>\n<p>For a third straight day soared to massive gains on Wednesday as retail traders piled into what is now another short squeeze on hedge funds and other institutional investors shorting the stock.</p>\n<p>GameStop was up almost 16%, pushing it to price levels not seen since early March, while AMC popped almost 19%, putting it back near $20 a share after increasing by roughly 95% in May, the highest it has been since January's wild short squeeze that introduced the world to the idea of meme stocks.</p>\n<p>Both stocks wildly outperformed the major indices which remained relatively flat on the day.</p>\n<p>On social media, talk of \"Diamond hands\", meant to convey an intense aversion to selling shares, turned to a new iteration of \"Diamond fists\", encapsulating the more militant outlook on \"HODLing\" shares to keep pumping them up in the face of hedge funds that new data shows are still shorting both stocks even after getting pummeled in January's squeeze.</p>\n<p>\"The short interest in GameStop is still remarkably high compared to the average company on the US stock market,\" said Peter Hillerberg, co-founder and chief technical officer of Ortex Analytics.</p>\n<p>According to Hillerberg, short positions in both GameStop and AMC have remained at high levels after falling in the wake of January's squeeze, with more than 20% of GameStop's entire float being shorted at <a href=\"https://laohu8.com/S/AONE\">one</a> point on Wednesday.</p>\n<p>But after creeping back up over the course of a few weeks, shorts have started to jump ship this week as retail investors on social media platforms like Reddit used the scarcity of available shares to tilt the trade back in their favor.</p>\n<p>\"Again, this is not the squeeze. This is just resets of their FTDs,\" posted user Damselindistress on Reddit board r/Superstonk, referring to the theory that hedge funds failed to deliver on their shorts the first time. \"It proves, again, that their shorts were never closed.\"</p>\n<p>And while both GameStop and AMC have used retail investor interest to fuel their growth by issuing new equity to pay down major debt loads, the most recent squeeze shows that the line between retail and short sellers is more of a taut rope.</p>\n<p>\"There is often a causality with the short interest and the share price,\" mused Hillerberg. \"This week, that causality has gone crazy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138149518","content_text":"GameStop and AMC surge again as retail traders see proof that short sellers are still messing with their favorite stocks.\n\nThese shorts are on fire. Again.\nFor a third straight day soared to massive gains on Wednesday as retail traders piled into what is now another short squeeze on hedge funds and other institutional investors shorting the stock.\nGameStop was up almost 16%, pushing it to price levels not seen since early March, while AMC popped almost 19%, putting it back near $20 a share after increasing by roughly 95% in May, the highest it has been since January's wild short squeeze that introduced the world to the idea of meme stocks.\nBoth stocks wildly outperformed the major indices which remained relatively flat on the day.\nOn social media, talk of \"Diamond hands\", meant to convey an intense aversion to selling shares, turned to a new iteration of \"Diamond fists\", encapsulating the more militant outlook on \"HODLing\" shares to keep pumping them up in the face of hedge funds that new data shows are still shorting both stocks even after getting pummeled in January's squeeze.\n\"The short interest in GameStop is still remarkably high compared to the average company on the US stock market,\" said Peter Hillerberg, co-founder and chief technical officer of Ortex Analytics.\nAccording to Hillerberg, short positions in both GameStop and AMC have remained at high levels after falling in the wake of January's squeeze, with more than 20% of GameStop's entire float being shorted at one point on Wednesday.\nBut after creeping back up over the course of a few weeks, shorts have started to jump ship this week as retail investors on social media platforms like Reddit used the scarcity of available shares to tilt the trade back in their favor.\n\"Again, this is not the squeeze. This is just resets of their FTDs,\" posted user Damselindistress on Reddit board r/Superstonk, referring to the theory that hedge funds failed to deliver on their shorts the first time. \"It proves, again, that their shorts were never closed.\"\nAnd while both GameStop and AMC have used retail investor interest to fuel their growth by issuing new equity to pay down major debt loads, the most recent squeeze shows that the line between retail and short sellers is more of a taut rope.\n\"There is often a causality with the short interest and the share price,\" mused Hillerberg. \"This week, that causality has gone crazy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177049380,"gmtCreate":1627171936240,"gmtModify":1703484927690,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"This article does not touch upon the valuation and the potential of moderna. Pity.","listText":"This article does not touch upon the valuation and the potential of moderna. Pity.","text":"This article does not touch upon the valuation and the potential of moderna. Pity.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/177049380","repostId":"2153989989","repostType":2,"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":147603448,"gmtCreate":1626353994784,"gmtModify":1703758477945,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Game changer and disruptor to the biotech firms. This is evident in how it has&nbsp;managed to produce effective vaccines in the shortest&nbsp;time than what many would expect.","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Game changer and disruptor to the biotech firms. This is evident in how it has&nbsp;managed to produce effective vaccines in the shortest&nbsp;time than what many would expect.","text":"$Moderna, Inc.(MRNA)$Game changer and disruptor to the biotech firms. This is evident in how it has managed to produce effective vaccines in the shortest time than what many would expect.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/147603448","isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170849435,"gmtCreate":1626422793827,"gmtModify":1703759870374,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"What does it mean? Is it negative? If so, why?","listText":"What does it mean? Is it negative? If so, why?","text":"What does it mean? Is it negative? If so, why?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170849435","repostId":"1194487154","repostType":4,"repost":{"id":"1194487154","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626422505,"share":"https://ttm.financial/m/news/1194487154?lang=&edition=fundamental","pubTime":"2021-07-16 16:01","market":"us","language":"en","title":"DIDI shares falls more than 8% in premarket trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1194487154","media":"Tiger Newspress","summary":"DIDI shares falls more than 8% in premarket trading.\n\nOfficials from seven Chinese government depart","content":"<p>DIDI&nbsp;shares&nbsp;falls&nbsp;more&nbsp;than 8% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/85b87d4a938496df4bd4077b1058de3b\" tg-width=\"1284\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<p>Officials from seven Chinese government department visited Didi's offices to conduct a cybersecurity review on Friday.</p>\n<p>This month, days after its high-profile listing in the U.S., the Cyberspace Administration of China (CAC)announced a cybersecurity review of Didi.</p>\n<p>The ride-hailing giant was forced to stop signing up new users and itsapp was also removed from Chinese app stores.</p>\n<p>The CAC, China's top cyberspace regulator, alleged that Didi had illegally collected users' data.</p>\n<p>The CAC as well as the State Administration for Market Regulation (SAMR), the leading antitrust regulator, were among the seven departments that visited Didi for the network security review.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DIDI shares falls more than 8% in premarket trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDIDI shares falls more than 8% in premarket trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DIDI&nbsp;shares&nbsp;falls&nbsp;more&nbsp;than 8% in premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/85b87d4a938496df4bd4077b1058de3b\" tg-width=\"1284\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<p>Officials from seven Chinese government department visited Didi's offices to conduct a cybersecurity review on Friday.</p>\n<p>This month, days after its high-profile listing in the U.S., the Cyberspace Administration of China (CAC)announced a cybersecurity review of Didi.</p>\n<p>The ride-hailing giant was forced to stop signing up new users and itsapp was also removed from Chinese app stores.</p>\n<p>The CAC, China's top cyberspace regulator, alleged that Didi had illegally collected users' data.</p>\n<p>The CAC as well as the State Administration for Market Regulation (SAMR), the leading antitrust regulator, were among the seven departments that visited Didi for the network security review.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194487154","content_text":"DIDI shares falls more than 8% in premarket trading.\n\nOfficials from seven Chinese government department visited Didi's offices to conduct a cybersecurity review on Friday.\nThis month, days after its high-profile listing in the U.S., the Cyberspace Administration of China (CAC)announced a cybersecurity review of Didi.\nThe ride-hailing giant was forced to stop signing up new users and itsapp was also removed from Chinese app stores.\nThe CAC, China's top cyberspace regulator, alleged that Didi had illegally collected users' data.\nThe CAC as well as the State Administration for Market Regulation (SAMR), the leading antitrust regulator, were among the seven departments that visited Didi for the network security review.","news_type":1},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":159733748,"gmtCreate":1624979339584,"gmtModify":1703849441034,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Time for moderna to quickly up its production capacity","listText":"Time for moderna to quickly up its production capacity","text":"Time for moderna to quickly up its production capacity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/159733748","repostId":"2147614088","repostType":2,"repost":{"id":"2147614088","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1624978500,"share":"https://ttm.financial/m/news/2147614088?lang=&edition=fundamental","pubTime":"2021-06-29 22:55","market":"us","language":"en","title":"Moderna's stock gains as it announces authorization for its COVID-19 shot in India","url":"https://stock-news.laohu8.com/highlight/detail?id=2147614088","media":"Dow Jones","summary":"MW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n\n\n  Shares of ","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n</p>\n<p>\n  Shares of Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> gained 6.3% in trading on Tuesday after the company said its COVID-19 vaccine has been authorized for adults in India. Moderna's shot has already been authorized in more than 50 countries, including the U.S. Moderna's stock is up 118.5% this year, while the broader S&amp;P 500  has gained 14.2%. \n</p>\n<p>\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 29, 2021 10:55 ET (14:55 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's stock gains as it announces authorization for its COVID-19 shot in India</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's stock gains as it announces authorization for its COVID-19 shot in India\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-29 22:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n</p>\n<p>\n  Shares of Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> gained 6.3% in trading on Tuesday after the company said its COVID-19 vaccine has been authorized for adults in India. Moderna's shot has already been authorized in more than 50 countries, including the U.S. Moderna's stock is up 118.5% this year, while the broader S&amp;P 500  has gained 14.2%. \n</p>\n<p>\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 29, 2021 10:55 ET (14:55 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147614088","content_text":"MW Moderna's stock gains as it announces authorization for its COVID-19 shot in India\n\n\n  Shares of Moderna Inc. $(MRNA)$ gained 6.3% in trading on Tuesday after the company said its COVID-19 vaccine has been authorized for adults in India. Moderna's shot has already been authorized in more than 50 countries, including the U.S. Moderna's stock is up 118.5% this year, while the broader S&P 500  has gained 14.2%. \n\n\n  -Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  June 29, 2021 10:55 ET (14:55 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172197506,"gmtCreate":1626942744005,"gmtModify":1703481005696,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172197506","repostId":"1197792637","repostType":4,"repost":{"id":"1197792637","kind":"news","pubTimestamp":1626941717,"share":"https://ttm.financial/m/news/1197792637?lang=&edition=fundamental","pubTime":"2021-07-22 16:15","market":"us","language":"en","title":"4 Biotech Stocks That Could Be Bargains","url":"https://stock-news.laohu8.com/highlight/detail?id=1197792637","media":"Barron's","summary":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnol","content":"<p>Biotech stocks have had an uneven 2021 so far.</p>\n<p>One major biotech fund, the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b>, which focuses on the bigger biotech players, is up 9%, just behind the&nbsp;S&amp;P 500 index,which is up 14.3%. Another important fund, the<b>&nbsp;<a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b>, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.</p>\n<p>The success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.</p>\n<p>Picking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.</p>\n<p>For those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.</p>\n<h3><b>4 Undervalued Biotech Stocks</b></h3>\n<p>These are the four biotech stocks in the <b><a href=\"https://laohu8.com/S/IBB\">iShares Nasdaq Biotechnology ETF</a></b> and the <b><a href=\"https://laohu8.com/S/XBI\">Spdr S&amp;P Biotech Etf</a></b> with market values over $5 billion that trade the farthest below their average analyst price targets.</p>\n<table>\n <thead>\n  <tr>\n   <th>Company / Ticker</th>\n   <th>Recent Price</th>\n   <th>Average Target Price</th>\n   <th>Implied Gain</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>TG Therapeutics / TGTX</td>\n   <td>$37.32</td>\n   <td>$75.88</td>\n   <td>103.3%</td>\n  </tr>\n  <tr>\n   <td>Vir Biotechnology / VIR</td>\n   <td>$37.91</td>\n   <td>$74.29</td>\n   <td>96.0%</td>\n  </tr>\n  <tr>\n   <td>Ultragenyx Pharmaceutical / RARE</td>\n   <td>$85.49</td>\n   <td>$153.12</td>\n   <td>79.1%</td>\n  </tr>\n  <tr>\n   <td>Exelixis / EXEL</td>\n   <td>$16.67</td>\n   <td>$29.54</td>\n   <td>77.2%</td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: FactSet</i></p>\n<p>Analysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we&nbsp;looked at the five health-care stocks in the S&amp;P 500 that trade the farthest below their average analyst&nbsp;price&nbsp;targets.</p>\n<p>This time, we’ve looked at the stocks in the SPDR S&amp;P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.</p>\n<p>We set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.</p>\n<p>The stocks that passed the screen are&nbsp;<b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology, Inc.</a></b>,&nbsp;<b><a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical</a></b>, and<b>&nbsp;<a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.</p>\n<p>The stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.</p>\n<p><b><a href=\"https://laohu8.com/S/TGTX\">TG Therapeutics</a></b> stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.</p>\n<p>Analysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.</p>\n<p>The average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.</p>\n<p>Another stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy&nbsp;jointly developed by Vir and&nbsp;<b><a href=\"https://laohu8.com/S/GSK\">GlaxoSmithKline PLC</a></b> to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.</p>\n<p>Vir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.</p>\n<p>Of the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.</p>\n<p>Also on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.</p>\n<p>The company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.</p>\n<p>“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.</p>\n<p>The average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.</p>\n<p>The final stock to pass our screen was <b><a href=\"https://laohu8.com/S/EXEL\">Exelixis</a></b>, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.</p>\n<p>The average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Biotech Stocks That Could Be Bargains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Biotech Stocks That Could Be Bargains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 16:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which ...</p>\n\n<a href=\"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","RARE":"Ultragenyx Pharmaceutical Inc","TGTX":"TG Therapeutics Inc.","IBB":"生物科技指数ETF-iShares Nasdaq","VIR":"Vir Biotechnology, Inc.","XBI":"SPDR S&P Biotech ETF","GSK":"葛兰素史克"},"source_url":"https://www.barrons.com/articles/undervalued-biotech-stocks-exelixis-51626879782","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197792637","content_text":"Biotech stocks have had an uneven 2021 so far.\nOne major biotech fund, the iShares Nasdaq Biotechnology ETF, which focuses on the bigger biotech players, is up 9%, just behind the S&P 500 index,which is up 14.3%. Another important fund, the Spdr S&P Biotech Etf, which spreads its assets across large and small biotech firms, is down 8.9% over the same period.\nThe success of biotech standouts at developing Covid-19 vaccines at a rapid pace has drawn new attention and investors to the sector, and a sample of health care/biotech-dedicated funds tracked by Piper Sandler analyst Christopher Raymond has seen $1.3 billion in inflows so far this year.\nPicking the next big biotech stock, however, is tricky, and requires a depth of specialized knowledge. The best advice is generally to let the specialists at biotech-and-health-care-focused ETFs and mutual funds do the work for you.\nFor those who want to make a pick on their own, one strategy is to search for value by looking for biotech stocks that trade at the steepest discount to where Wall Street analysts expect them to trade in the near term.\n4 Undervalued Biotech Stocks\nThese are the four biotech stocks in the iShares Nasdaq Biotechnology ETF and the Spdr S&P Biotech Etf with market values over $5 billion that trade the farthest below their average analyst price targets.\n\n\n\nCompany / Ticker\nRecent Price\nAverage Target Price\nImplied Gain\n\n\n\n\nTG Therapeutics / TGTX\n$37.32\n$75.88\n103.3%\n\n\nVir Biotechnology / VIR\n$37.91\n$74.29\n96.0%\n\n\nUltragenyx Pharmaceutical / RARE\n$85.49\n$153.12\n79.1%\n\n\nExelixis / EXEL\n$16.67\n$29.54\n77.2%\n\n\n\nSource: FactSet\nAnalysts publish target prices for the stocks they cover, a price they expect the stock to hit at some point in the future, usually around a year out. Last month, we looked at the five health-care stocks in the S&P 500 that trade the farthest below their average analyst price targets.\nThis time, we’ve looked at the stocks in the SPDR S&P Biotech and the iShares Biotechnology ETFs with market values of over $5 billion, and we found the four that trade the farthest below their average target prices, according to FactSet.\nWe set the $5 billion market value as a floor to exclude some smaller stocks with just a couple of analysts covering them, for which average analyst target prices don’t mean much.\nThe stocks that passed the screen are TG Therapeutics, Vir Biotechnology, Inc., Ultragenyx Pharmaceutical, and Exelixis, a group of interesting biotech stocks backed by substantial Wall Street analyst enthusiasm.\nThe stock in the group that trades the farthest below its average analyst target price is TG Therapeutics, a biotech that focuses on the biology of B-cells, a type of white blood cell involved in the adaptive immune system. In February, the U.S. Food and Drug Administration approved a TG Therapeutics drug called Ukoniq to treatcertain lymphoma patients.\nTG Therapeutics stock climbed sharply this past December, as the company released positive data on a number of trials, including a trial of its drugumbralisib in certain leukemia patients.The stock rose 77.3% in December of 2020, but is down 27.9% this year.\nAnalysts remain bullish on the stock. “We continue to think that the breadth of TGTX’s pipeline remains underappreciated at the current valuation,” wrote Cantor Fitzgerald analyst Alethia Young in a June 4 note.\nThe average target price on TG Therapeutics is $75.88, according to FactSet, which implies an 103.3% gain from the stock’s recent price of $37.32.\nAnother stock that passed our screen was Vir Biotechnology, the biotech firm that shot to prominence during the Covid-19 pandemic as one of the few focused on infectious disease. In May, the FDAauthorized a monoclonal antibody therapy jointly developed by Vir and GlaxoSmithKline PLC to treat Covid-19 patients. Unlike other antibody therapies, Vir’s has proven to be effective against variant strains of the virus that cause Covid-19.\nVir shares are up 41.7% so far this year. The company is also developing other products, including hepatitis B therapies that are in Phase 2 trials, and a flu antibody that is in Phase 1 trials.\nOf the eight analysts tracked by FactSet who maintain ratings on Vir, seven rate it at Buy or Overweight, while one rates it at Hold. Their average target price is $74.29, according to FactSet, which implies a gain of 96% over the stock’s recent price of $37.91.\nAlso on our list is Ultragenyx, which develops drugs for rare diseases. Its approved therapies include Crysvita, which treats a genetic disease called X-linked hypophosphatemia, and Mepsevii, which treats a disease called Mucopolysaccharidosis VII, another rare genetic condition.\nThe company is also developing gene therapies for other rare diseases. Ultragenyx stock has fallen 37.5% so far this year after a delay in the restart of its trials of a gene therapy for Angelman Syndrome, which had been put on clinical hold in the fall. Analysts, however, see a buying opportunity.\n“We find shares of RARE compelling at the current valuation,” Evercore ISI analyst Liisa Bayko wrote in a note upgrading the stock to Outperform from In Line in early May.\nThe average analyst target price on Ultragenyx stock is $153.12, according to FactSet, implying a gain of 79.1% over the recent share price of $85.49.\nThe final stock to pass our screen was Exelixis, an oncology-focused biotech with a number of products on the market, and a pipeline of cancer drugs. The stock is down 15.9% so far this year, after dropping 23.1% on a single day in late June when a trial of its drug cabozantinib in combination with another drugreturned disappointing data.\nThe average analyst target price on the stock is $29.54, according to FactSet, which is 77.2% above the stock’s recent price of $16.62. That average target price may not mean much, however, as many of the target prices set by analysts have not been updated since the late-June drop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170201552,"gmtCreate":1626432389176,"gmtModify":1703760050374,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Up up and away!","listText":"Up up and away!","text":"Up up and away!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170201552","repostId":"1166310062","repostType":4,"repost":{"id":"1166310062","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626425479,"share":"https://ttm.financial/m/news/1166310062?lang=&edition=fundamental","pubTime":"2021-07-16 16:51","market":"us","language":"en","title":"Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.","url":"https://stock-news.laohu8.com/highlight/detail?id=1166310062","media":"Tiger Newspress","summary":"Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.\nModerna Inc. will replace ","content":"<p>Moderna&nbsp;shares&nbsp;jumps&nbsp;6.85% in premarket&nbsp;trading,as&nbsp;to&nbsp;be&nbsp;joining S&amp;P 500.</p>\n<p><img src=\"https://static.tigerbbs.com/67fe1c018d8b5dfd6c9ed79f6402e3f0\" tg-width=\"1290\" tg-height=\"612\" referrerpolicy=\"no-referrer\">Moderna Inc.&nbsp;will replace Alexion Pharmaceuticals Inc. &nbsp;in the S&amp;P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc&nbsp;is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna shares jumps 6.85% in premarket trading,as to be joining S&P 500.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-16 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna&nbsp;shares&nbsp;jumps&nbsp;6.85% in premarket&nbsp;trading,as&nbsp;to&nbsp;be&nbsp;joining S&amp;P 500.</p>\n<p><img src=\"https://static.tigerbbs.com/67fe1c018d8b5dfd6c9ed79f6402e3f0\" tg-width=\"1290\" tg-height=\"612\" referrerpolicy=\"no-referrer\">Moderna Inc.&nbsp;will replace Alexion Pharmaceuticals Inc. &nbsp;in the S&amp;P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc&nbsp;is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","ALXN":"亚力兄制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166310062","content_text":"Moderna shares jumps 6.85% in premarket trading,as to be joining S&P 500.\nModerna Inc. will replace Alexion Pharmaceuticals Inc.  in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170962535,"gmtCreate":1626400181227,"gmtModify":1703759399010,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170962535","repostId":"1156481169","repostType":4,"repost":{"id":"1156481169","kind":"news","pubTimestamp":1626399008,"share":"https://ttm.financial/m/news/1156481169?lang=&edition=fundamental","pubTime":"2021-07-16 09:30","market":"us","language":"en","title":"Why Tesla Slipped Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1156481169","media":"Motley Fool","summary":"Elon utters the \"F\" word.\n\nWhat happened\nTesla(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, ","content":"<blockquote>\n Elon utters the \"F\" word.\n</blockquote>\n<p><b>What happened</b></p>\n<p><b>Tesla</b>(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, depending on your point of view -- for his pronouncements. The electric vehicle (EV) maker's stock price can gyrate up or down depending on what Musk expresses on a particular day.</p>\n<p>Sure enough, the boss' comment about an upcoming product made for lively trading Thursday with the shares, the price of which ended the day marginally lower.</p>\n<p><b>So what</b></p>\n<p>The subject was the futuristic Cybertruck, Tesla's version of a pickup. In an exchange on<b>Twitter</b>, Musk wrote the following:</p>\n<p>\"To be frank, there is always some chance that Cybertruck will flop, because it is so unlike anything else. I don't care. I love it so much even if others don't.\"</p>\n<p>Musk was only repeating the \"F\" word. His tweet was a reaction to a story published Thursday on niche website The Truth About Cars with the incendiary headline \"Opinion: Tesla's Cybertruck Will Be Company's First Flop.\"</p>\n<p>In the story, writer Tim Healey took aim at theEV's looks, and opined that rival pickups -- including the high-profile<b>Ford</b>(NYSE:F)F-150 Lightning-- will likely be \"more usable as trucks.\"</p>\n<p><b>Now what</b></p>\n<p>CEOs aren't supposed to admit that their products could be duds. But Musk has a high profile and a following largely because he<i>isn't</i>a CEO in the traditional mold. While some people undoubtedly turned bearish on his pronouncement about the Cybertruck, plenty of investors clearly still believe in the company's mission -- and in the actions of its colorful leader.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tesla Slipped Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tesla Slipped Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 09:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/15/why-tesla-slipped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Elon utters the \"F\" word.\n\nWhat happened\nTesla(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, depending on your point of view -- for his pronouncements. The electric vehicle (EV) maker's stock ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/15/why-tesla-slipped-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.fool.com/investing/2021/07/15/why-tesla-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156481169","content_text":"Elon utters the \"F\" word.\n\nWhat happened\nTesla(NASDAQ:TSLA)CEO Elon Musk is famous -- or notorious, depending on your point of view -- for his pronouncements. The electric vehicle (EV) maker's stock price can gyrate up or down depending on what Musk expresses on a particular day.\nSure enough, the boss' comment about an upcoming product made for lively trading Thursday with the shares, the price of which ended the day marginally lower.\nSo what\nThe subject was the futuristic Cybertruck, Tesla's version of a pickup. In an exchange onTwitter, Musk wrote the following:\n\"To be frank, there is always some chance that Cybertruck will flop, because it is so unlike anything else. I don't care. I love it so much even if others don't.\"\nMusk was only repeating the \"F\" word. His tweet was a reaction to a story published Thursday on niche website The Truth About Cars with the incendiary headline \"Opinion: Tesla's Cybertruck Will Be Company's First Flop.\"\nIn the story, writer Tim Healey took aim at theEV's looks, and opined that rival pickups -- including the high-profileFord(NYSE:F)F-150 Lightning-- will likely be \"more usable as trucks.\"\nNow what\nCEOs aren't supposed to admit that their products could be duds. But Musk has a high profile and a following largely because heisn'ta CEO in the traditional mold. While some people undoubtedly turned bearish on his pronouncement about the Cybertruck, plenty of investors clearly still believe in the company's mission -- and in the actions of its colorful leader.","news_type":1},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":115658480,"gmtCreate":1622989794540,"gmtModify":1704194126169,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/115658480","repostId":"2140540596","repostType":4,"repost":{"id":"2140540596","kind":"highlight","pubTimestamp":1622820692,"share":"https://ttm.financial/m/news/2140540596?lang=&edition=fundamental","pubTime":"2021-06-04 23:31","market":"us","language":"en","title":"3 Technology Stocks You Can Buy and Hold for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2140540596","media":"Motley Fool","summary":"It can be tough to get married to stocks -- especially tech -- but here are three to leave alone for the long haul.","content":"<p>Let's be honest. A lot of people say their positions in flashy technology companies are meant to be long-term holdings, but they're really just an effort to make a quick buck. And that's OK. Any profitable trade is technically a good trade. If you can get in and out at the right time, so be it.</p>\n<p>Thing is, there are plenty of tech names that are more than just flash-in-the-pan prospects, and are better suited for holding periods measured in years rather than weeks.</p>\n<p>Here's a closer look at three such technology companies. Not only will they be just as impressive 10 years from now as they are today, but their stocks should be trading at much higher prices.</p>\n<h2>Microsoft</h2>\n<p>It's tough to imagine a world without <b>Microsoft</b> (NASDAQ:MSFT). Its Windows operating system is installed on three-fourths of the world's desktops and laptops, according to GlobalStats, and its Office productivity software remains the gold standard for the category. <b>Sony</b>'s PlayStation gaming console enjoys more worldwide market share than Microsoft's Xbox, but the Xbox is closing the gap, and is still the most popular game console in the U.S.</p>\n<p>And these are things consumers can readily see. There's a whole different unseen array of Microsoft-made products that are doing similarly well. For instance, Canalys reports Microsoft's cloud computing business accounted for a second-best 19% of the world's first-quarter cloud infrastructure spending, and the company continues to close the gap with market-leader <b>Amazon</b>.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/362a8a5cb8d412d4e3895fa185d236b7\" tg-width=\"700\" tg-height=\"484\"><span>Image source: Getty Images.</span></p>\n<p>Now take a step back and ask a thoughtful, critical question: Is there any chance the world will have less need for computers, cloud computing, productivity software, or game consoles 10 years from now?</p>\n<p>Any reasonable and realistic answer has to be \"no.\" Indeed, it would be surprising if demand for these products and services wasn't considerably greater a decade from now. Being a market leader in multiple categories, Microsoft can steer the market's ongoing growth in a way that serves itself best. For example, the Windows operating system comes with trial versions of Office software pre-installed.</p>\n<p>Bolstering the bullish argument for long-term ownership of Microsoft is the company's evolving business model. Access to Azure, Office, and even video games can now be utilized on a monthly subscription basis, accessible via the cloud. This shift not only makes the company's products more affordable to begin using but also gives Microsoft a better chance of keeping those customers by making it easy to update and upgrade software.</p>\n<p>Last year, the last time Microsoft disclosed such data, it had already lined up more than $100 billion worth of subscription cloud revenue that had yet to be booked -- a figure that continues to edge upward.</p>\n<h2><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></h2>\n<p>Even after several high-profile cybersecurity gaffes embarrassed organizations ranging from <b>Target </b>to <b>Equifax</b> to Yahoo!, some of the world's most important companies are still being hacked. Most recently, Colonial Pipeline agreed to fork over $4.4 million to a computer hacking group known as Darkside to regain control of its 5,500 miles worth of refined oil pipelines.</p>\n<p>These things are preventable. They're just not being prevented, as too many organizations don't utilize all the digital defenses available to them. Perhaps the Colonial Pipeline debacle will encourage procurement of this protection.</p>\n<p>Enter <b>Palo Alto Networks</b> (NYSE:PANW). Simply put, Palo Alto offers software preventing unauthorized access to a company's network, internal apps, and data. It's even got a ransomware protection solution in its lineup that might have been able to save Colonial Pipeline a few million bucks.</p>\n<p>The opportunity is incredible, and should remain so for a while. P&amp;S Intelligence believes the cybersecurity market will grow at an average annual pace of 12.6%, from 2019's $120 billion to $434 billion by 2030. That's a lot, but it's only a fraction of the $10.5 trillion that Cybersecurity Ventures believes cybercrime will cost the world in 2025 alone if enterprises don't step up their digital defense games.</p>\n<p>Palo Alto is doing fine, logging more than seven consecutive years of rising revenue as more and more outfits build their digital moats. Given the outlook, more of the same kind of growth is in the cards for a while.</p>\n<h2>International Business Machines</h2>\n<p>Finally, add <b>International Business Machines</b> (NYSE:IBM) to your list of technology stocks to buy and hold for the next decade.</p>\n<p>Yes, this is the same IBM that failed to respond to the advent of things like cloud computing, mobile devices, and all that goes with both. The company's \"strategic imperatives\" plan unveiled in 2015 was meant to steer the company away from a legacy mainframe business that was already dying and toward more contemporary opportunities like the aforementioned cloud and mobile security. By and large, though, it was too little too late.</p>\n<p>The IBM of today, however, isn't the IBM from even as recently as two years ago. It's ready to compete where it counts.</p>\n<p>Take last month's revelation of new technologies capable of fabricating a 2-nanometer microchip as an example. The microscopic measure is in reference to how small a chip's transistors can be made and still function properly. The smaller, the better, as smaller transistors consume less power, operate faster, and require less space when room is a factor. For perspective, 7-nanometer chips are the best the market has to offer right now.</p>\n<p>It's not just more functional chips IBM is starting to develop, either. Just within the past few weeks, the company has unveiled a way for data centers to more efficiently store and retrieve data, and launched AutoSQL, which is capable of retrieving data eight times faster than previous approaches are. Both technologies have a myriad of potential uses, including in the artificial intelligence arena.</p>\n<p>Read between the lines. This isn't yesteryear's IBM.</p>\n<p>It could still take years for the company to fully monetize these and other breakthroughs, but they're worth the wait.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Technology Stocks You Can Buy and Hold for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Technology Stocks You Can Buy and Hold for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/04/3-technology-stocks-you-can-buy-and-hold-for-the-n/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Let's be honest. A lot of people say their positions in flashy technology companies are meant to be long-term holdings, but they're really just an effort to make a quick buck. And that's OK. Any ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/04/3-technology-stocks-you-can-buy-and-hold-for-the-n/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PANW":"Palo Alto Networks","IBM":"IBM","MSFT":"微软"},"source_url":"https://www.fool.com/investing/2021/06/04/3-technology-stocks-you-can-buy-and-hold-for-the-n/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140540596","content_text":"Let's be honest. A lot of people say their positions in flashy technology companies are meant to be long-term holdings, but they're really just an effort to make a quick buck. And that's OK. Any profitable trade is technically a good trade. If you can get in and out at the right time, so be it.\nThing is, there are plenty of tech names that are more than just flash-in-the-pan prospects, and are better suited for holding periods measured in years rather than weeks.\nHere's a closer look at three such technology companies. Not only will they be just as impressive 10 years from now as they are today, but their stocks should be trading at much higher prices.\nMicrosoft\nIt's tough to imagine a world without Microsoft (NASDAQ:MSFT). Its Windows operating system is installed on three-fourths of the world's desktops and laptops, according to GlobalStats, and its Office productivity software remains the gold standard for the category. Sony's PlayStation gaming console enjoys more worldwide market share than Microsoft's Xbox, but the Xbox is closing the gap, and is still the most popular game console in the U.S.\nAnd these are things consumers can readily see. There's a whole different unseen array of Microsoft-made products that are doing similarly well. For instance, Canalys reports Microsoft's cloud computing business accounted for a second-best 19% of the world's first-quarter cloud infrastructure spending, and the company continues to close the gap with market-leader Amazon.\nImage source: Getty Images.\nNow take a step back and ask a thoughtful, critical question: Is there any chance the world will have less need for computers, cloud computing, productivity software, or game consoles 10 years from now?\nAny reasonable and realistic answer has to be \"no.\" Indeed, it would be surprising if demand for these products and services wasn't considerably greater a decade from now. Being a market leader in multiple categories, Microsoft can steer the market's ongoing growth in a way that serves itself best. For example, the Windows operating system comes with trial versions of Office software pre-installed.\nBolstering the bullish argument for long-term ownership of Microsoft is the company's evolving business model. Access to Azure, Office, and even video games can now be utilized on a monthly subscription basis, accessible via the cloud. This shift not only makes the company's products more affordable to begin using but also gives Microsoft a better chance of keeping those customers by making it easy to update and upgrade software.\nLast year, the last time Microsoft disclosed such data, it had already lined up more than $100 billion worth of subscription cloud revenue that had yet to be booked -- a figure that continues to edge upward.\nPalo Alto Networks\nEven after several high-profile cybersecurity gaffes embarrassed organizations ranging from Target to Equifax to Yahoo!, some of the world's most important companies are still being hacked. Most recently, Colonial Pipeline agreed to fork over $4.4 million to a computer hacking group known as Darkside to regain control of its 5,500 miles worth of refined oil pipelines.\nThese things are preventable. They're just not being prevented, as too many organizations don't utilize all the digital defenses available to them. Perhaps the Colonial Pipeline debacle will encourage procurement of this protection.\nEnter Palo Alto Networks (NYSE:PANW). Simply put, Palo Alto offers software preventing unauthorized access to a company's network, internal apps, and data. It's even got a ransomware protection solution in its lineup that might have been able to save Colonial Pipeline a few million bucks.\nThe opportunity is incredible, and should remain so for a while. P&S Intelligence believes the cybersecurity market will grow at an average annual pace of 12.6%, from 2019's $120 billion to $434 billion by 2030. That's a lot, but it's only a fraction of the $10.5 trillion that Cybersecurity Ventures believes cybercrime will cost the world in 2025 alone if enterprises don't step up their digital defense games.\nPalo Alto is doing fine, logging more than seven consecutive years of rising revenue as more and more outfits build their digital moats. Given the outlook, more of the same kind of growth is in the cards for a while.\nInternational Business Machines\nFinally, add International Business Machines (NYSE:IBM) to your list of technology stocks to buy and hold for the next decade.\nYes, this is the same IBM that failed to respond to the advent of things like cloud computing, mobile devices, and all that goes with both. The company's \"strategic imperatives\" plan unveiled in 2015 was meant to steer the company away from a legacy mainframe business that was already dying and toward more contemporary opportunities like the aforementioned cloud and mobile security. By and large, though, it was too little too late.\nThe IBM of today, however, isn't the IBM from even as recently as two years ago. It's ready to compete where it counts.\nTake last month's revelation of new technologies capable of fabricating a 2-nanometer microchip as an example. The microscopic measure is in reference to how small a chip's transistors can be made and still function properly. The smaller, the better, as smaller transistors consume less power, operate faster, and require less space when room is a factor. For perspective, 7-nanometer chips are the best the market has to offer right now.\nIt's not just more functional chips IBM is starting to develop, either. Just within the past few weeks, the company has unveiled a way for data centers to more efficiently store and retrieve data, and launched AutoSQL, which is capable of retrieving data eight times faster than previous approaches are. Both technologies have a myriad of potential uses, including in the artificial intelligence arena.\nRead between the lines. This isn't yesteryear's IBM.\nIt could still take years for the company to fully monetize these and other breakthroughs, but they're worth the wait.","news_type":1},"isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111595568,"gmtCreate":1622685595454,"gmtModify":1704188888520,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Too much regulatory opaqueness&nbsp;","listText":"Too much regulatory opaqueness&nbsp;","text":"Too much regulatory opaqueness","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111595568","repostId":"1138216687","repostType":2,"repost":{"id":"1138216687","kind":"news","pubTimestamp":1622552095,"share":"https://ttm.financial/m/news/1138216687?lang=&edition=fundamental","pubTime":"2021-06-01 20:54","market":"hk","language":"en","title":"Alibaba: One Of The Really Cheap Bargains In This Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1138216687","media":"seekingalpha","summary":"Alibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.The company is clearly facing risks due to the tension between Jack Ma and the Chinese government, but I consider these risks to be only temporary.Alibaba is growing with a high pace, has a very stable balance sheet and outperforming many of its peers.So far, I have published over 300 articles on this site and the focus has been clearly on companies having the headquarters in the United Sta","content":"<p><b>Summary</b></p>\n<ul>\n <li>Alibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.</li>\n <li>The company is clearly facing risks due to the tension between Jack Ma and the Chinese government, but I consider these risks to be only temporary.</li>\n <li>Alibaba is growing with a high pace, has a very stable balance sheet and outperforming many of its peers.</li>\n <li>In my opinion, the stock is severely undervalued.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/15ac5f97c66688f6d16ce98819ebce4a\" tg-width=\"768\" tg-height=\"512\"><span>Photo by maybefalse/iStock Unreleased via Getty Images</span></p>\n<p>So far, I have published over 300 articles on this site and the focus has been clearly on companies having the headquarters in the United States and stocks listed on an US-based stock exchange. And while I am covering also companies from Germany, France, Great Britain, Sweden or Denmark, I have avoided one country almost completely although it has many interesting investment opportunities: Mainland China.The only company I covered so far&nbsp;is Tencent Holdings Limited (OTCPK:TCEHY).</p>\n<p>And although China has hundreds or thousands of successful companies, most of them are almost unknown in the Western Hemisphere (especially when moving outside of the investing world). And while most investors are familiar with Tencent, there is at least one other company almost every investor has heard of: Alibaba Group Holding Limited (BABA). In the following article, I will analyze Alibaba in my usual way. I will try to determine if Alibaba is a solid business with a wide economic moat and try to answer the question if Alibaba is a solid investment right now.</p>\n<p><b>Business Description</b></p>\n<p>Alibaba Group was founded in 1999 by 18 individuals. Nevertheless, one of these 18 stands out – the former English teacher from Hangzhou, Jack Ma. Over the years, Alibaba evolved in a multinational technology company and with a market capitalization of $570 billion, Alibaba is on the 10thspot on the list of most valuable companies in the world (by market cap). And behind Tencent, which is on the 7thspot on that list, Alibaba is the second most valuable company in China.</p>\n<p>While Alibaba is mostly focused on e-commerce and retail operations, the Alibaba Group is actually a holding company with many different sales services. This includes C2C services, B2C services and B2B services. Aside from retail, the Alibaba Group also offers electronic payment services, shipping search engines and could computing services. The group owns and operates a diverse portfolio of companies around the world in numerous business sectors.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b315044f4644568e7df5d95cc6720995\" tg-width=\"640\" tg-height=\"479\"><span>(Source:Alibaba Q4/20 Presentation)</span></p>\n<p>Alibaba is reporting in four different segments:</p>\n<ul>\n <li><b>Core Commerce Revenue</b>: This segment is comprised of platforms operating in retail and wholesale commerce in China as well as logistics services and local consumer services. In fiscal 2021, this segment generated RMB 621.1 billion in revenue and RMB 159 billion in income from operations.</li>\n <li><b>Cloud Computing Revenue</b>: This segment is comprised of Alibaba Cloud, which offers different cloud services to customers worldwide like database, storage, big data analytics, a machine learning platform and large-scale computing security. In fiscal 2021, this segment generated RMB 60.1 billion, but the segment was not profitable so far (a loss of RMB 9 billion).</li>\n <li><b>Digital Media and Entertainment Revenue</b>: This segment uses the deep data insights to serve the broader interests of consumers through key distribution platforms Youku and Alibaba Pictures as well as other content platforms that provide online videos, films, live events, literature and music. In fiscal 2021, this segment generated RMB 31.2 billion, but was also not profitable.</li>\n <li><b>Innovation Initiatives and Others Revenue</b>: This segment includes businesses like Amap, DingTalk, Tmall Genie and others. In fiscal 2021, this segment generated RMB 4.8 billion in revenue, but also an operating loss.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0529c547e87a4c0b023289ecb1822cbc\" tg-width=\"640\" tg-height=\"478\"><span>(Source: Alibaba Q4/20 Presentation)</span></p>\n<p>When looking at the last annual results (fiscal 2021), Alibaba generated RMB 717.3 billion in revenue. Compared to fiscal 2020 (RMB 509.7 billion) this is reflecting an increase of 41%. Adjusted EBITDA in fiscal 2021 was RMB 196.8 billion – an increase of 25% compared to fiscal 2020 (adjusted EBITA of RMB 157.7 billion). Diluted earnings per share actually decreased from RMB 6.99 in fiscal 2020 to RMB 6.84 in fiscal 2021 – reflecting a decrease of 2.1%. But we should not pay too much attention to the earnings per share. Instead, it makes much more sense to look at the free cash flow Alibaba is generating. In fiscal 2021, Alibaba generated RMB 172.7 billion in free cash flow compared to RMB 130.9 billion in free cash flow one year earlier.</p>\n<p><b>Strong Business Among Strong Competitors</b></p>\n<p>What is striking when looking at Alibaba – and what has been discussed several times – is the low multiple for which Alibaba is currently trading. When using the trailing twelve-month GAAP numbers, Alibaba is trading for 25 times earnings, when using the non-GAAP forward numbers, it is trading for a P/E ratio of 20.</p>\n<p>We can compare Alibaba to its peers – companies like Amazon (AMZN), Tencent, Facebook (FB), Microsoft (MSFT) or Alphabet (GOOG). And Alibaba actually belongs in that list as it is not only operating in similar business segments, but it is also growing with similarly high rates. And Alibaba is not only growing with a similar pace; it is actually outperforming most of its peers.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b576dcef2e37a02a6eba5677fded8ef8\" tg-width=\"640\" tg-height=\"299\"><span>(Source:Alibaba 2020 Investor Presentations)</span></p>\n<p>While Alibaba is growing with a similar pace like these companies, it is trading for a completely different multiple. Right now, Alibaba is trading for a price-cash-flow ratio of 17, while competitors like Tencent, Facebook or Microsoft are trading for a P/FCF ratio between 35 and 40. It is striking, that the market is assigning these competitors a multiple twice as high and Amazon is actually trading for a multiple more than 4 times higher (price-free-cash-flow ratio of 76).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6d2f58771a8062c7bb980622b93073e5\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p>\n<p>Right now, readers might point out, that the comparison to Amazon is misleading as Amazon is still spending a lot of money to achieve future growth and therefore has a lower profit than other companies. And it certainly is true, that Amazon is still focusing on top line growth – sometimes at the expense of bottom-line growth – but so does Alibaba.</p>\n<p>While Amazon spent 10.4% of its revenue as capital expenditures in the last fiscal year, Alibaba spent almost the same amount – 8.9% of revenue. And when looking at the expenses for research and development, we once again see similar numbers. In the last five years, Amazon spent 12.16% of revenue on R&amp;D on average while Alibaba spent 10.38% of its revenue on R&amp;D.</p>\n<p>But while these numbers are quite similar for both companies – Amazon is spending a bit more on R&amp;D than Alibaba – the free cash flow these two companies can generate is completely different. While Amazon only generated 6.7% of revenue as free cash flow in the last fiscal year, Alibaba generated 26.5% of revenue as free cash flow in the last fiscal year – almost four times higher.</p>\n<p>And Alibaba is not only extremely profitable – it was growing with an extremely high pace in the past. During the past ten years, Alibaba could not only grow revenue every single year, it also grew revenue with a CAGR of 62.6%. Earnings per share fluctuated a little bit during these ten years but grew with an even higher pace – a CAGR of 76.29% during the last decade. And finally, free cash flow increased with a CAGR of 59.62% during the last decade.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d3ccaf170c0d86cd8022a68bc3657c30\" tg-width=\"640\" tg-height=\"404\"><span>(Source: Author’s work based on numbers from Morningstar)</span></p>\n<p>When looking at Alibaba’s growth rates in the last few years compared to its competitors, Alibaba is also outperforming. When looking at the revenue CAGR of the last 5 years, we get the following numbers:</p>\n<ul>\n <li>Amazon: 29.26%</li>\n <li>Facebook: 36.82%</li>\n <li>Tencent: 36.20%</li>\n <li>Alphabet: 19.47%</li>\n <li>Microsoft: 8.85%</li>\n <li>Alibaba: 46.24%</li>\n</ul>\n<p>We can spin it how we want: Alibaba is an extremely profitable company growing with extremely high rates but is trading at an extremely low multiple compared to its competitors. It is growing with a higher pace than Microsoft and Facebook, but trading for half the multiple. It is much more profitable than Amazon and also growing at a higher pace, but trading for a quarter of the valuation multiple. At this point, profitability and growth of Alibaba on the one side and the valuation multiple on the other side does not add up. And we have to ask the question, why Alibaba is trading for such a low multiple although it is outperforming many of its peers that trade for much higher multiples.</p>\n<p><b>Risks</b></p>\n<p>When looking at the past performance of Alibaba, we can see, that steep selloffs are quite common as a similar sell-off happened already three times since the IPO in 2014 with the steepest sell-off being more than 50% off the previous high.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4da83a08f0dcfc73534c206e43cb09d3\" tg-width=\"635\" tg-height=\"403\"><span>Data byYCharts</span></p>\n<p>While this might help us a bit, we are still facing high levels of uncertainty and investors usually don’t like uncertainty. Basically, this uncertainty can be summed up in one short sentence: The tense relationship between Alibaba’s founder Jack Ma and the Chinese government is worrying for investors. And this tense relationship is exemplified by several events. It started last year, when the IPO of the company’s fintech affiliate Ant Financial was cancelled. </p>\n<p>This was followed by theinitiation of an antitrust investigation, in which it is investigated if Alibaba had engaged in monopolistic practices (like preventing vendors from selling on other platforms). Additionally, new supervision for Ant Group was also discussed. And finally, at the end of 2020, Jack Ma went missing and it took about three months before the public would hear from him again – another worrying aspect for investors.</p>\n<p>As long as we are talking about risks, there are other aspect I like to mention. I compared Alibaba to Amazon above – and I still think that comparison is appropriate. But we also have to acknowledge, that Alibaba growth potential is limited as the company is mostly focused on China and might have more difficulties to expand globally – compared to Amazon. But considering the growing middle class in China and the high pace with which the economy is still growing we should not worry too much about Alibaba’s growth potential.</p>\n<p>There is a final risk Imentioned in my last article about Tencentand that risk is also applying to Alibaba:</p>\n<blockquote>\n And a final risk is the fact that Tencent is a Chinese company. It is especially difficult to understand different trends before they are happening and predict the future, but while I am familiar with the German culture and the people (habits, preferences, etc.) and can deal with similar countries like France, the United Kingdom, Sweden or the United States, it is rather difficult for me to understand and analyze the consumer behavior and preferences of the Chinese population. This makes it difficult to assess the potential and development of the products and services Tencent offers.\n</blockquote>\n<p>But despite all these issues, there is a comparison I like very much. Very recently,one of my fellow contributorscompared Alibaba’s situation right now to Facebook a few years ago, when it was facing the Cambridge Analytics scandal and also trading for extremely low multiples due to the uncertainties. And it is also interesting, that Wall Street analysts as well as Seeking Alpha contributors are extremely bullish about Alibaba right now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44d2ece5c1460e539c9fd4fb4ba63bf7\" tg-width=\"640\" tg-height=\"195\"><span>(Source:Seeking Alpha)</span></p>\n<p><b>Balance Sheet</b></p>\n<p>When facing challenges, it is especially reassuring if we are dealing with a solid balance sheet enabling the company to withstand challenges and stormy market conditions. And similar to many companies mentioned above – like Facebook or Alphabet – Alibaba also has a great balance sheet. We don’t have to worry about high debt levels although Alibaba has current bank borrowings of RMB 3.6 billion and non-current bank borrowings of RMB 38.3 billion on its balance sheet. But compared to a total equity of RMB 1,075 billion, we get a D/E ratio of 0.04, which is negligible. Aside from the debt, the biggest problem is probably the company’s goodwill. On March 31, 2021, Alibaba had RMB 292.8 billion in goodwill. This means, that 17.3% of total assets (RMB 1,690 billion) is goodwill.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/532919e61e3feb83d46cbce44e3f3c42\" tg-width=\"640\" tg-height=\"354\"><span>(Source:Alibaba Q4/21 Earnings Release)</span></p>\n<p>But aside from goodwill, Alibaba also has RMB 321.3 billion in cash and cash equivalents as well as RMB 152.4 billion in short-term investments on its balance sheet. Aside from these rather liquid assets, Alibaba also has RMB 237.2 billion in equity securities and other investments, that are also worth mentioning. I included a screenshot of the latest balance sheet, which is also including the numbers in US$. Especially $72 billion in very liquid assets give Alibaba a lot of “financial power” and the ability to negative troubles.</p>\n<p><b>Intrinsic Value Calculation</b></p>\n<p>I already mentioned above that Alibaba is trading at rather low multiples – at least when compared to its peers and especially for a company growing with a high pace. And compared to the company’s history, the stock is right now trading almost for its lowest P/FCF ratio since the IPO. A few times – in 2016, 2018 and 2020 – the stock was trading at a similar low P/FCF ratio. From that point of view, Alibaba has to be considered extremely cheap.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d1da4ac18557b21c43feb2a338de9a3b\" tg-width=\"640\" tg-height=\"221\"><span>(Source:Seeking Alpha Charting)</span></p>\n<p>When you are familiar with my past articles, you know that I don’t just use valuation multiples but also a discount cash flow analysis, which is considered to be much more precise (although we have to make a lot more assumptions). When taking the free cash flow of fiscal 2021 (RMB 172.7 billion) as basis, Alibaba has to grow about 5.5% annually from now till perpetuity for the stock to be fairly valued (the intrinsic value is RMB 1,367; discount rate 10%).</p>\n<p>Instead, we can also calculate with more realistic growth rates. If we assume, that Alibaba won’t go under, we have to assume at least 20% growth for the next year. Let’s be rather pessimistic and assume, that growth will slowly decline over the next decade and in 10 years from now, the growth rate will only be 6% till perpetuity. When using these numbers, we get an intrinsic value of&nbsp;<b>RMB 2,596</b>. And we have to assume, that these growth assumptions are rather cautious for a company like Alibaba.</p>\n<p><b>Conclusion</b></p>\n<p>So far, we talked about risks, about past growth rates, compared Alibaba to its peers and provided an intrinsic value calculation. I also wanted to write about the growth potential as well as the wide economic moat, that Alibaba has without any doubt – similar toAmazon,FacebookorTencent. But the article would probably be too long then. Instead, I included links to three articles in which I described the economic moat of these businesses.</p>\n<p>When summing up, it is quite simple. When we assume, that Alibaba is in serious trouble and might be brought down in some way or is facing troubles, that will seriously mess with the company’s ability to grow, we should not invest in Alibaba. These risks are present, and we actually don’t know what could happen in the coming quarters (or years). However, I consider it extremely unlikely, that China will destroy its second most-valuable company. If we assume on the other side, that this is just a small hick-up and troubles Alibaba can work through in the coming quarters and Alibaba will continue to perform in a similar way as in the past (even with growth rates slowing down), Alibaba is probably one of the most undervalued stocks out there and an extreme bargain.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba: One Of The Really Cheap Bargains In This Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba: One Of The Really Cheap Bargains In This Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 20:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4432358-alibaba-one-of-the-really-cheap-bargains-in-market><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAlibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.\nThe company is clearly facing risks due to the tension between Jack Ma and the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4432358-alibaba-one-of-the-really-cheap-bargains-in-market\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://seekingalpha.com/article/4432358-alibaba-one-of-the-really-cheap-bargains-in-market","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1138216687","content_text":"Summary\n\nAlibaba is one of the largest corporations in the world and focusing on retail, cloud and payment services.\nThe company is clearly facing risks due to the tension between Jack Ma and the Chinese government, but I consider these risks to be only temporary.\nAlibaba is growing with a high pace, has a very stable balance sheet and outperforming many of its peers.\nIn my opinion, the stock is severely undervalued.\n\nPhoto by maybefalse/iStock Unreleased via Getty Images\nSo far, I have published over 300 articles on this site and the focus has been clearly on companies having the headquarters in the United States and stocks listed on an US-based stock exchange. And while I am covering also companies from Germany, France, Great Britain, Sweden or Denmark, I have avoided one country almost completely although it has many interesting investment opportunities: Mainland China.The only company I covered so far is Tencent Holdings Limited (OTCPK:TCEHY).\nAnd although China has hundreds or thousands of successful companies, most of them are almost unknown in the Western Hemisphere (especially when moving outside of the investing world). And while most investors are familiar with Tencent, there is at least one other company almost every investor has heard of: Alibaba Group Holding Limited (BABA). In the following article, I will analyze Alibaba in my usual way. I will try to determine if Alibaba is a solid business with a wide economic moat and try to answer the question if Alibaba is a solid investment right now.\nBusiness Description\nAlibaba Group was founded in 1999 by 18 individuals. Nevertheless, one of these 18 stands out – the former English teacher from Hangzhou, Jack Ma. Over the years, Alibaba evolved in a multinational technology company and with a market capitalization of $570 billion, Alibaba is on the 10thspot on the list of most valuable companies in the world (by market cap). And behind Tencent, which is on the 7thspot on that list, Alibaba is the second most valuable company in China.\nWhile Alibaba is mostly focused on e-commerce and retail operations, the Alibaba Group is actually a holding company with many different sales services. This includes C2C services, B2C services and B2B services. Aside from retail, the Alibaba Group also offers electronic payment services, shipping search engines and could computing services. The group owns and operates a diverse portfolio of companies around the world in numerous business sectors.\n(Source:Alibaba Q4/20 Presentation)\nAlibaba is reporting in four different segments:\n\nCore Commerce Revenue: This segment is comprised of platforms operating in retail and wholesale commerce in China as well as logistics services and local consumer services. In fiscal 2021, this segment generated RMB 621.1 billion in revenue and RMB 159 billion in income from operations.\nCloud Computing Revenue: This segment is comprised of Alibaba Cloud, which offers different cloud services to customers worldwide like database, storage, big data analytics, a machine learning platform and large-scale computing security. In fiscal 2021, this segment generated RMB 60.1 billion, but the segment was not profitable so far (a loss of RMB 9 billion).\nDigital Media and Entertainment Revenue: This segment uses the deep data insights to serve the broader interests of consumers through key distribution platforms Youku and Alibaba Pictures as well as other content platforms that provide online videos, films, live events, literature and music. In fiscal 2021, this segment generated RMB 31.2 billion, but was also not profitable.\nInnovation Initiatives and Others Revenue: This segment includes businesses like Amap, DingTalk, Tmall Genie and others. In fiscal 2021, this segment generated RMB 4.8 billion in revenue, but also an operating loss.\n\n(Source: Alibaba Q4/20 Presentation)\nWhen looking at the last annual results (fiscal 2021), Alibaba generated RMB 717.3 billion in revenue. Compared to fiscal 2020 (RMB 509.7 billion) this is reflecting an increase of 41%. Adjusted EBITDA in fiscal 2021 was RMB 196.8 billion – an increase of 25% compared to fiscal 2020 (adjusted EBITA of RMB 157.7 billion). Diluted earnings per share actually decreased from RMB 6.99 in fiscal 2020 to RMB 6.84 in fiscal 2021 – reflecting a decrease of 2.1%. But we should not pay too much attention to the earnings per share. Instead, it makes much more sense to look at the free cash flow Alibaba is generating. In fiscal 2021, Alibaba generated RMB 172.7 billion in free cash flow compared to RMB 130.9 billion in free cash flow one year earlier.\nStrong Business Among Strong Competitors\nWhat is striking when looking at Alibaba – and what has been discussed several times – is the low multiple for which Alibaba is currently trading. When using the trailing twelve-month GAAP numbers, Alibaba is trading for 25 times earnings, when using the non-GAAP forward numbers, it is trading for a P/E ratio of 20.\nWe can compare Alibaba to its peers – companies like Amazon (AMZN), Tencent, Facebook (FB), Microsoft (MSFT) or Alphabet (GOOG). And Alibaba actually belongs in that list as it is not only operating in similar business segments, but it is also growing with similarly high rates. And Alibaba is not only growing with a similar pace; it is actually outperforming most of its peers.\n(Source:Alibaba 2020 Investor Presentations)\nWhile Alibaba is growing with a similar pace like these companies, it is trading for a completely different multiple. Right now, Alibaba is trading for a price-cash-flow ratio of 17, while competitors like Tencent, Facebook or Microsoft are trading for a P/FCF ratio between 35 and 40. It is striking, that the market is assigning these competitors a multiple twice as high and Amazon is actually trading for a multiple more than 4 times higher (price-free-cash-flow ratio of 76).\nData by YCharts\nRight now, readers might point out, that the comparison to Amazon is misleading as Amazon is still spending a lot of money to achieve future growth and therefore has a lower profit than other companies. And it certainly is true, that Amazon is still focusing on top line growth – sometimes at the expense of bottom-line growth – but so does Alibaba.\nWhile Amazon spent 10.4% of its revenue as capital expenditures in the last fiscal year, Alibaba spent almost the same amount – 8.9% of revenue. And when looking at the expenses for research and development, we once again see similar numbers. In the last five years, Amazon spent 12.16% of revenue on R&D on average while Alibaba spent 10.38% of its revenue on R&D.\nBut while these numbers are quite similar for both companies – Amazon is spending a bit more on R&D than Alibaba – the free cash flow these two companies can generate is completely different. While Amazon only generated 6.7% of revenue as free cash flow in the last fiscal year, Alibaba generated 26.5% of revenue as free cash flow in the last fiscal year – almost four times higher.\nAnd Alibaba is not only extremely profitable – it was growing with an extremely high pace in the past. During the past ten years, Alibaba could not only grow revenue every single year, it also grew revenue with a CAGR of 62.6%. Earnings per share fluctuated a little bit during these ten years but grew with an even higher pace – a CAGR of 76.29% during the last decade. And finally, free cash flow increased with a CAGR of 59.62% during the last decade.\n(Source: Author’s work based on numbers from Morningstar)\nWhen looking at Alibaba’s growth rates in the last few years compared to its competitors, Alibaba is also outperforming. When looking at the revenue CAGR of the last 5 years, we get the following numbers:\n\nAmazon: 29.26%\nFacebook: 36.82%\nTencent: 36.20%\nAlphabet: 19.47%\nMicrosoft: 8.85%\nAlibaba: 46.24%\n\nWe can spin it how we want: Alibaba is an extremely profitable company growing with extremely high rates but is trading at an extremely low multiple compared to its competitors. It is growing with a higher pace than Microsoft and Facebook, but trading for half the multiple. It is much more profitable than Amazon and also growing at a higher pace, but trading for a quarter of the valuation multiple. At this point, profitability and growth of Alibaba on the one side and the valuation multiple on the other side does not add up. And we have to ask the question, why Alibaba is trading for such a low multiple although it is outperforming many of its peers that trade for much higher multiples.\nRisks\nWhen looking at the past performance of Alibaba, we can see, that steep selloffs are quite common as a similar sell-off happened already three times since the IPO in 2014 with the steepest sell-off being more than 50% off the previous high.\nData byYCharts\nWhile this might help us a bit, we are still facing high levels of uncertainty and investors usually don’t like uncertainty. Basically, this uncertainty can be summed up in one short sentence: The tense relationship between Alibaba’s founder Jack Ma and the Chinese government is worrying for investors. And this tense relationship is exemplified by several events. It started last year, when the IPO of the company’s fintech affiliate Ant Financial was cancelled. \nThis was followed by theinitiation of an antitrust investigation, in which it is investigated if Alibaba had engaged in monopolistic practices (like preventing vendors from selling on other platforms). Additionally, new supervision for Ant Group was also discussed. And finally, at the end of 2020, Jack Ma went missing and it took about three months before the public would hear from him again – another worrying aspect for investors.\nAs long as we are talking about risks, there are other aspect I like to mention. I compared Alibaba to Amazon above – and I still think that comparison is appropriate. But we also have to acknowledge, that Alibaba growth potential is limited as the company is mostly focused on China and might have more difficulties to expand globally – compared to Amazon. But considering the growing middle class in China and the high pace with which the economy is still growing we should not worry too much about Alibaba’s growth potential.\nThere is a final risk Imentioned in my last article about Tencentand that risk is also applying to Alibaba:\n\n And a final risk is the fact that Tencent is a Chinese company. It is especially difficult to understand different trends before they are happening and predict the future, but while I am familiar with the German culture and the people (habits, preferences, etc.) and can deal with similar countries like France, the United Kingdom, Sweden or the United States, it is rather difficult for me to understand and analyze the consumer behavior and preferences of the Chinese population. This makes it difficult to assess the potential and development of the products and services Tencent offers.\n\nBut despite all these issues, there is a comparison I like very much. Very recently,one of my fellow contributorscompared Alibaba’s situation right now to Facebook a few years ago, when it was facing the Cambridge Analytics scandal and also trading for extremely low multiples due to the uncertainties. And it is also interesting, that Wall Street analysts as well as Seeking Alpha contributors are extremely bullish about Alibaba right now.\n(Source:Seeking Alpha)\nBalance Sheet\nWhen facing challenges, it is especially reassuring if we are dealing with a solid balance sheet enabling the company to withstand challenges and stormy market conditions. And similar to many companies mentioned above – like Facebook or Alphabet – Alibaba also has a great balance sheet. We don’t have to worry about high debt levels although Alibaba has current bank borrowings of RMB 3.6 billion and non-current bank borrowings of RMB 38.3 billion on its balance sheet. But compared to a total equity of RMB 1,075 billion, we get a D/E ratio of 0.04, which is negligible. Aside from the debt, the biggest problem is probably the company’s goodwill. On March 31, 2021, Alibaba had RMB 292.8 billion in goodwill. This means, that 17.3% of total assets (RMB 1,690 billion) is goodwill.\n(Source:Alibaba Q4/21 Earnings Release)\nBut aside from goodwill, Alibaba also has RMB 321.3 billion in cash and cash equivalents as well as RMB 152.4 billion in short-term investments on its balance sheet. Aside from these rather liquid assets, Alibaba also has RMB 237.2 billion in equity securities and other investments, that are also worth mentioning. I included a screenshot of the latest balance sheet, which is also including the numbers in US$. Especially $72 billion in very liquid assets give Alibaba a lot of “financial power” and the ability to negative troubles.\nIntrinsic Value Calculation\nI already mentioned above that Alibaba is trading at rather low multiples – at least when compared to its peers and especially for a company growing with a high pace. And compared to the company’s history, the stock is right now trading almost for its lowest P/FCF ratio since the IPO. A few times – in 2016, 2018 and 2020 – the stock was trading at a similar low P/FCF ratio. From that point of view, Alibaba has to be considered extremely cheap.\n(Source:Seeking Alpha Charting)\nWhen you are familiar with my past articles, you know that I don’t just use valuation multiples but also a discount cash flow analysis, which is considered to be much more precise (although we have to make a lot more assumptions). When taking the free cash flow of fiscal 2021 (RMB 172.7 billion) as basis, Alibaba has to grow about 5.5% annually from now till perpetuity for the stock to be fairly valued (the intrinsic value is RMB 1,367; discount rate 10%).\nInstead, we can also calculate with more realistic growth rates. If we assume, that Alibaba won’t go under, we have to assume at least 20% growth for the next year. Let’s be rather pessimistic and assume, that growth will slowly decline over the next decade and in 10 years from now, the growth rate will only be 6% till perpetuity. When using these numbers, we get an intrinsic value of RMB 2,596. And we have to assume, that these growth assumptions are rather cautious for a company like Alibaba.\nConclusion\nSo far, we talked about risks, about past growth rates, compared Alibaba to its peers and provided an intrinsic value calculation. I also wanted to write about the growth potential as well as the wide economic moat, that Alibaba has without any doubt – similar toAmazon,FacebookorTencent. But the article would probably be too long then. Instead, I included links to three articles in which I described the economic moat of these businesses.\nWhen summing up, it is quite simple. When we assume, that Alibaba is in serious trouble and might be brought down in some way or is facing troubles, that will seriously mess with the company’s ability to grow, we should not invest in Alibaba. These risks are present, and we actually don’t know what could happen in the coming quarters (or years). However, I consider it extremely unlikely, that China will destroy its second most-valuable company. If we assume on the other side, that this is just a small hick-up and troubles Alibaba can work through in the coming quarters and Alibaba will continue to perform in a similar way as in the past (even with growth rates slowing down), Alibaba is probably one of the most undervalued stocks out there and an extreme bargain.","news_type":1},"isVote":1,"tweetType":1,"viewCount":160,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805438269,"gmtCreate":1627897494651,"gmtModify":1703497421005,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Why still negotiating with the vaccine makers when the covid is still rampant in india?","listText":"Why still negotiating with the vaccine makers when the covid is still rampant in india?","text":"Why still negotiating with the vaccine makers when the covid is still rampant in india?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/805438269","repostId":"2156191887","repostType":4,"repost":{"id":"2156191887","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627893983,"share":"https://ttm.financial/m/news/2156191887?lang=&edition=fundamental","pubTime":"2021-08-02 16:46","market":"us","language":"en","title":"India says J&J withdraws proposal for speedy vaccine approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2156191887","media":"Reuters","summary":"(Adds details, background)\nBENGALURU, Aug 2 (Reuters) - India's drug regulator said on Monday that J","content":"<p>(Adds details, background)</p>\n<p>BENGALURU, Aug 2 (Reuters) - India's drug regulator said&nbsp;on Monday that Johnson &amp; Johnson withdrew its proposal seeking accelerated approval of its COVID-19 vaccine in the country, without giving additional details.</p>\n<p>The U.S.-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen COVID-19 vaccine candidate in India. Trials in the United States at that time were paused on reports&nbsp;of rare blood clots.</p>\n<p>The drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.</p>\n<p>\"This team is in continuous dialogue with Pfizer, Moderna and Johnson &amp; Johnson to discuss and address various issues including the issue of indemnity,\" Bharati Pravin Pawar had said.</p>\n<p>Johnson &amp; Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to Reuters' requests for comments on why the company withdrew its application.</p>\n<p>As of July 31, Johnson &amp; Johnson is yet to request a full approval for its shot with the U.S. FDA, while Pfizer Inc, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> , and Moderna Inc have already sought full approval of their vaccines with the FDA.</p>\n<p>In India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June.</p>\n<p>(Reporting by Shivani Singh in Bengaluru; editing by Uttaresh.V)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India says J&J withdraws proposal for speedy vaccine approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia says J&J withdraws proposal for speedy vaccine approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-02 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Adds details, background)</p>\n<p>BENGALURU, Aug 2 (Reuters) - India's drug regulator said&nbsp;on Monday that Johnson &amp; Johnson withdrew its proposal seeking accelerated approval of its COVID-19 vaccine in the country, without giving additional details.</p>\n<p>The U.S.-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen COVID-19 vaccine candidate in India. Trials in the United States at that time were paused on reports&nbsp;of rare blood clots.</p>\n<p>The drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.</p>\n<p>\"This team is in continuous dialogue with Pfizer, Moderna and Johnson &amp; Johnson to discuss and address various issues including the issue of indemnity,\" Bharati Pravin Pawar had said.</p>\n<p>Johnson &amp; Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to Reuters' requests for comments on why the company withdrew its application.</p>\n<p>As of July 31, Johnson &amp; Johnson is yet to request a full approval for its shot with the U.S. FDA, while Pfizer Inc, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> , and Moderna Inc have already sought full approval of their vaccines with the FDA.</p>\n<p>In India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June.</p>\n<p>(Reporting by Shivani Singh in Bengaluru; editing by Uttaresh.V)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156191887","content_text":"(Adds details, background)\nBENGALURU, Aug 2 (Reuters) - India's drug regulator said on Monday that Johnson & Johnson withdrew its proposal seeking accelerated approval of its COVID-19 vaccine in the country, without giving additional details.\nThe U.S.-based company had said in April it was seeking an approval to conduct a bridging clinical study of its Janssen COVID-19 vaccine candidate in India. Trials in the United States at that time were paused on reports of rare blood clots.\nThe drugmaker's withdrawal comes as India tackles legal challenges with manufacturers over indemnity issues, with its junior health minister saying last week that a team had been formed to engage with vaccine makers.\n\"This team is in continuous dialogue with Pfizer, Moderna and Johnson & Johnson to discuss and address various issues including the issue of indemnity,\" Bharati Pravin Pawar had said.\nJohnson & Johnson and the Central Drugs Standard Control Organisation (CDSCO) did not immediately respond to Reuters' requests for comments on why the company withdrew its application.\nAs of July 31, Johnson & Johnson is yet to request a full approval for its shot with the U.S. FDA, while Pfizer Inc, BioNTech SE , and Moderna Inc have already sought full approval of their vaccines with the FDA.\nIn India, the drug regulator had given emergency use authorisation to Moderna's vaccine in June.\n(Reporting by Shivani Singh in Bengaluru; editing by Uttaresh.V)","news_type":1},"isVote":1,"tweetType":1,"viewCount":539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173589204,"gmtCreate":1626669935108,"gmtModify":1703763062231,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Really?!","listText":"Really?!","text":"Really?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173589204","repostId":"2152368129","repostType":4,"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173589371,"gmtCreate":1626669900793,"gmtModify":1703763060612,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Seems like ample liquidity&nbsp;","listText":"Seems like ample liquidity&nbsp;","text":"Seems like ample liquidity","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173589371","repostId":"1183956332","repostType":4,"repost":{"id":"1183956332","kind":"news","pubTimestamp":1626568120,"share":"https://ttm.financial/m/news/1183956332?lang=&edition=fundamental","pubTime":"2021-07-18 08:28","market":"us","language":"en","title":"US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1183956332","media":"renaissancecap...","summary":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.The largest deal of the week, specialty insurance brokerage Ryan Specialty Group plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in t","content":"<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.</p>\n<p>The largest deal of the week, specialty insurance brokerage&nbsp;<b>Ryan Specialty Group</b>(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.</p>\n<p>Water infrastructure company&nbsp;<b>Core &amp; Main</b>(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.</p>\n<p>HR software provider&nbsp;<b>Paycor HCM</b>(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.</p>\n<p>Latin <a href=\"https://laohu8.com/S/AFG\">American</a> e-commerce platform&nbsp;<b><a href=\"https://laohu8.com/S/VTEX\">VTEX</a></b>(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&amp;A and R&amp;D have weighed on profits.</p>\n<p>Learning management platform&nbsp;<b>Instructure Holdings</b>(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.</p>\n<p>Protein discovery and development platform&nbsp;<b>AbSci</b>(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include <a href=\"https://laohu8.com/S/MRK\">Merck</a> and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.</p>\n<p>Organic beverage brand&nbsp;<b><a href=\"https://laohu8.com/S/ZVIA\">Zevia PBC</a></b>(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.</p>\n<p>Content marketing platform&nbsp;<b>Outbrain</b>(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.</p>\n<p>Fitness franchisor&nbsp;<b>Xponential Fitness</b>(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.</p>\n<p>Legal software provider&nbsp;<b>CS Disco</b>(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.</p>\n<p>Following its postponement in May, Brazil’s&nbsp;<b>Zenvia</b>(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.</p>\n<p><b>Couchbase</b>(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&amp;M costs.</p>\n<p>Following its postponement in April,<b>Kaltura</b>(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.</p>\n<p><b>Gambling.com Group</b>(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.</p>\n<p>Three biotechs are expected to round out the week: cancer biotech&nbsp;<b>Candel Therapeutics</b>(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech&nbsp;<b>Ocean Biomedical</b>(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech&nbsp;<b>Elicio Therapeutics</b>(ELTX), which plans to raise $40 million at a $201 million market cap.</p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Software, soft drinks, specialty insurance, and more debut in a 17 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-18 08:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BASE":"Couchbase, Inc.","ABSI":"Absci Corporation.","LAW":"CS Disco, Inc.","CNM":"Core & Main, Inc.","GAMB":"Gambling.com Group Limited","OB":"Outbrain Inc.","ELTX":"Elicio Therapeutics","CADL":"Candel Therapeutics, Inc.","OCEA":"Ocean Biomedical","VTEX":"VTEX","INST":"Instructure Holdings, Inc.","ZVIA":"Zevia PBC","PYCR":"Paycor HCM, Inc.","RYAN":"Ryan Specialty Group Holdings, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/84265/US-IPO-Week-Ahead-Software-soft-drinks-specialty-insurance-and-more-debut-i","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183956332","content_text":"The IPO market’s breakneck pace is expected to continue in the week ahead, with a whopping 17 IPOs slated to raise $4.7 billion.\nThe largest deal of the week, specialty insurance brokerage Ryan Specialty Group(RYAN) plans to raise $1.3 billion at a $6.1 billion market cap. The company assists in the placement of hard-to-place risks for retail insurance brokers, and the sourcing, onboarding, underwriting, and servicing of those hard-to-place risks for insurance carriers. Profitable on an EBIT basis in the 1Q21, the company will be leveraged post-IPO.\nWater infrastructure company Core & Main(CNM) plans to raise $750 million at a $5.2 billion market cap in a 100% synthetic secondary offering. Profitable with solid growth, the company distributes water infrastructure products that connect 4,500 suppliers to over 60,000 municipal, non-residential, and residential customers.\nHR software provider Paycor HCM(PYCR) plans to raise $361 million at a $3.4 billion market cap. Paycor provides human capital management software to small and mid-sized businesses, covering the payroll process and key HR functionality. While net revenue retention fell in the FY20, the company is targeting a large addressable market and has a track record of profitability.\nLatin American e-commerce platform VTEX(VTEX) plans to raise $304 million at a $3.2 billion market cap. VTEX operates a business-to-consumer e-commerce platform to enterprise customers that natively combines commerce, order management, and marketplace functionality. The company has demonstrated growth, though investments in SG&A and R&D have weighed on profits.\nLearning management platform Instructure Holdings(INST) plans to raise $250 million at a $2.9 billion market cap. The company provides a next-generation Learning Management System (LMS), assessments for learning, actionable analytics, and dynamic content. Instructure states that it is the LMS market leader in both Higher Education and paid K-12, with over 6,000 global customers across 90 countries.\nProtein discovery and development platform AbSci(ABSI) plans to raise $200 million at a $1.6 billion market cap. AbSci currently has nine active programs across seven partners, which include Merck and Astellas, for which it has either negotiated or plans to negotiate license agreements. The company is highly unprofitable, and 90% of its tech development revenue came from a single partner in the 1Q21.\nOrganic beverage brand Zevia PBC(ZVIA) plans to raise $200 million at a $1.0 billion market cap. Zevia provides six product lines of zero calorie, zero sugar, naturally sweetened beverages in the US and Canada. The company has demonstrated growth and achieved profitability in the 1Q21.\nContent marketing platform Outbrain(OB) plans to raise $200 million at a $1.5 billion market cap. Outbrain’s platform enables over 7,000 online properties, helping them engage their users and monetize their visits by gathering over 1 billion data events each minute. Profitable with strong growth, the company had over 20,000 advertisers using its platform in 2020.\nFitness franchisor Xponential Fitness(XPOF) plans to raise $200 million at a $711 million market cap. Xponential Fitness is the largest boutique fitness franchisor in the US with over 1,750 studios operating across nine distinct brands. While the company’s business was impacted by the pandemic in 2020, preliminary results for the 2Q21 show 60%+ revenue growth and adjusted EBITDA swinging positive.\nLegal software provider CS Disco(LAW) plans to raise $193 million at a $1.6 billion market cap. Fast growing and unprofitable, DISCO provides a cloud-native, AI-powered legal solution that simplifies ediscovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments.\nFollowing its postponement in May, Brazil’s Zenvia(ZENV) plans to raise $162 million at a $548 million market cap. The company’s software platform facilitated the flow of communication for more than 10,190 customers throughout Latin America as of March 31, 2021. While it achieved a net revenue expansion rate of nearly 110%, Zenvia’s EBITDA turned negative in the 1Q21.\nCouchbase(BASE) plans to raise $151 million at a $992 million market cap. Couchbase provides a NoSQL database that enables enterprises and developers to build and run applications across the cloud, on-premise, hybrid, or mobile and edge environments. The company has a sticky customer base that includes 30% of the Fortune 100, though it remains unprofitable due to high S&M costs.\nFollowing its postponement in April,Kaltura(KLTR) plans to raise $150 million at a $1.4 billion market cap. Kaltura provides live, real-time, and on-demand video products to a wide range of businesses including educational institutions, and media and telecom companies. Thanks to the growing adoption of virtual events, the company saw revenue expand in the 1Q21, though gross margin contracted.\nGambling.com Group(GAMB) plans to raise $90 million at a $435 million market cap. Gambling.com Group is a performance marketing company and a digital marketing services provider active exclusively in the online gambling industry, with a principal focus on iGaming and sports betting. Profitable and fast growing, the company has increased its customer base from 131 in 2017 to over 200 in 2020.\nThree biotechs are expected to round out the week: cancer biotech Candel Therapeutics(CADL), which plans to raise $85 million at a $398 million market cap; preclinical biotech Ocean Biomedical(OCEA), which plans to raise $50 million at a $506 million market cap; and cancer biotech Elicio Therapeutics(ELTX), which plans to raise $40 million at a $201 million market cap.","news_type":1},"isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170968780,"gmtCreate":1626400110740,"gmtModify":1703759396877,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Any details on the tie up?","listText":"Any details on the tie up?","text":"Any details on the tie up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170968780","repostId":"2151856310","repostType":2,"repost":{"id":"2151856310","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626175200,"share":"https://ttm.financial/m/news/2151856310?lang=&edition=fundamental","pubTime":"2021-07-13 19:20","market":"us","language":"en","title":"BRIEF-Marqeta And Payfare Enter Into Strategic Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2151856310","media":"Reuters","summary":"July 13 (Reuters) - Marqeta Inc   :   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIPSource t","content":"<html><body><p>July 13 (Reuters) - Marqeta Inc   :</p><p>   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIP</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Marqeta And Payfare Enter Into Strategic Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Marqeta And Payfare Enter Into Strategic Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-13 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>July 13 (Reuters) - Marqeta Inc   :</p><p>   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIP</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CGEM":"Cullinan Therapeutics","LHDX":"Lucira Health, Inc.","MQ":"Marqeta, Inc.","LABP":"Landos Biopharma, Inc.","APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc."},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151856310","content_text":"July 13 (Reuters) - Marqeta Inc   :   * MARQETA AND PAYFARE ENTER INTO STRATEGIC PARTNERSHIPSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186964108,"gmtCreate":1623470024704,"gmtModify":1704204535113,"author":{"id":"3574987111088333","authorId":"3574987111088333","name":"FCY","avatar":"https://static.tigerbbs.com/57540ce9384964d094b3b7ee163ea81e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574987111088333","authorIdStr":"3574987111088333"},"themes":[],"htmlText":"Good update","listText":"Good update","text":"Good update","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186964108","repostId":"2142204460","repostType":2,"repost":{"id":"2142204460","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623438180,"share":"https://ttm.financial/m/news/2142204460?lang=&edition=fundamental","pubTime":"2021-06-12 03:03","market":"us","language":"en","title":"New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2142204460","media":"Dow Jones","summary":"MW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow wi","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n</p>\n<p>\n  Tomi Kilgore \n</p>\n<p>\n  Current vaccination rates suggest U.S. will fall well short of President Biden's vaccination goal \n</p>\n<p>\n  The number of new daily COVID-19 cases and deaths fell for the first time in four days, but vaccine hesitancy, amid reports of a heart inflammation side effect in teens and some supply concerns, is increasing the risk that President Biden's vaccination goal may not be reached. \n</p>\n<p>\n  There were at least 11,841 new cases of the coronavirus-borne illness on Thursday, down from 20,153 new cases on Wednesday, according to a New York Times tracker , to snap a three-day streak of increases. \n</p>\n<p>\n  Deaths fell to 412 on Thursday from 449 the day before, to also snap a 3-day rising streak. \n</p>\n<p>\n  The seven-day average of cases declined to 13,409 from 14,505, down 42% from two weeks ago and the lowest count since March 2020. For deaths, the seven-day average dropped to 387, the lowest since June 1, from 417 on Wednesday, and was 22% below where it was two weeks ago. \n</p>\n<p>\n  There are 12 states showing an increase in the weekly trend in cases on Friday, JHU data show , down from 15 on Thursday. \n</p>\n<p>\n  On the vaccination front, 305.69 million COVID-19 vaccines have been administered, and 165.12 million people aged at least 18 years old, or 64.0% of the U.S.'s adult population, have received at least <a href=\"https://laohu8.com/S/AONE\">one</a> shot, the latest data from the Centers for Disease Control and Prevention . \n</p>\n<p>\n  At that daily pace of vaccinations, the U.S. will fall well short of Biden's goal of 70% of adult Americans receiving at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> shot by the Fourth of July. About 15.48 million more adults need to get one vaccine dose to reach Biden's goal, which translates to roughly 700,000 a day. \n</p>\n<p>\n  The number of fully vaccinated Americans increased to 141.58 million, or 42.6% of the total population. \n</p>\n<p>\n  Within age groups, 50.5% of Americans who are at least 12 years old are fully vaccinated, as are 53.4% of the U.S. adult population and 75.8% of Americans at least 65 years old. \n</p>\n<p>\n  In the U.S., fully vaccinated means it has been two weeks since the second of the two-dose vaccines developed by Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) or Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> have been administered, or it's been two weeks since receiving the lone dose of Johnson &amp; Johnson's <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine. \n</p>\n<p>\n  Regarding the J&amp;J vaccine, the CDC temporarily halted shipments in an effort to clear a backlog of unused doses, according to a report in The Wall Street Journal  this month. \n</p>\n<p>\n  On Friday, the U.S. Food and Drug Administration said it extended the expiration dating for J&amp;J's vaccine to 4 1/2 months from 3 months when refrigerated at 2 degrees to 8 degrees Celsius (35.6 degrees-46.4 degrees Fahrenheit). \n</p>\n<p>\n  Separately, the FDA said it has authorized for use  Baltimore facility, even though it is \"not yet ready\" to include the plant in the EUA as an authorized facility. \n</p>\n<p>\n  \"Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson &amp; Johnson) COVID-19 vaccine to be made available,\" the FDA said in a statement. \n</p>\n<p>\n  The statement comes as the New York Times reported , citing people familiar with the situation, that the FDA told J&amp;J to discard 60 million doses of its vaccine made at the Baltimore plant because of possible contamination. \n</p>\n<p>\n  Separately, vaccine hesitancy has been fueled as reports circulated that mRNA vaccines, the kind made by Pfizer-BioNTech and Moderna, have led to a small number of reports of myocarditis , or heart inflammation, in teens. \n</p>\n<p>\n  Dr. Ashish Jha, a dean of the Brown University School of Public Health, said on NBC's \"Today\"  that it increasingly looks like the vaccine is leading to some \"rare\" cases in teens. \n</p>\n<p>\n  He tried to dispel concerns, however, saying that almost all of the cases of myocarditis are \"incredibly mild\" and people recover \"very, very quickly,\" but acknowledged that \"it's not irrelevant\" and can occasionally be more severe. \n</p>\n<p>\n  When asked about how that might fuel vaccine hesitancy, Jha noted that \"every vaccine, every medicine\" can have side effects. \n</p>\n<p>\n  \"You can get myocarditis, you can get many other things, with COVID infection itself, \"Jha said. \"And your risk of having complications from infection remain way higher than your risk from vaccines.\" \n</p>\n<p>\n  In the U.S., there are now four states with more than half of their population fully vaccinated -- Vermont (54.3%), Massachusetts (53.5%), Connecticut (51.4%) and Maine (50.22%) -- and 16 states and the District of Columbia have fully vaccinated more than the U.S. average, according to JHU data . \n</p>\n<p>\n  The states with the lowest percentage of their populations fully vaccinated are Mississippi (26.2%), Alabama (27.8%) and Louisiana (29.8%) \n</p>\n<p>\n  Latest tallies \n</p>\n<p>\n  The global case tally for the coronavirus-borne illness rose to 175.01 million on Thursday, while the death toll rose to 3,776,263, according to JHU data  and about 1.8 million deaths. \n</p>\n<p>\n  There have been 2.28 million vaccine doses administered worldwide as of Thursday, the data show. \n</p>\n<p>\n  The U.S. leads the world in total cases with 33.43 million and deaths with 599,023. \n</p>\n<p>\n  India continues to move closer to the U.S., with cases rising to 29.27 million, but is third in the world in deaths with 363,079. \n</p>\n<p>\n  Brazil is second in deaths at 482,019 and third in cases with 17.21 million. \n</p>\n<p>\n  The U.K. is fourth in deaths worldwide, and it leads Europe, at 28,148, while France is fourth globally in cases and leads Europe with 5.80 million. \n</p>\n<p>\n  China, where the virus was first discovered late in 2019,  has had 103,285 cases and has held steady at 4,846 deaths, according to its official numbers, which are widely held to be massively underreported. \n</p>\n<p>\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 11, 2021 15:03 ET (19:03 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-12 03:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n</p>\n<p>\n  Tomi Kilgore \n</p>\n<p>\n  Current vaccination rates suggest U.S. will fall well short of President Biden's vaccination goal \n</p>\n<p>\n  The number of new daily COVID-19 cases and deaths fell for the first time in four days, but vaccine hesitancy, amid reports of a heart inflammation side effect in teens and some supply concerns, is increasing the risk that President Biden's vaccination goal may not be reached. \n</p>\n<p>\n  There were at least 11,841 new cases of the coronavirus-borne illness on Thursday, down from 20,153 new cases on Wednesday, according to a New York Times tracker , to snap a three-day streak of increases. \n</p>\n<p>\n  Deaths fell to 412 on Thursday from 449 the day before, to also snap a 3-day rising streak. \n</p>\n<p>\n  The seven-day average of cases declined to 13,409 from 14,505, down 42% from two weeks ago and the lowest count since March 2020. For deaths, the seven-day average dropped to 387, the lowest since June 1, from 417 on Wednesday, and was 22% below where it was two weeks ago. \n</p>\n<p>\n  There are 12 states showing an increase in the weekly trend in cases on Friday, JHU data show , down from 15 on Thursday. \n</p>\n<p>\n  On the vaccination front, 305.69 million COVID-19 vaccines have been administered, and 165.12 million people aged at least 18 years old, or 64.0% of the U.S.'s adult population, have received at least <a href=\"https://laohu8.com/S/AONE\">one</a> shot, the latest data from the Centers for Disease Control and Prevention . \n</p>\n<p>\n  At that daily pace of vaccinations, the U.S. will fall well short of Biden's goal of 70% of adult Americans receiving at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> shot by the Fourth of July. About 15.48 million more adults need to get one vaccine dose to reach Biden's goal, which translates to roughly 700,000 a day. \n</p>\n<p>\n  The number of fully vaccinated Americans increased to 141.58 million, or 42.6% of the total population. \n</p>\n<p>\n  Within age groups, 50.5% of Americans who are at least 12 years old are fully vaccinated, as are 53.4% of the U.S. adult population and 75.8% of Americans at least 65 years old. \n</p>\n<p>\n  In the U.S., fully vaccinated means it has been two weeks since the second of the two-dose vaccines developed by Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (BNTX) or Moderna Inc. <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> have been administered, or it's been two weeks since receiving the lone dose of Johnson &amp; Johnson's <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine. \n</p>\n<p>\n  Regarding the J&amp;J vaccine, the CDC temporarily halted shipments in an effort to clear a backlog of unused doses, according to a report in The Wall Street Journal  this month. \n</p>\n<p>\n  On Friday, the U.S. Food and Drug Administration said it extended the expiration dating for J&amp;J's vaccine to 4 1/2 months from 3 months when refrigerated at 2 degrees to 8 degrees Celsius (35.6 degrees-46.4 degrees Fahrenheit). \n</p>\n<p>\n  Separately, the FDA said it has authorized for use  Baltimore facility, even though it is \"not yet ready\" to include the plant in the EUA as an authorized facility. \n</p>\n<p>\n  \"Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson &amp; Johnson) COVID-19 vaccine to be made available,\" the FDA said in a statement. \n</p>\n<p>\n  The statement comes as the New York Times reported , citing people familiar with the situation, that the FDA told J&amp;J to discard 60 million doses of its vaccine made at the Baltimore plant because of possible contamination. \n</p>\n<p>\n  Separately, vaccine hesitancy has been fueled as reports circulated that mRNA vaccines, the kind made by Pfizer-BioNTech and Moderna, have led to a small number of reports of myocarditis , or heart inflammation, in teens. \n</p>\n<p>\n  Dr. Ashish Jha, a dean of the Brown University School of Public Health, said on NBC's \"Today\"  that it increasingly looks like the vaccine is leading to some \"rare\" cases in teens. \n</p>\n<p>\n  He tried to dispel concerns, however, saying that almost all of the cases of myocarditis are \"incredibly mild\" and people recover \"very, very quickly,\" but acknowledged that \"it's not irrelevant\" and can occasionally be more severe. \n</p>\n<p>\n  When asked about how that might fuel vaccine hesitancy, Jha noted that \"every vaccine, every medicine\" can have side effects. \n</p>\n<p>\n  \"You can get myocarditis, you can get many other things, with COVID infection itself, \"Jha said. \"And your risk of having complications from infection remain way higher than your risk from vaccines.\" \n</p>\n<p>\n  In the U.S., there are now four states with more than half of their population fully vaccinated -- Vermont (54.3%), Massachusetts (53.5%), Connecticut (51.4%) and Maine (50.22%) -- and 16 states and the District of Columbia have fully vaccinated more than the U.S. average, according to JHU data . \n</p>\n<p>\n  The states with the lowest percentage of their populations fully vaccinated are Mississippi (26.2%), Alabama (27.8%) and Louisiana (29.8%) \n</p>\n<p>\n  Latest tallies \n</p>\n<p>\n  The global case tally for the coronavirus-borne illness rose to 175.01 million on Thursday, while the death toll rose to 3,776,263, according to JHU data  and about 1.8 million deaths. \n</p>\n<p>\n  There have been 2.28 million vaccine doses administered worldwide as of Thursday, the data show. \n</p>\n<p>\n  The U.S. leads the world in total cases with 33.43 million and deaths with 599,023. \n</p>\n<p>\n  India continues to move closer to the U.S., with cases rising to 29.27 million, but is third in the world in deaths with 363,079. \n</p>\n<p>\n  Brazil is second in deaths at 482,019 and third in cases with 17.21 million. \n</p>\n<p>\n  The U.K. is fourth in deaths worldwide, and it leads Europe, at 28,148, while France is fourth globally in cases and leads Europe with 5.80 million. \n</p>\n<p>\n  China, where the virus was first discovered late in 2019,  has had 103,285 cases and has held steady at 4,846 deaths, according to its official numbers, which are widely held to be massively underreported. \n</p>\n<p>\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  June 11, 2021 15:03 ET (19:03 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","MRNA":"Moderna, Inc.","JNJ":"强生","EBS":"Emergent Biosolutions","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142204460","content_text":"MW New daily COVID-19 cases and deaths fall for first time in 4 days, while vaccine concerns grow with reports of side effects\n\n\n  Tomi Kilgore \n\n\n  Current vaccination rates suggest U.S. will fall well short of President Biden's vaccination goal \n\n\n  The number of new daily COVID-19 cases and deaths fell for the first time in four days, but vaccine hesitancy, amid reports of a heart inflammation side effect in teens and some supply concerns, is increasing the risk that President Biden's vaccination goal may not be reached. \n\n\n  There were at least 11,841 new cases of the coronavirus-borne illness on Thursday, down from 20,153 new cases on Wednesday, according to a New York Times tracker , to snap a three-day streak of increases. \n\n\n  Deaths fell to 412 on Thursday from 449 the day before, to also snap a 3-day rising streak. \n\n\n  The seven-day average of cases declined to 13,409 from 14,505, down 42% from two weeks ago and the lowest count since March 2020. For deaths, the seven-day average dropped to 387, the lowest since June 1, from 417 on Wednesday, and was 22% below where it was two weeks ago. \n\n\n  There are 12 states showing an increase in the weekly trend in cases on Friday, JHU data show , down from 15 on Thursday. \n\n\n  On the vaccination front, 305.69 million COVID-19 vaccines have been administered, and 165.12 million people aged at least 18 years old, or 64.0% of the U.S.'s adult population, have received at least one shot, the latest data from the Centers for Disease Control and Prevention . \n\n\n  At that daily pace of vaccinations, the U.S. will fall well short of Biden's goal of 70% of adult Americans receiving at least one shot by the Fourth of July. About 15.48 million more adults need to get one vaccine dose to reach Biden's goal, which translates to roughly 700,000 a day. \n\n\n  The number of fully vaccinated Americans increased to 141.58 million, or 42.6% of the total population. \n\n\n  Within age groups, 50.5% of Americans who are at least 12 years old are fully vaccinated, as are 53.4% of the U.S. adult population and 75.8% of Americans at least 65 years old. \n\n\n  In the U.S., fully vaccinated means it has been two weeks since the second of the two-dose vaccines developed by Pfizer Inc. $(PFE)$ and partner BioNTech SE (BNTX) or Moderna Inc. $(MRNA)$ have been administered, or it's been two weeks since receiving the lone dose of Johnson & Johnson's $(JNJ)$ vaccine. \n\n\n  Regarding the J&J vaccine, the CDC temporarily halted shipments in an effort to clear a backlog of unused doses, according to a report in The Wall Street Journal  this month. \n\n\n  On Friday, the U.S. Food and Drug Administration said it extended the expiration dating for J&J's vaccine to 4 1/2 months from 3 months when refrigerated at 2 degrees to 8 degrees Celsius (35.6 degrees-46.4 degrees Fahrenheit). \n\n\n  Separately, the FDA said it has authorized for use  Baltimore facility, even though it is \"not yet ready\" to include the plant in the EUA as an authorized facility. \n\n\n  \"Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 vaccine to be made available,\" the FDA said in a statement. \n\n\n  The statement comes as the New York Times reported , citing people familiar with the situation, that the FDA told J&J to discard 60 million doses of its vaccine made at the Baltimore plant because of possible contamination. \n\n\n  Separately, vaccine hesitancy has been fueled as reports circulated that mRNA vaccines, the kind made by Pfizer-BioNTech and Moderna, have led to a small number of reports of myocarditis , or heart inflammation, in teens. \n\n\n  Dr. Ashish Jha, a dean of the Brown University School of Public Health, said on NBC's \"Today\"  that it increasingly looks like the vaccine is leading to some \"rare\" cases in teens. \n\n\n  He tried to dispel concerns, however, saying that almost all of the cases of myocarditis are \"incredibly mild\" and people recover \"very, very quickly,\" but acknowledged that \"it's not irrelevant\" and can occasionally be more severe. \n\n\n  When asked about how that might fuel vaccine hesitancy, Jha noted that \"every vaccine, every medicine\" can have side effects. \n\n\n  \"You can get myocarditis, you can get many other things, with COVID infection itself, \"Jha said. \"And your risk of having complications from infection remain way higher than your risk from vaccines.\" \n\n\n  In the U.S., there are now four states with more than half of their population fully vaccinated -- Vermont (54.3%), Massachusetts (53.5%), Connecticut (51.4%) and Maine (50.22%) -- and 16 states and the District of Columbia have fully vaccinated more than the U.S. average, according to JHU data . \n\n\n  The states with the lowest percentage of their populations fully vaccinated are Mississippi (26.2%), Alabama (27.8%) and Louisiana (29.8%) \n\n\n  Latest tallies \n\n\n  The global case tally for the coronavirus-borne illness rose to 175.01 million on Thursday, while the death toll rose to 3,776,263, according to JHU data  and about 1.8 million deaths. \n\n\n  There have been 2.28 million vaccine doses administered worldwide as of Thursday, the data show. \n\n\n  The U.S. leads the world in total cases with 33.43 million and deaths with 599,023. \n\n\n  India continues to move closer to the U.S., with cases rising to 29.27 million, but is third in the world in deaths with 363,079. \n\n\n  Brazil is second in deaths at 482,019 and third in cases with 17.21 million. \n\n\n  The U.K. is fourth in deaths worldwide, and it leads Europe, at 28,148, while France is fourth globally in cases and leads Europe with 5.80 million. \n\n\n  China, where the virus was first discovered late in 2019,  has had 103,285 cases and has held steady at 4,846 deaths, according to its official numbers, which are widely held to be massively underreported. \n\n\n  -Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  June 11, 2021 15:03 ET (19:03 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}